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Abstract 
Work was undertaken in this thesis to assess the use of somatostatin image 
quantification with SPET and SPET-CT to aid the characterisation of disease 
within the body. Two radionuclide somatostatin analogues were used for this 
assessment, the first was NeoSPECT and the second, OctreoScan.  
The primary aim of work in this thesis was to assess the role of NeoSPECT 
imaging in the characterisation of disease within the lungs, that is, to 
differentiate benign from malignant disease. Two forms of image quantification 
were used in the NeoSPECT assessment, a tumour to background ratio (T:B) and 
a value of tumour percentage uptake (% uptake).  
Values of T:B and % uptake were calculated from SPET images acquired 2 hours 
post injection. T:B results from the benign group (n = 8) demonstrated a median 
T:B of 2.21, whilst the malignant group (n = 28) demonstrated a median T:B of 
2.01. The differences between the groups were tested statistically via a Mann-
Whitney test, which showed there to be no statistical difference between the 
groups (p=0.90, 95.4% CI of (-0.5598, 0.5498)).  
To undertake the calculation of % uptake a non-patient acquisition (a standard 
acquisition) was also required, unfortunately not all of the patient cohort used 
for the T:B assessment had this additional acquisition. As a result of this 
numbers were low for the % uptake assessment in patients with a benign 
histology (n = 2), therefore statistical analysis could not be performed. However, 
review of the range of values for each histology within the malignant group 
proved useful as no differences were demonstrated between the ranges of 
values which could help to differentiate between the histologies.  
Quantification of dual time point imaging was also assessed to determine if there 
were any variations in values calculated that could also help differentiate the 
different histologies. For this assessment patients were images at 2 and 4 hours 
post injection. Results from the Wilcoxon Signed Rank test of the T:B assessment 
found there to be no statistically significant difference between values of T:B 
calculated at 2 and 4 hours that was characteristic of tumour type (p=1.0 and 3 
p=0.14). The difference in % uptake between 2 and 4 hours was also assessed via 
a Wilcoxon Signed Rank test, this test also concluded there to be no significant 
difference value of % uptake between the two acquisitions of the malignant 
group (p = 0.73).   
An attempt was also made to quantify ‘other’ uptake within the mediastinum, 
however, a lack of anatomical information made correlation with histology 
impossible and as a result no firm conclusions relating image quantification to 
histology could be drawn from this work.  
Work from this thesis concluded no quantitative difference between tissue 
histology could be demonstrated using NeoSPECT, either from single or dual time 
point imaging.  
As a result of the NeoSPECT work a number of factors which limited the accuracy 
and reproducibility of SPET image quantification were identified. Towards the 
end of the NeoSPECT work hybrid imaging (SPET-CT) became available within the 
department at Glasgow Royal Infirmary.  It was believed that hybrid imaging 
could resolve some of the limitations and subsequently improve the accuracy of 
SPET image quantification. However, NeoSPECT was removed from the market 
for a short period of time and therefore a similar somatostatin analogue, 
OctreoScan, was used to investigate if the accuracy of somatostatin image 
quantification could be improved as a result of SPET-CT and its associated 
reconstruction algorithms including a CT based attenuation correction.  
Firstly, a qualitative assessment of image quality using the new hybrid 
reconstructions techniques was undertaken via an observer study. Images were 
reconstructed with the existing reconstruction techniques, as used for the 
NeoSPECT work, and with the new hybrid imaging techniques. Four experienced 
observers blinded to reconstruction technique were asked to score images in 
terms of their overall image quality. A Friedman test was performed on the 
scores for each observer, three of the four observers demonstrated a statistically 
significant difference in their scores between the existing and new hybrid 
technique (p = 0.00, p = 0.003, p= 0.00), with the new hybrid technique being 
assigned the highest scores in terms of image quality. 4 
Images were also assessed semi-quantitatively via profile analysis which also 
demonstrated a clear differentiation between the existing and new hybrid 
techniques with increased image quality being demonstrated in the hybrid data 
set.  
The quantitative accuracy of hybrid imaging was also assessed using phantom 
data. For 
111In the difference of the value of absolute activity calculated and 
that measured varied by 35% but this improved to 21 % when scatter and CT-
attenuation based corrections were applied. For 
99mTc a much more notable 
difference between the existing techniques used in chapter 2 and those 
available from the use of hybrid imaging was demonstrated, the difference in 
the value of absolute activity calculated and that measured improved from 67% 
to 0.04%, respectively.  
Work in this thesis clearly demonstrated an improvement in image quality and 
accuracy in SPET quantification as a result of hybrid imaging techniques.  
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Chapter 1 - Introduction 
Nuclear medicine imaging (now also often referred to as molecular imaging) is 
known for its truly functional nature which, in part, offsets the lack of spatial 
resolution when compared to other imaging modalities.  In particular, 
tomographic nuclear medicine imaging with a resolution of 8mm at best, 
compares somewhat unfavourably to CT or MRI which can have sub 1-mm 
resolution. Despite this limitation, nuclear medicine imaging provides valuable 
physiological information which is unobtainable by CT or MRI.  As a result, 
molecular imaging has a long and well established role in the diagnosis and 
management of patients with cancer and is successfully used worldwide (see 
Table 1) in imaging a number of cancers such as those involving the thyroid and 
other neuroendocrine tumours, liver and brain. 
Country  Annual frequency of nuclear medicine procedures          
(per thousand population) 
Canada  65 
Germany  34 
USA  32 
Netherlands  16 
Australia  12 
UK  11 
New Zealand  8 
Portugal  4 
Table 1 - Annual Frequency of Nuclear Medicine Investigations Worldwide  
(Gemmel, 2008) 
Confidence in the effectiveness of nuclear medicine’s role in managing patients 
with cancer has been demonstrated by the inclusion of nuclear medicine imaging 
procedures into UK’s National Institute of Health and Clinical Excellence 
guidelines (NICE Clinical Guideline). NICE is an independent organisation within 
the UK which provides national guidelines to promote good health and also to 
prevent, treat and manage ill health, NICE recommends nuclear medicine 
imaging in their guidelines for the management of many of the main cancer 
groups, most notably prostate and breast cancer.  In Scotland a similar body 
produces Scottish Intercollegiate Guidelines Network guidelines (SIGN).  Chapter 1     16 
1.1 Current Radiopharmaceuticals used in imaging of 
cancer 
There are a number of radioisotopes currently used in imaging, all of which 
possess at least two of the following characteristics which are ideal for 
diagnostic imaging purposes: 
·  Half –life, this must be long enough to image and assess the metabolic 
process of organs of interest, whilst it must also be short enough to 
minimise the radiation dose to the patient and others.  
·  Decay process is also important, isomeric transition being the most 
desirable as this mechanism emits gamma rays and low energy electrons 
only, that is, no beta emissions. In this way the radiation dose to the 
patient can be kept low and imaging can be achieved.  
·  Energy of the emitted gamma rays; radioisotopes which emit low energy 
gamma rays (<250keV but > 80keV) are ideal as they can easily escape the 
human body and can be detected by a gamma camera. Again this allows 
the radiation dose to the patient to be minimised.  
·  The chemistry of the radioisotope is also important to allow binding to a 
suitable pharmaceutical.  
The main radioisotope used currently in nuclear medicine in the UK is Tc-99m 
but In-111, I-123 and Ga-67 are also used. Technetium (Tc-99m) is heavily used  
mainly because of its flexible chemistry which allows it to be bound to many 
different pharmaceuticals. It also has a six hour half life and emits low (140 keV) 
energy gamma rays.  Some typical radiopharmaceuticals which are licensed and 
marketed for imaging in the UK to investigate various cancers are shown in 
Table 2, (UKRG Radiopharmacy Handbook): 
 
 Chapter 1     17 
Radiopharmaceutical  Area of Interest 
99mTc Methyldiphosphonate (MDP)  Bone malignancy and metastasis 
123I Iodide or 
 201Tl Chloride or 
131I Iodide  For thyroid tumours 
123I Iodide or 
201Tl Chloride  For thyroid metastases 
99mTc (V) Dimercaptosuccinic acid (DMSAV)  Medullary carcinoma of thyroid 
123I metaiodobenzylguanidine (mIBG)  Neuroendocrine tumours 
111In Pentetreotide   Somatostatin producing tumours 
99mTc Depreotide   Lung malignancy 
99mTc Colloid   Sentinel node localisation in breast & melanomas 
201Tl Chloride  Active brain tumours 
67Ga Citrate   Lymphoma (recurrence, restaging & management) 
99mTc Sestamibi    Parathyroid adenoma imaging.  
Table 2 - Radiopharmaceuticals licensed in UK for Imaging (UKRG, 2002) 
 
Not all of the radiopharmaceuticals on this list are included in NICE guidelines 
but the products listed are being currently used to either diagnose or to aid in 
the diagnosis of some cancers. 
 
1.1.1  
99mTc – Methylene Diphosphonate – Radiopharmaceutical 
Properties 
Radionuclide bone imaging was first demonstrated in 1961 using Strontium – 85, 
85Sr. During the next 10 years there were a number of redevelopments of bone 
imaging radiopharmaceuticals, all of which where found to be somewhat limited 
either in terms of their physical or physiological characteristics. In 1971, 
Technetium – 99m was labelled to a number of phosphate compounds 
(polyphosphates, pyrophosphates and diphosphonates) all of which demonstrated 
a good target to background ratio. However, it was found that both the poly - 
and pyro – phosphates were susceptible to in vivo breakdown by tissue 
phosphatases, a characteristic which the diphosphonates did not share. This 
inability of the diphosphonates to breakdown down under tissue phosphatases 
along with their ability to bind to bone surface meant that this 
radiopharmaceutical had no loss in uptake over the time required to image a 
patient. At present 
99mTc diphosphonates are the gold standard for imaging 
bone. In the UK 
99mTc methylene diphosphonate (MDP) is used and in the UK and Chapter 1     18 
elsewhere (for example Europe) 
99mTc hydroxymethylene diphosphonate (HDP) is 
used (McKillop and Fogleman, 1991). 
Glasgow makes use extensively of 
99mTc MDP which is useful in demonstrating 
bone disease because the mechanism of uptake is due to bone turnover, that is,  
osteoblastic activity. This means that areas of high osteoblastic activity will 
demonstrate high uptake of diphosphonates; there are a number instances in 
which the body will produce an increased osteoblastic response: 
·  Growth (Babies, children and young adults) 
·  Trauma 
·  Infection (Osteomyelitis) 
·  Metabolic bone disease (Paget’s disease) 
·  Malignancy(Primary bone tumours, metastases from prostate, breast and 
lung cancer)  
 
The most common use of a 
99mTc MDP bone scan today is in imaging of bone 
metastases. The bone scan can be used as part of the initial diagnosis and 
staging of the disease but may also be used to monitor disease progression or 
response to treatment and an example of an abnormal bone scan is shown in 
Figure 1. Chapter 1     19 
 
Figure 1 - 
99mTc MDP Bone Scan (Sclerotic Metastases) 
Images shown are whole body planar images, these images demonstrate multiple areas of 
increased 
99mTc MDP uptake in keeping with sclerotic bone metastases. 
 
In addition to an increase in osteoblastic response, that is sclerotic deposits, 
there are a number of bone diseases which result in reduced or no osteoblastic 
activity. These often produce lytic lesions and are usually demonstrated by x-ray 
and CT. Figure 2 shows an example of a lytic and a sclerotic lesion as 
demonstrated by CT.   Chapter 1     20 
 
Figure 2 - Example CT Lytic & Sclerotic Bone Lesion 
Images show transverse CT slices through the pelvis (upper left image) which demonstrates 
a lytic area of the bone and a transverse CT slice through the thorax (bottom right image) 
which demonstrates an area of sclerosis in one of the vertebrae.   
 
The sclerotic lesion demonstrated in Figure 2, will be easily identified on the 
bone scan in a similar manner to the increased uptake demonstrated in Figure 
1. The lytic lesion, however, may not be identified on the bone scan. There may 
be instances, however, when a bone scan is able to identify a lytic lesion. This 
usually only occurs when either the lytic lesion has become so large that it 
appears as a photopenic area or when there is an osteoblastic response in the 
area surrounding a lytic lesion, an example of which is shown in Figure 3.  
Myeloma is a bone disease that produces lytic lesions and the bone scan’s ability 
to detect these lesions lies solely in the extent of the osteoblastic reactive 
response to the damage evoked by the lytic component. The extent of reactive 
osteoblastic activity is variable and therefore the bone scan is not the ideal tool 
for imaging myeloma as there is a risk of missing a lesion.  Chapter 1     21 
Prostate cancer metastases in the bone are usually sclerotic lesions whilst breast 
and lung cancer metastases in the bone may have both a lytic and sclerotic 
component (Hayat, 2008). Depending on the primary source of cancer the bone 
metastases can be sclerotic or lytic or both as in Figure 3 .  
 
Figure 3 - 
99mTc MDP Bone Scan (Bone metastases sclerotic and lytic) 
Images shown are whole body planar images, the image demonstrates areas of reduced 
uptake along with areas of increased 
99mTc MDP uptake, as indicated by the arrows and in 
keeping with both lytic and sclerotic lesions.  
 
Figure 3 is a bone scan from a breast cancer patient who has bone metastases 
that are both sclerotic and lytic in nature. 
Lytic Lesion 
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More recently the positron emitter 
18F fluoride (PET-CT) has been reconsidered 
as a bone imaging agent. Despite this imaging technique being very effective it is 
also very expensive and its availability throughout the UK remains limited in 
some areas, whilst Tc
99m MDP bone imaging remains a low cost, readily available 
and effective imaging agent. 
1.1.2 Somatostatin Receptor Imaging  
One of the major steps forward in molecular imaging of tumours and in 
particular neuroendocrine type tumours came with the introduction of several 
agents which allowed somatostatin receptor imaging.  
Somatostatin (SST) is a Growth Hormone - Inhibiting Hormone (GH-IH), and is 
present on one of two forms; SST - 14 (consisting of 14 amino acids) and SST - 28 
(consisting of 28 amino acids). 
SST is produced by a number of organs in the body - most notably brain, 
intestines and pancreas. In the brain SST is produced in the hypothalamus and is 
released into the anterior pituitary gland - see Figure 4. The presence of SST 
inhibits the release of Growth Hormone and Thyroid Stimulating Hormone (de 
Herder, 2003). 
 
Figure 4 - Anatomy: Hypothalamus and Pituitary Gland 
Image showing basic structures within the brain.  
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In addition to the Hypothalamus, SST is also produced in a number of locations in 
the gastrointestinal system (stomach, intestines and pancreas) - See Figure 5.  
 
Figure 5 - Anatomy: Stomach, Pancreas and Intestines 
Image showing basic structures within the abdomen (Carrieshealth). 
 
The job of SST is to help regulate the release of hormones, as a result of which, 
SST has an affect on many physiological processes, most notably those which 
involve the gastrointestinal tract. The presence of SST in these areas inhibits the 
release of many gastrointestinal and pancreatic hormones, this leads to a 
reduction in the rate of gastric emptying whilst also reducing blood flow to the 
intestines and smooth muscle contractions. In addition to its hormone regulatory 
role, SST also controls cell proliferation in both normal and tumour tissues.  
SST is able to target cells via Somatostatin Receptors (SSTR), of which there are 
5 different types, SSTR 1-5. All five SSTR demonstrate a high binding affinity to 
both SST - 14 and SST - 28. Like SST’s, SSTR’s can be found throughout the 
central and peripheral nervous system (de Herder, 2003).  
In terms of imaging, the major breakthrough came with the realization that 
some disease processes over expressed SSTRs. Many tumours are known to over 
express SSTRs, see Table 3. As a result of this SSTR imaging was established in 
the mid 1990s.  
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    Affinity 
 
 
Neuroendocrine tumours  
 
{Pituitary Adenomas, Carcinoids, Islet cell Ca, 
Paragangliomas, Pheochromocytomas, 
Medullary thyroid Ca, SCLC} 
 
 
High 
Tumours of nervous 
system 
{Astrocytomas, Neuroblastomas, 
Meningiomas}  High 
Lymphomas    High 
Breast tumours    ~50% 
Ovarian Ca, Colon Ca    Low 
Glioblastomas, NSCLC    No receptors 
Exocrine Pancreatic Ca, 
Prostate Ca    No receptors 
Table 3 - Affinity of SSTR expression  
(Reubi, 1992) 
 
Table 3 shows non small cell lung cancer, NSCLC, using in-vitro testing, to have 
demonstrated no over expression of SSTR. However, further in-vivo tests found 
that NSCLC demonstrated uptake of some synthetic SST analogs therefore 
indicating that NSCLC did in fact over express SSTR. This was contradictory to 
the in-vitro findings and led to further investigations which concluded that 
NSCLC tumour tissue did not over express SSTRs however, the other pathologies 
associated with NSCLC did i.e. inflammatory processes surrounding the tumour 
such as granulomas (Blum, 2000). 
Based on their affinity to bind to the various synthetic SST analogs, the five 
SSTRs described previously have been further divided into two subgroups, see 
Figure 6.  Group 1 includes SSTR 2, 3 and 5 and these have a binding affinity 
with synthetic SST analogs, whilst Group 2 is comprised of SSTR1 and 4 which 
have an extremely poor binding affinity with synthetic SST analogs (Srikant, 
2004). 
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Figure 6 - Somatostatin Receptor and Sub-Groups 
Chart categorising somatostatin receptors subgroups based on their affinity to bind with 
synthetic SST analogs. Group 1 - are receptors with high affinity indicated by black arrows 
and Group 2 - are receptors with low affinity indicated by the red arrows. 
An overview of some of the more successful peptides available or investigated 
over the years are detailed in Table 4. 
Radioligand  Availability  Receptor binding data 
123I-octreotide  No longer in use  Not studied 
123I- Tyr
3-octreotide   No longer in use  hSSTR2, 5 
111In-DTPA-D-Phe
1-octreotide (pentetreotide)  Commercially available  hSSTR2, 5 
111In-DOTA-Tyr
3-octreotide  May be prepared in house  hSST2, 5 
111In-DOTA-lantreotide (MAURITIUS)  In house  hSST2-5 
99mTc-HYNIC- octreotide  In house  Not studied 
99mTc-depreotide  Commercially available  hSSTR2, 3, 5 
123I-VIP  In house  hSSTR 3, VIPR1, 2 
Table 4 - Somatostatin Based Imaging Agents  
(Baert and Sartor, 2006) 
 
In 2004, of those described in Table 4 only 2 radiopharmaceuticals were 
considered effective in imaging tumours which over expressed somatostatin 
receptors in: these had the trade names of OctreoScan (
111In pentetreotide) and 
NeoSPECT (
99mTc depreotide).  Chapter 1     26 
1.1.2.1  Lung Cancer and NeoSPECT Radiopharmaceutical Properties 
Lung cancer remains one of the leading causes of mortality within the world.  It 
can be subclassified into various types with the two major sub-types of primary 
lung cancer being Small Cell (SCLC) and Non-Small Cell (NSCLC).  These are 
defined by how the tumour cells look under a microscope. 
Lung cancer of a small cell nature is responsible for 1 in 5 lung cancers and is 
usually as a direct result of smoking. This form of lung cancer is usually treated 
with chemotherapy and radiotherapy, whilst NSCLC can be treated using surgery, 
chemotherapy and radiotherapy (MacMillan-Lung, 2011).  
Around 80% of lung cancers are of the NSCLC type. NSCLC are prone to spread 
and distant metastasis can be found.  Around 7% - 10% of patients are 
asymptomatic and disease in these patients is found incidentally. The NSCLC 
types are divided into a further three subsets, squamous cell carcinomas, 
adenocarcinomas and large cell carcinomas.   
Squamous cell carcinoma is the commonest of the NSCLC group and is often as a 
direct result of smoking. These types of tumours usually form around the centre 
of the lung, near the large airways, the bronchi - see Figure 7. 
 
Figure 7 - Anatomy of the Lungs  
Image showing basic structures within the lungs (W-Healthy, 2011) Chapter 1     27 
Most peripheral tumours are of the adenocarcinoma type and these are most 
often associated with non-smokers (CancerResearchUK-Lung, 2011). Unlike 
squamous cell and adenocarcinomas, tumours of a large cell type can occur in 
any part of the lung and are rapidly growing tumours. 
As discussed in section 1.1.2, disease and processes surrounding the disease 
associated with both small and non small lung cancer (SCLC and NSCLC) have 
been found to over express somatostatin receptors relative to normal tissue. 
99mTc-labelled Depreotide, commercially known as 
99mTc –labeled NeoSPECT, is a 
Technetium, 
99mTc, labeled, 10 amino acid, synthetic peptide that contains a 
SSTR-binding domain. Details of NeoSPECT administration to patients are 
detailed in Table 5. 
Activity Administered (MBq):  600 
Volume Administered (ml):  5 
Route:  Intravenously 
Effective Dose (mSv):  12 
Preparation of Patient:  No special preparation 
Imaging Time:  2 hours post injection 
Table 5 - NeoSPECT Administration Details (NeoSPECT
TM, 2001) 
 
Of the 5-SSTR subgroups demonstrated in Figure 6, depreotide binds to three of 
these; SSTR2, 3, and 5 with a high affinity. Not only do SST peptide analogs bind 
to SSTRs but they also clear rapidly from the circulation. 
1.1.2.2  Neuroendocrine Tumours and OctreoScan Radiopharmaceutical 
Properties 
The terms Neuroendocrine tumour (NET) covers a large family of tumours that 
originate from the neuroendocrine system since neuroendocrine cells are found 
all over the body. However, most NET’s fall into one of the two main groups; 
Pancreatic Neuroendocrine Tumours (PNT) and Carcinoid Tumours. Table 6 
details some of the various forms of the PNT along with organs where carcinoid 
tumours may originate. 
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Pancreatic Neuroendocrine Tumours  Carcinoid Tumours 
Insulinoma  Small Bowel 
Gastrinoma  Large Bowel 
Glucagonoma  Pancreas 
Somatostatinoma  Lung 
VIPoma  Ovaries 
Table 6 - Neuroendocrine tumour types  
(Baert and Sartor 2006) (MacMillan-NET, 2011) 
 
It is the carcinoid group which are usually imaged with OctreoScan as the PNT 
group contains tumours for which Octreoscan is not as sensitive, this is because 
this group of tumours may or may not overexpress SSTR and in particular SSTR2, 
or 5 (Baert and Sartor, 2006). 
Around 85% of carcinoid tumours occur in the digestive system 
(CancerResearchUK-NET, 2011) but can be found in other organs as described in 
Table 6. These types of tumours are, however, rare and can be difficult to 
diagnose, with currently only 1500 people in the UK being diagnosed each year 
(MacMillan-NET). OctreoScan is most commonly used to identify and localize 
carcinoid tumours and their metastases. 
111In-labelled Pentetreotide, commercially known as 
111In–labeled OctreoScan, is 
an Indium, 111In, labeled, synthetic peptide that contains a SSTR-binding 
domain pharmaceutical called pentetreotide. Details of OctreoSCAN 
administration to patients are detailed in Table 7. 
Activity Administered (MBq):  220 
Volume Administered (ml):  2 
Route:  Intravenously 
Effective Dose (mSv):  17 
Preparation of Patient:  Bowel Prep evening before imaging and information regarding 
Sandostatin therapy should be obtained. 
Imaging Time:  2 hours post injection 
Table 7 - OctreoScan Administration Details 
 
OctreoScan is similar to NeoSPECT in that it is also a somatostatin analogue but 
it binds to a fewer SSTRs.  Of the 5-SSTR subgroups demonstrated in Figure 6, 
pentetreotide binds to two of these; SSTR2, and 5 with a high affinity. It should 
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Sandostatin therapy therefore it is important that this information is known prior 
to imaging (OctreoScan®). 
Physiological uptake of OctreScan is demonstrated in the pituitary gland, 
thyroid, liver, spleen and bowel. Also, since almost all of the tracer is 
eliminated from the body via the renal system, uptake is demonstrated in the 
kidneys, ureters and urinary bladder (OctreoScan®).  
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1.2 Past and current imaging techniques 
The gamma camera was first designed by Hal Anger in the 1960s.  Since then 
although there have been major technological advances, the basic concepts 
proposed by Anger still form the basis of today’s gamma cameras. 
 
1.2.1 Gamma Camera Technology 
The gamma camera makes use of the scintillation properties of the NaI(Tl) 
crystal. Using a lead collimator to minimise scattered radiation, gamma rays 
incident on the crystal produce light which is detected using an array of 
photomultiplier tubes. 
In 1960, Anger’s first camera had a circular field of view, since then 
improvements in crystal growing and manufacture mean that most modern 
cameras are rectangular in shape and of significant size (540mm x 400mm). In 
the original systems a single camera head was used, nowadays multi-headed 
systems are the norm. Improvements in mechanics and electronics have made it 
possible to move from images where the camera remained static throughout the 
study to those where the camera moves with respect to the bed to allow 
wholebody imaging.  This was followed by the use of the camera being rotated 
through 360
o to obtain projections around the patient’s body. Major advances in 
computing power within the last 20 years then meant that these projections 
could be reconstructed to allow tomographic images which could be manipulated 
in three dimensions. In a general department which undertakes mainly 
wholebody and tomographic studies it is usual to have a double headed camera 
with the heads mounted 180
o opposed. 
Gamma Cameras now utilise analogue to digital converters (ADC’s) on each 
photomultiplier tube (PMT) allowing for on-the-fly corrections and 
microprocessor driven calculations of the x, y and z signals to be made, moving 
away from the inherent problems of Anger arithmetic. (Farr & Allisy-Roberts, 
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Most recently, technology has allowed hybrid type cameras to become a reality, 
and the SPET-CT and PET-CT systems are now the norm.  These usually use a 
doubled headed gamma camera with an X-Ray CT tube bolted on. The latest 
systems on the market include a SPET gantry and CT gantry which are able to be 
used independently.   The SPET-CT images then allow the registered SPET and 
CT data to be interpreted together using a fused image, and separately. This has 
been a huge step forward in the use of nuclear medicine imaging renowned for 
the poor spatial resolution inherent in Anger’s design. These hybrid systems 
allow maximum use of molecular imaging’s high sensitivity, functional nature 
and contrast, displaying these along with the high spatial resolution and 
anatomical information of the CT image. 
SPET MRI systems are now being planned which will need to dispense with the 
Anger type camera and replace the nuclear medicine component with a solid 
state type detector. 
The move to tomographic imaging has been welcomed by the professions within 
nuclear medicine but much of the published work looks at qualitative image 
quality. Little literature has looked specifically at quantifiable quantities within 
patient data which would allow more use of nuclear medicine when considering 
treatment response to, for example, chemotherapy agents. Part of the work of 
this thesis aims to investigate one small area of this tomographic quantification 
and its reproducibility. 
 
1.2.2 SPET Image Reconstruction 
 
SPET data are a series of planar images taken at various angles around the 
patient/object - see Figure 8. The problem with the raw image data acquired is 
that they are not a true representation of the distribution of radioactivity within 
the patient. The photons emitted from the organ or tissue are attenuated by 
various structures within the body before reaching the detector. In addition the 
3D image is generated from a series of 2D acquisition.  Chapter 1     32 
 
Figure 8 - Series Projections/Frames 
Image showing four randomly selected projections from a complete SPET acquisition of the 
upper body, neck and head. 
 
Reconstruction of these images can be handled in one of two ways; Analytical 
via Filtered Back Projection techniques or Iteratively (Bruyant, 2002). 
1.2.2.1  Filtered Back Projection, FBP 
Filtered Back Projection (FBP) has long been the traditional reconstruction 
method for tomographic data reconstruction and not only in Nuclear Medicine. 
As discussed, tomographic data consist of a series of planar images acquired at 
various angles also known as projections. The first step in the FBP reconstruction 
process is to create a sinogram from the acquired data. For each transverse slice 
a sinogram is simply a series of projections which represent the distribution of a 
tracer in the body at every angle. An example of a sinogram is shown in Figure 
9. Chapter 1     33 
 
Figure 9 - Sinogram generation 
Image showing three example projection images (on the left) along with the resultant 
sinogram (on the right) for the transverse slice shown in green.  
 
The sinogram created is used to reconstruct the data, but to reconstruct the 
data at this stage would produce poor quality images.  In particular an artifact 
known as the star artifact would be introduced.  This star artifact is a bi-product 
of back projection and can be best seen on the reconstruction of a point source 
which in fact looks like a star because of the projection lines which radiate 
centrally from the reconstructed image.  This is characteristic 1/r blurring, so 
named because the density of the artifact diminishes by 1/r with distance r from 
the point.  If the whole image is considered, each point has this associated 
blurring meaning that the image quality is very poor. In order to remove this 
blurring a filter step is required and the entire process becomes filtered back 
projection.  To filter the data in the spatial domain is computationally intensive, 
however, by converting the data into the frequency domain the same results can 
be achieved by simply applying a weighting factor to the data. The sinogram is 
converted into the frequency domain by performing a Fourier Transform on the 
data.  
Once in the frequency domain a high pass filter is used to remove this 1/r 
blurring. The type of filter used, known as a ramp filter, works by multiplying 
the image data, at each frequency by a weighting factor that increases linearly 
with increasing frequencies - see Figure 10 .  
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Figure 10 - Ramp Filter 
Image showing the linear characteristics of a ramp filter used in FBP. 
 
Despite being able to remove some of the low to mid frequency components 
from the data the ramp filter has the disadvantage of amplifying the statistical 
noise (which is high frequency) present in the data and this also degrades the 
image.  
High frequency noise components can be removed using a low-pass filters which 
has the effect of smoothing the image. There are various low-pass filters 
available; Hamming, Butterworth, Shepp-Logan, Metz, Wiener, each of which 
has different curve characteristics in the frequency domain. The degree of high 
frequency components removed is dependent upon the cut-off frequency (the 
frequency above which all other frequencies are removed).  However, depending 
on the filter, further characteristics of the curve may be altered. An example of 
this type of filter is the butterworth, this filter has an additional factor to 
consider known as the order (gradient of the curve) - see Figure 11.  
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Figure 11 - Butterworth Filter 
Image showing the curve characteristics of a butterworth filter which can be used in FBP. 
 
The difficulty with any filtering of this type is that it in addition to removing the 
high frequency noise within the data, the fine detail of the image which is also 
high frequency can be lost as the filter cannot distinguish between the high 
frequency components.  The cut-off value of the filter is therefore important so 
that image quality can be optimised.  Too much smoothing and the image 
becomes blurred. 
In FBP a combined ramp and low-pass filter are used pre back projection 
(reconstruction), therefore 2D filtering is performed. Once filtered the sinogram 
is converted back into the spatial domain and the data back projected (Delebeke 
and Israel, 2010; Bruyant, 2002). The Back Projection reconstruction technique 
can be described using a simple 3x3 pixel array [A]. Each 3x3 array represents a 
single projection through the patient i.e. P1-4 [A]. Contained in each cell is the 
value for the number of photons detected in that voxel [B] - refer to Figure 12.   Chapter 1     36 
 
Figure 12 - FBP Simplified  
Image showing a post filtered 3x3 projection matrix and a simplified reconstruction process 
achieved via FBP(Farr & Allisy-Roberts, 1998). 
The 3x3 array in [B] are summed together and the result is [C]. A background 
subtraction is then applied i.e. in this case a global background value of 45 is 
subtracted from each voxel in the array. The values are then rescaled or 
normalised. In this example this is achieved by dividing each cell by 5 and the 
result given in array [D]. Figure 12 provides a simplified explanation, in reality 
in order to minimise any artefacts as a result of attenuation from the patient for 
example attenuation artefact
1, opposing projections are added pixel by pixel.  
In recent years for most reconstructions filtered back projection (FBP) has been 
replaced/superseded by forms of Expected Maximisation algorithms which 
previously were only really used in CT reconstruction.  
                                         
1 This is when the image appears less intense in the centre, the intensity of counts gradually 
increases as you move away from the centre towards the edge of the patient or object which 
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1.2.2.2  Ordered Subset Expectation Maximisation, OSEM  
OSEM reconstruction is an iterative reconstruction technique unlike FBP which is 
an analytical technique. Figure 13 illustrates just some of the many different 
approaches to iterative image reconstruction. Iterative reconstruction 
techniques can be split into two very discreet branches; ‘Algebraic’ and 
‘Statistical’. The main difference between these two branches is in how the 
measured projection and the estimated projection are compared, corrected and 
updated through the reconstruction process (Vandenberghe, 2001). 
 
Figure 13 - Iterative approaches to image reconstruction  
Chart categorising iterative reconstruction techniques into statistical (OSEM, Ordered 
Subset Expectation Maximisation; MLEM, Maximum Likelihood Expectation Maximisation; 
CG, Conjugate Gradient) and algebraic (SIRT - Simultaneous Iterative Reconstruction 
Technique; ART - Algebraic Reconstruction Technique; ILST - Iterative Least-Squares 
Technique) approaches (Vadenberghe, 2001). 
OSEM falls into the likehood category as the basis of this technique is formed by 
the Expectation - Maximisation, E-M, algorithm. The E-M algorithm is used to 
find a solution when there is an unknown variable in the measured data set. The 
algorithm has two basic components; an Expectation and a Maximisation Step. 
The very first stage in this ‘Expectation’ process is to create an estimated slice, 
an arbitrary estimate. To do this, the first slice of the raw data is taken and 
from it’s projection an estimated slice is created, this is usually a homogenous 
slice whose values can be derived from an average of the projection values (Step 
1 of Figure 14). Chapter 1     38 
 
Figure 14 - OSEM Reconstruction Process  
Image showing a non-mathematical representation of the OSEM reconstruction algorithm 
(Lawson, 2011). 
 
The estimated transaxial image is then forward projected (Step 2 of Figure 14). 
A comparison is then made between the projection of the estimated slice and 
the projection of the measured slice (i.e. the raw data), (Step 3 of Figure 14).  
The measured slice projection is then amended to match the expected - this is 
known as the ‘Maximisation’ step (Step 5 of Figure 14). This whole process is 
then repeated until the difference between the actual and the estimated / 
expected reaches convergence in other words approaches zero or when the 
number of iterations which has been set is reached. 
It is at stages 2 and 4 of Figure 14 that corrections such as resolution recovery, 
attenuation and scatter should be applied to the estimated forward projection 
data and the back projected data. 
This process is repeated for each slice measured (for every frame acquired). 
However, the homogenous slice used as the estimate for the first slice is now 
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image for slice 3 is therefore the resultant image created from slice 2 and so on 
and so forth until the last slice.  
This sequential approach means that reconstructing with EM algorithms requires 
a significant amount of computer processing and until recent years the 
limitations in computer processing hardware dictated the limited use of these 
commercially. Only in recent years has the development of more powerful 
computer processors and subsequent reduction in price allowed a number of 
forms of EM to be viable commercially (Bruyant, 2002). 
The Ordered Subset Expectation Maximisation, OSEM, algorithm has found an 
application in Nuclear Medicine. This algorithm essentially produces the same 
quality reconstructed data as an EM algorithm but it is able to perform the 
reconstruction at a much faster rate, therefore making it more clinically suitable 
and commercially viable (Hudson, 1994). The OSEM reconstruction technique is 
able to achieve faster reconstruction rates as it is a more general form of EM. It 
processes the data in sequential subsets (group’s frames) which is ideal since the 
data is acquired sequentially. 
The number of subsets influences how quickly the data can be reconstructed. 
Increasing the number of subsets reduces the overall reconstruction time. The 
number subsets can be between 1 and 16, however this value is dictated by the 
number of projections acquired and there should be at least 4 projections per 
subset.  
The outcome of the first subset is used to define the outcome of the second 
subset and therefore the 2
nd subset will be used to define the outcome of the 3
rd 
and so on and so forth.  
It should be noted that the number of iterations will influence factors such as 
resolution, contrast and noise. Increasing the number of effective OSEM 
iterations will increase the noise, the effective OSEM Iterations is defined in 
Equation 1: 
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n n I S Iterations OSEM Effective ´ = _ _  
Equation 1  
 
where Sn is the number of subsets and In is the number of iterations. It should be 
noted that in cases where the number of effective OSEM Iterations is greater 
than 20, a post reconstruction filter is required (Hermes, 2008). Also, if 
resolution recovery is used then the number of iterations should also be 
increased. 
Resolution recovery is when information about the acquisition system, collimator 
parameters and resolution of the crystal are used to ‘inform’ the subsequent 
iterations and in theory produce a more accurate reconstructed image. 
It is also possible to ‘inform’ the iterative process about other known 
information in particular if an attenuation map is available, say from a CT image 
then this information can be used during the iterations again in theory producing 
a more accurate reconstructed volume. 
Once the data are reconstructed they can also be filtered to achieve a smoother 
image, this is undertaken by removing any high frequency components. Low pass 
filters available for use with OSEM reconstruction at GRI are the Butterworth, 
Low Pass, Hamming, Metz and Gaussian. Unlike FBP, since this filtering is 
performed on the reconstructed data it is referred to 3D image filtering 
(whereas FBP uses 2D filtering). 
As always there are a number of “Pro’s and Con’s” for both the analytical and 
iterative techniques, some of which have been summarized in Table 8. 
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Analytical Reconstruction Techniques 
(Filtered Back Projection) 
 
 
Iterative Techniques 
(Optimised Subset Expectation Maximisation) 
PROs  CONs  PROs  CONs 
Fast Recon Rate  Correcting data for scatter 
etc can be difficult 
Discreteness of data 
included in model 
Number of iterations should 
be optimized for good image 
quality  
Direct Inversion of 
Projection Formula 
Data requires pre and post 
recon filtering 
Projection noise can better 
estimated and corrected  
Slow Recon Rates 
  Quantitation unreliable  Correct for collimator 
geometry, scatter and 
attenuation. 
 
  Amplification of noise 
requiring more filtering 
Able to Quantify   
    Reduced image noise   
Table 8 - The “Pros’s and Con’s” of Analytical versus Iterative reconstruction techniques  
(Bruyant, 2002; Vandenberghe, 2001).  
The tomographic acquired data are not a direct measurement of the distribution 
of radioactivity within the patient but are a measure of the distribution of 
emission events which will include scatter events and background radiation, 
when applying FBP technique to reconstructions, the reconstruction will include 
all this additional ‘dirty data’ (noisy data). In addition to higher noise content 
FBP can also introduce a streaking affect because of the back projection lines. 
When compared with the traditional FBP reconstruction techniques, EM 
algorithms are shown to demonstrate a reduction in overall image noise whilst 
also removing the streaking affect which is a common characteristic of FBP 
(OSEM Technologies, 2006; Bryuant, 2002). Elimination of the streaking effect 
and noise can be achieved because the data reconstruction process does not rely 
on the fact that the emission events lie anywhere on a line. 
1.2.2.3  Attenuation Correction 
Nuclear medicine images have always had a major issue because of the inherent 
attenuation from within the patient. Several mathematical corrections have 
been used over the years to correct for this. Although attenuation is present in 
all nuclear medicine imaging, it becomes more apparent in SPET imaging where 
the central parts of the transverse slices are significantly reduced in counts with 
respect to the outer edges. 
Until the last few years the most acceptable way of correcting for this has been 
to apply a uniform attenuation correction. This means defining the outer edge of 
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co-efficient, usually taken to be that of water. Chang’s algorithm is the most 
commonly used uniform attenuation correction algorithm (Prekeges, 2011). 
 
Figure 15 - Changs Attenuation Correction 
Image shows a basic pictorial representation of Chang’s attenuation correction process. 
 
To perform a Chang’s type correction, the patients body habitus has to be 
defined (Step 2 Figure 15), that is the circumference of the patient. This is 
achieved by drawing either a circle or ellipse, whichever fits best around the 
patient’s body shape on the reconstructed transverse slices. 
The next step in creating the MU map is to generate a uniform attenuation map 
which matches the user defined circumference for each slice. For each pixel on 
the uniform attenuation map a correction coefficient is calculated at each 
projection / angle based on its distance from the circumference boundary (d1, 
d2, d3 are shown as examples of this in Figure 15). An average is taken of these 
values and applied to the pixel, see Equation 2.  
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where µ is the attenuation coefficient of water, dn is the distance a photon will 
travel between any given pixel within the circumference and any given point on 
the edge of the circumference (see Figure 15) and n is the number of 
projections / angles 
Thus a new non uniform map is produced (Step 3 Figure 15).The corresponding 
transverse slice is then multiplied by this MU map and the corrected slice/image 
created (Step 4 Figure 15) (Hutton, 2002).  
Patients, however, are not made up entirely of water but are comprised of bone 
(which is dense) and lungs (which are full of air) both of which are at either end 
of the spectrum in terms of attenuation. Therefore this technique can provide 
either an under or over estimate of the counts in each pixel depending on the 
part of the body being imaged. 
SPET CT has allowed the use of a CT attenuation map to permit actual measured 
values of attenuation coefficient for each patient to be used. In addition, the 
increased use of iterative type reconstruction algorithms means that these can 
be informed with the information about attenuation leading to what in theory 
should be a much better image representation of the patient, see Chapter 3 
section 3.1.2.1.  
1.2.2.4  Image Registration 
Image  registration  is  a  very  useful  tool  in  enabling  the  comparison  of  two 
volumes  on  a  slice  by  slice  basis.  This  is  an  optional  processing  step  and  is 
performed using the reconstructed data.  
This technique can be used to compare, for example, two reconstructed SPET 
volumes, or a CT with a SPET volume. The image registration process simply 
transforms one volume to match another.  
All image processing and review at Glasgow Royal Infirmary, is performed on the 
Hermes system. The Hermes system uses two approaches to image registration: 
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1.  Automated 
2.  Manual 
The automated approach employs a ‘multi-resolution technique’. This technique 
essentially blurs the image i.e. reduces image resolution. It then tries to look for 
similar small volumes that are of a similar shape and size within the main 
volume and calculates the difference between them. The technique then adjusts 
this second volume to match the first (1 iteration). A number of iterations are 
performed each time increasing the overall image resolution and therefore fine 
tuning the technique.   
The manual approach allows the user to identify and define specific landmarks 
on one volume via crosshairs and co-locate these landmarks on the 
corresponding slice on the second volume, again via the placement of crosshairs. 
The second volume will therefore be shifted to match the first by matching the 
position of the crosshairs.  
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1.3 Role of image quantification  
There are several important areas where specific quantification of an image is 
vital. Usually these are related to treatment response or treatment planning.   
Historically, image quantification has been used in the planning for thyroid 
iodine treatment, and for treatment planning and response to for example 
mIBG. This has been used extensively in planar images for many years. This 
technique is reproducible and easy to perform in a general nuclear medicine 
department. 
At present cardiac imaging is the only investigation which relies on 
quantification from SPET reconstructed images and this quantification forms an 
integral part of many Nuclear Cardiology reports. There are a number of factors 
which can be quantified from cardiac perfusion studies; including regional 
myocardial perfusion, perfusion defects and left ventricular size and function. 
All of these are assessed via relative differences in perfusion distribution of the 
myocardium between end-diastole and end-systole or between rest and stress 
states. (Hesse, 2005).  However, quantification of uptake from other SPET 
investigations, and in particular, in the form of an absolute value of activity, 
has not been extensively used. Filtered back projection data is inherently noisy 
making quantification unreliable and this is probably the reason that more data 
are not available investigating SPET quantification. Only the advent of 
commercially available iterative reconstruction algorithms has led to the 
possibility of accurate image quantification. In addition, as mentioned 
previously, the ability to use SPET CT data to allow non-uniform attenuation 
correction has meant that systems are now available which in theory should 
provide a suitable reconstructed data set for quantification.    
The usefulness and the role of SPET quantification has not been fully exploited 
and therefore has, as yet, to be clearly defined. Very little has been published 
looking at SPET quantification in terms of treatment planning or response. 
The purpose of this work was to investigate the role of SPET image 
quantification in the diagnosis and subsequent management of patients. Work 
has been undertaken on image data from patients with suspected Non Small Cell Chapter 1     46 
Lung Cancer. During the timescale of the work detailed in this thesis, hybrid 
systems (SPET -CT Units) became widely available for the first time which led to 
one of these units being installed in the site where this investigation was 
carried out in 2007. SPET - CT units have since had a significant impact on the 
way in which patients are imaged in Nuclear Medicine in terms of additional 
anatomical information and also the promise of improved image quality with 
respect to tomographic imaging via the use of CT attenuation correction and 
other corrections available in the software. This therefore prompted questions 
as to the extent to which the reconstructed image quality could be improved 
and what, if any, impact this would have on the accuracy of tomographic image 
quantification.  
The data set of non-small cell cancer patients which formed the basis for the 
first part of work within this thesis was complete prior to the installation of the 
SPET CT unit. However many of the questions raised by these data suggested 
that attenuation correction using non-uniform attenuation maps generated from 
CT might improve the data. In an effort to try and answer some of these 
questions it was necessary to find data which could be used for this. It was 
reasonable to assess such factors using OctreoScan patients since these patients 
have SPET imaging performed of the pelvis and abdomen, as standard, whilst 
some patients have further imaging taken of the chest. In addition the agent 
used for these patients was very similar to that used for the lung cancer 
patients, albeit targeting a different cancer set. 
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1.4 Aim of this thesis 
The initial aim of this study was to investigate the ability to use quantitative 
values from SPET images to determine whether these could be used to aid 
definitive diagnosis and predict or measure response to any intervention.  There 
has been no significant published work looking specifically at SPET image 
quantification in this context. 
Unfortunately, midway through the original work, the license for NeoSPECT, the 
radiopharmaceutical being used was bought over by another company. As a 
result NeoSPECT was removed from the market for a substantial period of time. 
As a result the original number of 50 patients anticipated for the study was not 
achieved.   
In addition, during the period of time when NeoSPECT was unavailable a SPET-CT 
system was introduced within Glasgow Royal Infirmary. Along side the 
introduction of image capture on computer, the introduction of SPET-CT has 
been the most major advance in the nuclear medicine technology field since 
Anger’s original work in the 1960s. Many of the drawbacks associated with 
nuclear medicine images are theoretically addressed by the use of hybrid 
imaging and it was important for a thesis on this subject to consider these and 
determine whether the use of a hybrid system was able to address some of the 
inadequacies.    
Due to SPET-CT’s infancy an opportunity was realised that allowed some of the 
postulated solutions to the pitfalls identified from the original SPET 
quantification work to be investigated further and comparison to be drawn 
between quantification of SPET with a SPET-CT data set. 
To this end, the work presented in this thesis attempts to investigate 
quantification of both SPET alone, and SPET-CT images, in the diagnostic use of 
somatostatin receptor imaging.48 
Chapter 2 - NeoSPECT  
Currently, patients who have resectable lung cancer, that is, lung cancer that 
may be treatable by surgery, will undergo surgical staging by mediastinoscopy 
before definitive resection. In the past 10 years, many more therapies have 
become available to treat disease both in the lung and more specifically within 
the mediastinum.  There is, therefore, an increased need to determine whether 
these new treatments are effective in individual cases. Nuclear medicine 
imaging is functional, and it would seem reasonable to use functional imaging 
such as SPET (Single Photon Emission Tomography) or Positron Emission 
Tomography (PET) to determine disease progress and to predict therapy efficacy 
since anatomical imaging will miss any subtle changes in function. 
PET imaging using 
18F Fluro-deoxy-glocose (FDG) has been shown to offer 
benefits over CT (which is an anatomical imaging modality) in terms of nodal 
staging of bronchial carcinoma. In a meta-analysis by Dwamena et al. (1999), the 
mean sensitivity and specificity were reported as 79% and 91% for PET and 60 
and 77% for CT.  When the work for this thesis began, there were only six PET 
scanners in the UK. These scanners were often used primarily for research and 
had significant running costs. Due to a large NHS capital injection, the number of 
PET scanners has risen dramatically within NHS departments in the last few 
years but there are still major restrictions placed on those patients who can 
have a PET scan because of limited availability. The cost of these scans remains 
relatively high when compared with SPET. In 2011, the typical cost of a PET-CT 
scan performed by Greater Glasgow and Clyde NHS health board was in the 
region of sixteen hundred pounds whilst a SPET-CT can range between five to 
seven hundred pounds (Dr J Dennis & Dr A Bolster, personal communication). 
A widely available, inexpensive, non-invasive tool to accurately stage patients 
with lung cancer is required to benefit both the patients and also from a health 
economic point of view to best target therapy. 
99mTc labelled Depreotide 
imaging (NeoSPECT), may offer such a tool. The radiopharmaceutical marketed 
as NeoSPECT is presently licensed only for the assessment of solitary pulmonary 
nodules. Images for this purpose are obtained using a gamma camera and can be Chapter 2    49 
used to measure tissue uptake of the depreotide. Depreotide, as described in 
Chapter 1, is a 10 amino acid peptide that binds with high affinity to certain 
subtypes of somatostatin receptors (SSR’s). Several malignant processes 
(including small and non-small cell lung cancer) and some benign processes 
hyper-express varying subtypes of the SSR’s. NeoSPECT has been shown to have 
high sensitivity (96.6%) and reasonable specificity (73.1%) in detecting malignant 
pulmonary nodules (Blum, 2000). There is conflicting evidence, however, as to 
its use in assessing potential hilar and mediastinal nodal involvement. Despite 
small studies showing sensitivities of 81-100% and specificities of 80-86% 
(Berkowitz, 2001; Waxman, 2002), there is no available convincing data on which 
to base clinical decisions. In addition, there is no standard technique available 
which has good reproducibility and accuracy and can be used to quantify and 
measure changes in these types of functional images. 
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2.1 Literature Review  
To date, the literature is supportive of the use of 
99mTc labelled depreotide as a 
non-invasive diagnostic tool in the differentiation of benign disease from 
malignant solitary pulmonary nodules (SPN). 
Dwamena et al. (1999) demonstrated that functional imaging using FDG PET was 
significantly more accurate than CT for the characterisation of mediastinal 
nodes in patient with Non Small Cell Lung Cancer, NSCLC. 
Blum et al. (2000) performed 
99mTc labelled Depreotide SPET acquisitions on 114 
patients with solitary pulmonary nodules of less than or equal to 6cm as seen on 
a chest x-ray. These patients had demonstrated an absence of any benign 
pattern of calcification on CT and also showed no demonstrable radiographic 
stability during the 2 years prior to the study. All of the 114 patients had a 
NeoSPECT scan (
99mTc-Depreotide SPET Scan) performed and subsequently 
underwent histological examination. The SPET images were reported by 3 
nuclear medicine specialists who were blinded to the histological findings and 
gave each scan a positive or negative scoring based on the presence or absence 
of a region of intense tracer uptake in an area corresponding to the SPN region 
shown on the chest x-ray. The final score allocated to each patient was taken as 
being the majority score between observers, this was then compared with the 
histological findings. 
Histological findings showed that of the 114 patients involved, 88 were found to 
have a histological result compatible with malignant neoplasm. Of the 88 
patients the NeoSPET images correctly identified 85 with 3 false-negative 
determinations when comparison was made with the histology report. 7 false 
positive determinations were demonstrated of which 6 were granulomas and one 
hamartoma. The NeoSPECT scan correctly excluded malignancy in 19 of the 26 
patients who had benign histological findings. These finding gave a sensitivity of 
96.6% with a specificity of 73.1%. 
Blum et al. (2000) concluded that 
99mTc-Depreotide SPET scanning was a safe 
and useful method in the non-invasive investigation of solitary pulmonary Chapter 2    51 
nodules with sensitivity comparable to fluorine-18 fluordeoxyglucose (FDG) 
positron emission tomography (PET).  
Work presented by Berkowitz et al. (2001) showed that for SPN the sensitivity of 
NeoSPECT was 94% and specificity of 78%. These investigators also quoted 
sensitivity and specificity of NeoSPECT for hilur and mediastinal disease to be 
100% and 80% respectively.  
Waxman et al. (2002) concluded NeoSPECT to be a sensitive agent for the 
detection of lymph node metastasis in the hilum and mediastinum, with 
specificity by site which was clinically acceptable.  
Recent research within nuclear medicine has been heavily driven towards PET 
imaging and the use of F-18 FDG and other agents in tumour localisation and 
quantification. Research has demonstrated PET imaging to be extremely 
effective in tumour localisation and is now considered by many to be the gold 
standard imaging tool in the detection and staging of many cancers. Availability 
of PET imaging facilities is, however, very limited in Britain, in fact up until 2008  
Scotland did not have a clinically run PET service and whilst England had some 
PET centres, access to such facilities was dependant upon a patient’s 
geographical location and was subject to large waiting lists. 
Kernstein et al.(2001) presented work comparing PET imaging of the 
mediastinum with SPET imaging and found SPET to be just as effective at 
differentiating between benign and malignant disease in terms of sensitivity and 
specificity. This is good news for patients who require such a service, as most 
general nuclear medicine departments are capable of performing SPET imaging. 
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2.2 Pan Glasgow Study - Depreotide Imaging   
The work of this section of thesis focussed on a pan-Glasgow study which was 
undertaken to investigate the role of NeoSPECT (depreotide) imaging in the 
staging of lung cancer by means of a prospective, multicentre trial based within 
the West of Scotland. A copy of the local research ethics committee at GRI 
approval notice can be found in Appendix A. Two groups of patient were 
included in the trial; 
Group 1 - Patients who required mediastinoscopy
2 to determine if lung cancer 
had spread to the lymph glands.  
Group 2 - Patients with lung cancer going forward for surgery to remove the 
lung or part thereof. These patients had samples of lymph glands taken during 
their operation as part of routine clinical care to make sure the cancer had not 
spread to the lymph glands.  
Patients were identified at multidisciplinary lung cancer meetings held 
throughout the West of Scotland. Patients eligible to take part in the study were 
those identified as having potentially curable lung cancer and/or patients with 
equivocal mediastinal lymphadenopathy, requiring further classification.  
Patients who were not considered eligible for the study were those who had 
undergone cardiothoracic surgery in the preceding 2 months, had previous 
radiotherapy to the thorax or previous surgery for lung cancer or tuberculosis, 
previous antituberculous chemotherapy (in the last 2yrs), previous systemic 
chemotherapy for intra-thoracic malignancy, pregnancy, known contrast allergy, 
lung lesions greater than 1cm in diameter or those already taking part in any 
other clinical trials.  
The consultant in charge of the patient’s care was then responsible for selecting 
which of their patients would be suitable to be included in the trial. Patient’s 
suitability being paramount since the patient would be required to spend a 
significant amount of time being imaged. The trial involved an injection of the 
                                         
2 Mediastinoscopy is a surgical procedure which takes samples of the lymph glands situated in the 
chest behind the breast bone to determine if there is disease present. Chapter 2    53 
radiopharmaceutical - NeoSPECT, see section 1.1.2.1 of Chapter 1 for details - 
SPET imaging of the thorax and planar images of the abdomen. Both the SPET 
and planar images were acquired at two discrete time points post injection 
namely 2 hrs and 4 hrs. Imaging at two discrete time points post injection 
allowed changes in the distribution of uptake over time to be identified and 
investigated to determine if this helped characterise the disease process.    
To assess the role of NeoSPECT imaging qualitatively, the images acquired were 
reviewed along side the conventional CT scan images used for staging, thus 
allowing any additional information provided by NeoSPECT to be identified and 
its value determined.  
2.2.1 Aim 
The main aim of the study was to determine whether NeoSPECT could be used to 
accurately stage disease in the mediastinum. In addition, dual time point 
imaging was included in the protocol to determine whether this aided disease 
diagnosis or patient prognosis. 
The most exciting aspect of this research proposal lay in the lack of published 
literature available both qualitatively and more specifically quantitatively. This 
was indicative of a need for further investigation which would hope to exploit all 
characteristics of the radiopharmaceutical through investigation of the imaging 
parameters and reconstruction techniques.  
To date, none of the published literature discusses or demonstrates any 
reproducible technique, which could be used quantitatively to monitor the 
response of the mediastinum to chemotherapy treatment, or that would allow 
staging of disease in the mediastinum. It was therefore clear that further 
research was required in order to define the role of NeoSPECT imaging in the 
assessment of disease in the mediastinum.  
This project investigated techniques to determine absolute uptake in a 
reproducible and useful fashion which could then be used to determine any 
significant changes.  Chapter 2    54 
For each patient SPET and planar data were acquired (discussed in more detail 
in section 2.4). In addition to the SPET data acquired for patients, each patient 
data set were accompanied by an acquisition of a standard source so that this 
could be used for quantification. 
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2.3 Optimisation of reconstruction techniques and 
reproducibility using NeoSPECT Phantom 
Acquisitions 
Phantoms allow workers in nuclear medicine to develop acquisition and analysis 
procedures without the need for exposing patients to radiation. It is important 
to make the parameters used for the phantom acquisitions as near the clinical 
situation as possible.  
There were 2 phantoms used to assess and validate the NeoSPECT work, the first 
was the RSD (Radiology Support Devices) (RSD, 2010) anthropomorphic thoracic 
phantom as shown in Figure 16 and the second was an in-house designed and 
manufactured phantom, see Figure 17.  
Components of the RSD anthropomorphic phantom were considered tissue 
equivalent in accordance with the International Commission on Radiation Units 
and Measurement Report No. 44. and anatomically correct; further information 
about this phantom can be found at www.rsdphantoms.com, supported by a 
number of references detailed on the website. The phantom contained a bone 
component to replicate thoracic skeleton including vertebrae and rib cage , and 
was hollow to allow fillable organs to be inserted for example lungs, heart, liver. 
 
Figure 16 - Anthropomorphic Thoracic Phantom  
Image showing the RSD anthropomorphic thoracic phantom, the phantom contained all the 
major organs found in the thorax (Bone, lungs, heart, and liver).  Chapter 2    56 
The body of the phantom was made from polyurethane, which was modified to 
produce a tissue equivalent material with a mass density of 1.10g cc
-1 and a 
linear attenuation coefficient of 0.160cm
-1 for 
99mTc. 
RSD stated that the components used in the thoracic skeleton closely met the 
values of mass densities quoted in a report by the International Commission on 
Radiation Units and Measurement (ICRU, 1989), which are quoted for both 
cortical and spongiosa components of the human skeleton as 1.88gcc
-1 and 1.16g 
cc
-1 respectively, (RSD, 2010). The cortical bone component of this material 
demonstrated a linear attenuation coefficient of 0.280cm
-1 for 
99mTc. 
Although liver, heart and lung inserts were available, the only organs used were 
the lungs and heart inserts. The lungs were hollow shells that were filled with 
Styrofoam beads; these mimicked the air occupancy within the lungs. In addition 
to the Styrofoam beads these shells could also be filled with a radioactive 
solution which provided an overall mass density of 0.4gcc
-1.   
The second phantom used was an in-house phantom. The design for the in-house 
phantom was born out of limitations in the RSD phantom in that there was no 
mechanism for adding/creating an abnormal area within either lung volume to 
mimic lung tumour tissue.   
 
Figure 17 - In-house designed Phantom 
Image showing the in-house designed lung phantom; this phantom contains two main 
chambers (left and right lung) which allowed additional volumes to be added to each lung 
chamber to simulate tumour volumes.  
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The in-house phantom was made from moulded perspex and contained two 
hollow inserts which were filled with polystyrene balls to replicate the air within 
the lungs. The size of the hollow inserts were based on values quoted in the 
“Report of the Task Group on Reference Man” (ICRP Task Group), whilst the 
thickness of Perspex used was based on the resolution of the gamma camera, 
that it is no thicker than 10mm. 
To achieve and replicate an abnormality in the lung, each insert contained a 
small aperture on its anterior face where a small vial could be inserted (one was 
located in what would be the right lung apex and one in the base of the left 
lung). These small vials could be easily filled with known quantities of activity. 
The actual phantom manufactured is shown in Figure 17.  
Phantom work was undertaken for the following reasons: 
1.  To optimise acquisition and reconstruction parameters of the standard 
volume. 
2.  To determine reproducibility and hence to determine the smallest 
significant difference which could be detected between the two time 
points. These differences might be due to experimental setup of the 
orbit, or simply because of the statistical fluctuations in the counting 
statistics. 
3.  To determine an accurate method of calculating the activity within a 
specific tissue or organ. This involved an acquisition of both a standard 
volume of known activity and an acquisition of the phantom with the 
components filled with known activities of radioisotope - these activities 
were as close to activities demonstrated in patient investigations as 
possible. 
The following sections and subsections detail this work both in terms of image 
acquisition and reconstruction.  
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2.3.1 Optimisation of NeoSPECT Standard Acquisition and 
Reconstruction Parameters   
For quantification of nuclear medicine images, standard acquisitions are often 
acquired. These are images of a known activity and volume and are usually 
acquired under the same conditions as the patient. A standard (STD) acquisition 
is essential for image quantification in order to translate counts into an 
appropriate value of activity which is often expressed as percentage uptake. It 
was also important to undertake work to ensure that the set-up, acquisition and 
reconstruction parameters for the ‘Standard’ were appropriate and close to 
those of the patient acquisitions since these formed the basis for the image 
quantification. 
The patient area of interest, the thorax, is comprised of many different 
components including bone, muscle, soft tissue and air.  Each of these 
components has different attenuating properties. It is important for true 
quantification that the STD acquisition should mimic that of the patient. 
However as camera time is at a premium in a busy department, it was important 
to determine whether a reduction in acquisition time for the STD only was 
possible. To simulate the attenuation of the photons within the actual patient, 
the STD volume was placed in a perspex phantom (see Figure 16 of section 2.3) 
which contained bony structures and had lung inserts containing polystyrene 
beads to mimic the air space of lungs.  
The STD volume was placed in between the two lung inserts to mimic as best as 
possible the attenuation of a lung lesion.  The phantom includes the spine and 
ribs and therefore mimics this attenuation.  The removable breast tissue from 
the phantom was not used to standardise the acquisition for both male and 
female. 
The following acquisition and reconstruction variables were investigated: 
Investigation 1  Frame time; reproducibility of 3 sec STD acquisition frame. 
Investigation 2  Influence of attenuation correction on STD reconstructed 
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2.3.1.1  Methods for Investigation 1 - Reproducibility of 3 Sec STD 
Acquisition 
Each patient had data acquired over 360 degrees using 2 gamma camera heads 
(180 degrees each), each frame was acquired for 30 seconds. The duration of 
each frame is important as this ensures that the images acquired are statistically 
sufficient in counts and thus produce high quality images both quantitatively and 
qualitatively. 
A frame time of 30 seconds resulted in a total patient acquisition time of 30 
minutes (excluding set up time). Whilst this was acceptable for a patient 
acquisition it was considered too lengthy for a non-patient acquisition in a busy 
patient department. Consideration had to be given to reducing the frame time 
to a value that would not disrupt the patient flow in a busy department but 
would maintain statistical stability in terms of counts and image quality. The 
frame time for the STD acquisition only was reduced to a tenth of the patient 
acquisition frame time that is from 30 second to 3 seconds. To assess whether or 
not 3 second frames would produce images statistically sufficient in counts the 
repeatability of the measurement was assessed. 
The STD acquisitions were performed using a source of known activity placed in 
the phantom as described in section 2.3 for this purpose the phantom was used 
simply to mimic the attenuation of a human thorax. A small plastic vial 
containing approximately 5MBq of 
99mTc was used as the standard (STD) - see 
Figure 18. It should be noted that neither the lungs nor the thoracic cavity were 
filled with a radioactive solution. For the purpose of illustrating the edge of the 
phantom in Figure 18, a number of radioactive wraps were placed over its 
surface, this form of edge delineation was not used in the actual acquisitions 
which formed the analysis.  Chapter 2    60 
 
Figure 18 - Planar view of a typical standard acquisition 
Image showing the standard volume placed centrally within the RSD anthropomorphic 
thoracic phantom, equivalent to a patient lying supine on the imaging couch. 
 
A total of 10 consecutive acquisitions were performed - there was no 
repositioning of the standard between acquisitions. The acquisition parameters 
are described in Table 9.   The gamma camera used for all the work within this 
chapter was the Philips Forte camera (previously sold by ADAC).   It is a double 
headed large field of view gamma camera (500mm x 370mm field of view).  The 
collimator used was the VXHR, this is a parallel hole, low energy, high resolution 
collimator with longer bore septa.  It is designed for use with Krypton but it’s 
sensitivity and resolution compare well with other manufacturer’s LEHR (low 
energy high resolution) collimators. 
Collimator:  VXHR 
Degrees of Rotation :  Non-circular, 
360 degree acquisition using 2 heads (180 degrees per head) 
Frame time:  3 seconds 
Interval:  3 degrees 
Energy Window (keV):  10% window on 140 
Matrix:  128 x 128 
Set Up @:  
0 & 180 degrees 
 
For the purpose of these acquisitions the heads were set round the circumference of 
the phantom. 
Table 9 - Acquisition Parameters 
 
Each acquisition was reconstructed using the predefined parameters described in 
Table 10. 
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Reconstruction Method:  Iterative HOSEM – Hermes Ordered Subset Expectation Maximisation 
Protocol:  NeoSPECT 
Number of slices:   16 (STD counts > BKG counts) 
Start slice:  42 
Filter:  Low Pass with cut-off 1.5 cycles/cm 
Iterations  4 
Subsets  6 
Zoom:  No Zoom 
Table 10 - Reconstruction Parameters 
 
The reconstruction parameters used in the patient protocol ‘NeoSPECT’ will be 
described later in Table 23 of section 2.4.1. To assess reproducibility, each 
acquisition was analysed quantitatively using region of interest analysis. Using 
the reconstructed data, regions were drawn on the transverse plane of the 
images; one around the standard and one around an appropriate area of 
background as shown in Figure 19. 
 
Figure 19 - Transverse Slice of STD ROIs 
Image showing a reconstructed transverse slice of the standard volume with regions of 
interest depicted by arrows. 
 
These regions were saved and copied onto each transverse slice in turn, 
throughout the total reconstructed volume. The saved regions were uploaded 
and applied to the remaining 9 acquisitions in a similar way to allow a 
comparison to be made. 
2.3.1.2  Results for Investigation 1 - Reproducibility of 3 sec STD Acquisition 
From the regions of interest, values of total counts and number of pixels were 
extracted. The standard volume was visualised on 16 slices in the transverse 
plane, Table 11 details the total counts per slice per acquisition. The value of 
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total counts from the ‘standard ROI’ was corrected for background by applying 
area normalisation to the background region as described in Equation 3. 
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where CCor is the counts corrected for background, CBKG is the counts from 
background, ABKG is the area of the background ROI, CSTD is the counts from the 
standard, ASTD is the area of the standard ROI. 
For a more accurate comparison a decay correction was also applied to the total 
counts from STD acquisitions 2 -10, as described in Equation 4 and 5. 
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where A is activity at the image time, A0 is the original activity at time zero 
(time of measurement), t is the difference in time from the time of 
measurement to time of imaging, and T is the half life of the isotope which for 
Tc99m is 6 hours. 
  STD 1  STD 2  STD 3  STD 4  STD 5  STD 6  STD 7  STD 8  STD 9  STD 10 
Slice 42  865  453  498  462  498  412  561  533  423  415 
Slice 43  2606  1682  1526  1823  1582  1637  1608  1648  1534  1523 
Slice 44  4797  3819  3656  4136  3404  3540  3578  3177  3419  3400 
Slice 45  6575  5748  5958  5774  5118  5145  5416  5037  5076  5243 
Slice 46  7227  6797  6964  6521  6177  5952  6114  6544  5761  6178 
Slice 47  7137  7417  7144  6935  6725  6494  6420  6738  6056  6297 
Slice 48  7368  7557  7348  7008  6875  7075  6751  6473  6473  6313 
Slice 49  7761  7225  7182  7031  6832  7298  6656  6729  6477  6495 
Slice 50  7505  7209  6807  7126  6962  6872  6357  6685  6279  6549 
Slice 51  7236  7518  7075  6923  7095  6428  6380  6258  6383  6332 
Slice 52  7043  7158  7154  6504  6621  6307  6436  6202  6078  5779 
Slice 53  5980  6089  6156  5900  5617  5969  5956  5847  5180  5170 
Slice 54  4213  4890  4701  4725  4487  4712  4705  4466  4289  4513 
Slice 55  2668  1820  3262  3314  3263  3185  3109  2892  3134  3253 
Slice 56  1403  1820  1845  2048  1872  1844  1880  1653  1661  1581 
Slice 57  383  650  645  859  671  781  868  682  626  506 
Total  80767  79459  80849  81268  79054  80167  80573  80379  78605  80674 
Table 11 - Repeatability of 3 sec Acquisition 
 
The last row on the table is the sum of the total counts over the complete 
standard volume.  Chapter 2    63 
A mean of the sum of the total counts value was taken and the standard 
deviation calculated; 80179 ± 862 (2.15%). The trend in values is demonstrated 
in Figure 20.  
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Figure 20 - Graph of Variation in Total Cts per Acquisition 
The graph shows the plot of the sum of the total counts obtained from ROIs placed on the 
transverse slice containing the standard volume for each acquisition (green line) and the 
upper and lower 2x standard deviations (red and blue lines respectively).  
  
From Figure 20 it can be seen that the total counts for the acquisitions lie 
within +/- 2 standard deviations.  
2.3.1.3  Methods for Investigation 2 - Influence of Attenuation Correction on 
STD Reconstructed Data 
In addition to optimising the STD acquisition parameters, it was also important 
to ensure that the reconstruction parameters of the STD matched those of the 
patient and were appropriate. This included establishing whether or not to use a 
geometric attenuation correction on the STD data. A total of 18 patients had a 
standard acquisition i.e. an acquisition of a vial of known activity used to 
calculate sensitivity, performed along with their diagnostic study. The 
reconstruction of the patient data included the use of a geometric attenuation 
correction which was mapped to the circumference of the patient.   Chapter 2    64 
It was important to assess the influence this correction would have on the 
reconstructed data and what impact this would have on quantitative analysis, 
that is the sensitivity and the subsequent calculation of uptake. This was 
undertaken by using the acquisition data from the 10 consecutive STD 
acquisitions performed in section 2.3.1.1, this data were subsequently 
reconstructed with and without an attenuation correction using the parameters 
detailed in Table 10.  
Figure 21 shows a transverse slice of the STD, the Standard volume being the 
most central of the hot areas on the slice. 
 
Figure 21 - Attenuation Circumference Delineations 
The image shows a transverse slice of the standard volume (centrally) and the markers to 
define the outer edges of the phantom as shown by the red and blue arrows. required for 
the attenuation correction,  
 
To identify the surface of the phantom a number of small radioactive markers 
were placed on the outside body of the phantom - these are indicated by the red 
arrows. These markers allowed the circumference of the phantom to be 
identified shown with the blue arrow. This allowed an ellipse to be drawn where 
everything inside the ellipse was corrected for attenuation using a Chang’s 
correction - see Chapter 1 section 1.2.2.3 for details. This correction assumes 
uniform attenuation within the defined circumference and the attenuation co-
efficient for water is usually used. On the Hermes system this is set as 0.12 cm
-1 
for 
99mTc.  Chapter 2    65 
The ROIs are shown in Figure 19. ROIs were drawn on all slices on which the 
standard volume was identified. These regions were saved and applied to each 
transverse slice, throughout the total volume of the standard.  
2.3.1.4  Results for Investigation 2 - Influence of Attenuation Correction on 
STD Reconstructed data 
From the regions of interest, values of total counts and number of pixels were 
extracted for both reconstructed data sets and on both reconstructed volumes 
(with and without attenuation correction). The standard volume was visualised 
on 16 slices in the transverse plane. The value of total counts from the ‘standard 
ROI’ was corrected for background by applying area normalisation to the 
background region as described by Equation 3.  
The values of total counts were then summed over the entire volume of the 
standard. There was a period of ninety minutes between the first and last 
acquisition therefore values of total counts were corrected for decay using 
Equation 4 and Equation 5 to allow a direct comparison. Figure 22 
demonstrates the influence of the application of attenuation correction on the 
counts in this standard volume.  
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Figure 22 - Graph of Influence of Attenuation Correction Chapter 2    66 
The graph shows plots of the total counts from the standard volume obtained from ROIs 
placed on the transverse slice for each acquisition; image data corrected for attenuation 
correction are shown by the blue points and trendline whilst image data with no attenuation 
correction applied is shown by the red points and trendline. 
 
Whilst the trend in total counts within the ROIs was the same there was a 
significant difference in magnitude of the total counts, a ratio of total counts 
from the attenuation corrected volume to the non-attenuation corrected volume 
of approximately 4:1 was observed.  
Differences in the value of total counts between the two reconstruction 
techniques are detailed further in Table 12.  
Table 12 - Difference in Total Counts per acquisition 
 
The number of slices over which the standard was visualised did not differ 
between reconstruction techniques only between acquisitions which could be 
accounted for by slight variations in the transverse position of the bed.  
From the values of the total counts, length of acquisition and activity in the 
volume the system sensitivity was found. The average of this value over the 10 
acquisitions was calculated as 40 cps per MBq (SD of 0.4) and 167 cps per MBq 
(SD of 2.0) for the non-corrected and corrected data respectively - details of the 
calculation of sensitivity can be found in section 2.3.2.3 - Equation 6. 
  STD 1  STD 2  STD 3  STD 4  STD 5  STD 6  STD 7  STD 8  STD 9  STD 10 
Slice 1  2764  1428  1495  1431  1469  1286  1636  1666  1332  1328 
Slice 2  8246  5178  4734  5749  4926  5165  4997  5192  4825  4830 
Slice 3  15129  12050  11537  13099  10699  11074  11332  10026  10712  10816 
Slice 4  20753  18150  18786  18190  16072  16139  17073  15877  15994  16618 
Slice 5  22727  21399  21994  20508  19479  18770  19268  20508  18195  19545 
Slice 6  22474  23355  22463  21948  21284  20439  20280  21218  19123  19898 
Slice 7  23295  23780  23145  22049  21635  22302  21284  20390  20408  19972 
Slice 8  24390  22659  22529  22060  21413  22920  20947  21030  20314  20405 
Slice 9  23532  22567  21319  22379  21833  21506  19969  21074  19650  20485 
Slice 10  22679  23496  22040  21672  22115  20005  19940  19501  19890  19767 
Slice 11  22033  22356  22349  20323  20627  19610  19968  19304  18909  18059 
Slice 12  18572  18870  19233  18280  17423  18404  18476  18138  15961  16123 
Slice 13  13040  14980  14531  14535  13790  14495  14502  13772  13165  13967 
Slice 14  8271  12343  9986  10238  10016  9802  9515  8861  9594  10054 
Slice 15  4359  5551  5611  6324  5736  5667  5806  4996  5105  4924 
Slice 16  1280  1968  1985  2690  2072  2408  2704  2058  1945  1569 
Total  253545  250131  243738  241476  230589  229994  227697  223612  215121  218363 
Total 
(decay 
Cor) 
253545  255288  252901  254566  247004  250336  252030  251157  245599  253300 Chapter 2    67 
2.3.1.5  Discussion  
The data contained in the results section above is not that of the original 
analysis but has been corrected for a scaling factor present in some of the 
standard data reconstructions.  It is worth mentioning that original analysis in 
section 2.3.1.2 of the 10 consecutive acquisitions highlighted that in some of 
the standard acquisitions there seemed to be a significant difference in the total 
number of counts within the standard volume. This was unrelated to the natural 
decay of the isotope with the total counts being either doubled or halved from 
the expected value.  
A similar anomaly was also observed when comparing the corrected versus the 
non-corrected count data - section 2.3.1.4. For a large number of the 
reconstructions the value of sensitivity calculated for the corrected and non-
corrected were the same. Interrogation of the header file information of the 
reconstructed data highlighted a factor applied to some of the reconstructions 
which was independent to the use of an attenuation correction although the 
factor was seen more in the attenuation corrected volumes.  
This correction factor was called an ‘RPAH Scale factor’ (Royal Prince Albert 
Hospital), on investigation it was found that this factor was a feature of OSEM 
reconstruction and was used when the number of counts per pixel exceeded +/- 
32000. The RPAH factor essentially corrects for pixel saturation and therefore 
affects the count statistics which has a subsequent affect on both image contrast 
and on any value of sensitivity calculated. Unaffected data was assigned a scale 
factor of 1 whilst the value of the scale factor used ranged between 0.10 and 
0.57 for the data affected. A review of all SPET data discussed in the thesis 
demonstrated that none of the actual reconstructed patient data required the 
use of the RPAH factor and that the application of this factor was restricted to 
the Standard acquisition data. All ROI count statistics with an RPAH scale factor 
were corrected and restored by dividing the counts by the RPAH scale factor.  
The results demonstrate that repeated acquisitions under the same conditions 
gave reproducible quantitative values for counts within the standard volume. 
Total counts for each acquisition were all within +/- 2 standard deviations, that 
is ± 2.15%, which demonstrated reproducibility of measurement. Standard Chapter 2    68 
acquisition frames of 3 seconds were therefore considered to be acceptable 
showing stability of the resultant count statistics.  
The use of an attenuation correction in the reconstruction of the raw data gave 
on average an increase of 4:1 in the total counts demonstrated in the STD 
reconstructed volume of the standard.  
Since the standard reconstruction was used to define the sensitivity of the 
system, which in turn allowed quantification of areas of uptake to be calculated, 
the question over the use of attenuation correction is an important one. From 
the results in section 2.3.1.4 there is no way to determine whether or not the 
use of an attenuation correction would provide an accurate estimation of system 
sensitivity but instead to realise the implications of its use on the data. Using an 
attenuation correction produced a much larger value of system sensitivity in 
comparison to the non - corrected data. The use of the corrected sensitivity 
value could lead to an underestimation in the uptake and of course the use of 
the uncorrected sensitivity could lead to the over estimation of uptake. Further 
work with a phantom was required to determine which reconstruction technique 
provided the most accurate measure of system sensitivity - see section 2.3.2.3. 
The RPAH factor should also be considered when undertaking any quantification 
of iteratively reconstructed SPET data to ensure data are corrected or restored 
appropriately, particularly in the standard acquisitions where the small volume 
means that the image comprises only a very few pixels. 
 
2.3.2 Determining reproducibility and accuracy of quantification 
of 2 versus 4 hour imaging 
In order to establish how reproducible SPET imaging could be in evaluating and 
quantifying areas of uptake the in-house phantom was used. A retrospective 
review of normal NeoSPECT patient data was undertaken to try to determine 
typical lung to background ratios. This information along with the liquid volume 
of each component was used to help select appropriate activities and create 
radioactive solutions to fill each component. Chapter 2    69 
2.3.2.1  Methods 
The filled phantom along with 1 abnormality insert was placed on the imaging 
bed and left for an hour to allow the solution to equilibrate, see Figure 23.  
 
Figure 23 - In-house Phantom Filled 
Image showing a coronal slice of the in-house lung phantom filled with a 
99mTc solution, 
including an additional tumour insert placed in the apex of the right lung (left  on image 
volume).   
 
Table 13 details the activities in each insert/component at time of first set of 
imaging. 
  Body  Lung (right and left)  Abnormality/vial 
Activity (MBq)   458.7   176.6   0.54 
Volume (ml)   14500   700 & 650   1 
Table 13 - Activities and volumes used to fill the in-house phantom  
 
The phantom set up, acquisition and reconstruction had to replicate those of a 
patient. These are described in section 2.4.1 and summarised in Table 22 and 
Table 23. The phantom was imaged twice with a 2 Hour gap between the first 
and second acquisition. On completion of the first acquisition, the phantom 
remained on the imaging couch. Since there was no change to the phantom, any 
variations in T:Bs (tumour to background ratio – described in more detail in 
section 2.4.1) demonstrated were a combination of statistical variations and 
reproducibility of the AC correction and ROI analysis technique and not 
reproducibility of the set-up (this was therefore the minimum difference to 
expect). In reality for the patient data, the patient did not remain on the bed 
between imaging, therefore values of bed height, detector distance etc. were 
all noted and used to set up the second acquisition.  Chapter 2    70 
Both reconstructed data sets were viewed using ‘Volume Fusion Display’ on the 
Hermes system, which allows both reconstructions to be displayed 
simultaneously and registered. The focal area of uptake representing the 
abnormality was identified on both sets of images, and regions of interest, ROIs, 
were drawn on the transverse slices. Image quantification was in the form of: 
1.  Tumour to background ratio, T:B 
2.  Absolute Uptake (MBq and expressed as % uptake) 
For analysis of T:B values, ROIs were drawn around the abnormality and around 
an adjacent area which was representative of normal lung uptake (Background) 
as shown in Figure 24. For T:B ROI analysis the only stipulation on the 
placement of the background ROI was that it was consistent between the two 
sets of images. 
 
Figure 24 - Phantom Transverse Slices 0Hr versus 2Hr 
Images shown are reconstructed transverse slices through the in-house lung phantom. Also 
shown on each slice are the background (BKG) and tumour (TUM) ROIs used to calculate 
the T:B. The image on the left is a reconstructed transverse from the 0Hr acquisition whilst 
the image on the right is the corresponding slice from an acquisition performed 2 hours 
later.  
 
The use of a background correction is almost always applied to planar data since 
the total counts contained in a ROI usually contains a contribution of counts 
from adjacent and overlying organs/structures. The advantage of SPET imaging 
is that organs and structures in the body can be viewed without having to 
distinguish between uptake in an area of interest and an overlying organ. To 
assess the accuracy of calculating a value of absolute uptake from SPET imaging 
consideration had to be given to the use of a background correction. However, 
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since this relies on a background ROI an equally important factor was the 
placement of this ROI. As the main concern for SPET data arises from the 
contribution of counts from adjacent areas it would be more appropriate that 
the background ROI encompassed that of the tumour/vial as shown in          
Figure 25.  
 
         Figure 25 - ROIs for Uptake Analysis 
Images shown are reconstructed transverse slices through the in-house lung phantom. Also 
shown on each slice are the background (BKG) and tumour (TUM) ROIs used to calculate a 
value of percentage uptake. The image on the left is a reconstructed transverse from the 0Hr 
acquisition whilst the image on the right is the corresponding slice from an acquisition 
performed 2 hours later. 
 
For both assessments of quantification technique namely measurement of T:B 
and calculation of uptake values, values of total and maximum counts along with 
the number of pixels (area) were extracted from the ROIs. Data were obtained 
from all transverse slices which demonstrated the tumour vial.  
2.3.2.2  Results 1 - Assessment of tumour to background ratio T:B, 
reproducibility 
Tumour to background ratios, T:Bs were calculated using data from the 
reconstructed transverse slices. On the transverse plane the tumour/vial was 
identified on 3 slices on both the 0 hour acquisition and the 2 hour acquisition. 
Table 14 details the values of T:B calculated over the tumour/vial volume from 
the transverse plane. 
 
0 Hours  2 Hours 
TUM ROI 
BKG ROI Chapter 2    72 
Total Counts  Maximum Counts   
0 Hour ACQ  2 Hour ACQ  0 Hour ACQ  2 Hour ACQ 
Slice 55  1.15  1.13  1.61  1.42 
Slice 56  1.20  1.14  1.69  1.63 
Slice 57  1.07  0.95  1.35  1.28 
Table 14 - T:B calculated per transverse slice at 0 and 2Hrs. 
 
Using the values of total counts the maximum T:B calculated from the 0 hour 
acquisition was 1.20 and for the 2 hour acquisitions was 1.14, the maximum ratio 
for both acquisitions was found on slice 56.  
The maximum difference in T:B demonstrated between 0 and 2 hour acquisition 
was 0.07. Repeated reconstruction and analysis (x10) of the 0Hr acquisition 
demonstrated a maximum difference of 0.19 with mean a T:B of 1.22 +/- 0.02. 
Comparing the T:B calculated from maximum counts per pixel it can be seen 
that the maximum value of T:B calculated at 0 hours was 1.69 and at 2 hours 
was 1.63, whilst the maximum difference demonstrated was 0.06. 
2.3.2.3  Results 2 - Evaluation of uptake calculation and assessment of 
washout reproducibility 
To calculate a value of percentage uptake, a value of absolute activity in the 
area of interest/tumour must be calculated first. To assess the accuracy of this 
calculation with SPET data, the in-house phantom acquisitions described in 
section 2.3 were used along with data from a standard acquisition. The standard 
acquisition being used to calculate the sensitivity of the gamma camera. The 
standard was reconstructed with and without an attenuation correction (AC and 
non-AC). ROIs were drawn on the transverse slices, one around the standard vial 
and one over an area of background as shown previously in Figure 19.  
From the STD ROIs values of total counts and number of pixels were extracted. 
Since these ROIS differed in size the counts in the background ROI were 
normalised to the STD ROI as described by Equation 3.  Chapter 2    73 
Table 15 and Table 16 detail the counts demonstrated in each slice.  
  Standard Counts  Background Counts  BKG Corrected Counts 
Slice  44  1451  12  1439 
Slice  45  3822  9  3813 
Slice  46  6921  11  6909 
Slice  47  8923  7  8917 
Slice  48  9379  4  9375 
Slice  49  9612  6  9606 
Slice  50  9884  7  9878 
Slice  51  9397  8  9388 
Slice  52  8632  10  8621 
Slice  53  8306  18  8287 
Slice  54  7879  18  7861 
Slice  55  6693  4  6688 
Slice  56  4761  1  4760 
Slice  57  2638  4  2634 
Slice  58  1079  4  1075 
Slice  59  279  1  278 
Total  99655 
 
126 
 
99529 
 
Table 15 - Non-AC Recon Data 
 
  Standard Counts  Background Counts  BKG Corrected Counts 
Slice  44  7847  49  7799 
Slice  45  20647  45  20602 
Slice  46  37233  43  37190 
Slice  47  48071  25  48046 
Slice  48  50678  4  50673 
Slice  49  51720  25  51696 
Slice  50  53229  52  53178 
Slice  51  50774  38  50735 
Slice  52  46411  61  46351 
Slice  53  44559  94  44465 
Slice  54  42309  84  42226 
Slice  55  35957  23  35934 
Slice  56  25476  15  25461 
Slice  57  14144  33  14111 
Slice  58  5721  28  5693 
Slice  59  1468  4  1464 
Total  536245  622  535624 
 
Table 16 - AC Recon Data 
 
Values of standard counts and background corrected counts from each transverse 
slice for both AC and non-AC data were summed over the entire volume of the 
vial. These values were then used in Equation 6 along with length of acquisition 
and activity contained in the vial to calculate the sensitivity.  Chapter 2    74 
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where CSTD is the counts from the standard, TACQ is the sum of the length of the 
acquisition from each head (measured in seconds), ASTD is the measured activity  
of the standard.  
The activity in the standard vial at the time of imaging was 3.64 MBq, this was 
measured just prior to imaging using the Capintec isotope calibrator. Each frame 
was 3 seconds long with 120 frames acquired meaning the total duration of the 
acquisition was 360 seconds. Using these values the sensitivity (counts per 
second per MBq) was calculated - see Table 17. 
No Attenuation Correction  Attenuation Correction   
No Bkg Corr 
(c s
-1 MBq
-1)
 
Bkg Corr 
(c s
-1 MBq
-1) 
No Bkg Corr 
(c s
-1 MBq
-1) 
Bkg Corr 
(c s
-1 MBq
-1) 
Sensitivity  76  76  409  409 
Table 17 - Sensitivities 
 
The background activity can essentially be considered as being negligible 
relative to the STD volume activity as its subtraction has no reflection on the 
value of sensitivity calculated as demonstrated in Table 17.  
As with the standard data processing, the phantom was reconstructed with and 
without attenuation correction. The use of the background correction in 
calculating a value of absolute activity had to be considered and assessed.  
From the ROIs, values of counts and number of pixels were extracted. These 
values were used in Equation 7 to obtain a true value of background counts, the 
counts in the background ROI were corrected for tumour counts and then 
normalised to the tumour region. 
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Equation 7 Chapter 2    75 
where CBKG is the background counts, CBKG+T is the counts from the ROI containing 
both background and tumour, ABKG+T is the area of the ROI containing both 
background and tumour, CT is the counts from the tumour ROI, AT is the area of 
the tumour. 
Values of counts from tumour and background areas are given in Table 18, the 
value of counts in each slice were summed over the volume of the vial/tumour 
as shown in the last row.  
No Attenuation Correction  Attenuation Correction 
O Hrs ACQ  2 Hrs ACQ  O Hrs ACQ  2 Hrs ACQ 
 
BKG  Tum  BKG  Tum  BKG  Tum  BKG  Tum 
Slice 55  7437  14686  5819  11168  30201  61275  23424  46157 
Slice 56  7320  15415  5819  11616  30198  65959  23390  48806 
Slice 57  7313  12302  5428  9235  32512  56447  22237  39710 
Total  22070  42403  17066  32019  92911  183681  74051  134673 
Table 18 - Phantom Count Data 
 
The activity of the vial/abnormal region demonstrated in the reconstructed 
images was calculated using Equation 8.  
STD
ACQ Total
T S
C T
A


 

 ¸
=  
Equation 8 
 
where AT is the activity (MBq), TACQ is the sum of the length of the acquisition 
from each head (measured in seconds), SSTD is the sensitivity, CTotal is the total 
counts from the tumour ROI. 
Table 19 details the values of activities at 0 hours and 2 hours calculated from 
the image data and the actual values corrected for decay. A background 
correction is almost always applied to planar data since the counts from an area 
of interest are usually contributed by adjacent and overlying structures.  
Consideration as to whether or not a background correction was appropriate for 
SPET tomographic imaging was considered. To allow a comparison, an uptake 
was calculated using values of total counts which had been corrected for 
background alongside data that had not been corrected for background.  Chapter 2    76 
  No Attenuation Correction (MBq)  Attenuation Correction (MBq)   
Actual  (MBq)  Tum  Tum (Bkg Corrreted)  Tum  Tum (Bkg Corrreted) 
0 Hrs  0.54  0.16  0.07  0.67  0.33 
2 Hrs  0.42  0.12  0.05  0.49  0.24 
Diff  0.12  0.04  0.02  0.18  0.09 
Table 19 - Activities: Actual Versus Calculated 
 
The difference between 0 and 2 hours was calculated for the expected 
difference (due to decay of the source only) and for the image derived 
activities. In addition to this differences between the calculated and the known 
at 0 and 2 hours are shown in Figure 26.  
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Figure 26 - Graph of Relative Error in Activity Calculation 
Bar chart comparing the difference between values of absolute activities calculated from the 
reconstructed image data with the values measured on the radionuclide calibrator. The red 
bars indicate the differences observed at 0 hours and the blue at 2 hours.  
 
The largest difference was demonstrated when no attenuation correction was 
applied. The smallest difference demonstrated between the calculated and 
measured values of activity at 0 hours was -0.13 and -0.07 at 2 hours, which 
were calculated using the data corrected for attenuation but not for 
background. From the repeated reconstruction and analysis (x10) of the 0Hr 
acquisition data with no background correction but with AC the maximum 
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difference in the range of activities calculated was 0.39MBq, the mean activity 
calculated was found to be 0.95MBq +/- 0.04.  
Comparison with the attenuation and background corrected data demonstrated a 
difference of 0.21MBq and 0.18MBq at 0 and 2 hours respectively. From the 
repeated reconstruction and analysis (x10) of the 0Hr acquisition data with AC 
and background correction the maximum difference in activities calculated was 
0.29MBq with a mean activity of 0.55MBq +/- 0.03.  
It should also be noted that the error in isotope calibrator reading is +/- 
0.02MBq. 
2.3.2.4  Discussion and Conclusion  
As discussed previously, it is important that the acquisition of the standard data 
matches closely the conditions of the patient acquisition and that the standard 
reconstructions match the patient data reconstructions. However, results 
demonstrated that the application of an attenuation correction to the 
reconstructed standard data grossly increased the value of sensitivity calculated. 
This increased sensitivity meant that the activity calculated became 
meaningless. This is most likely as a result of over-compensating the data for a 
attenuation when the medium causing the attenuation was essentially air (with 
very low attenuation) and not water. For this work, it was more accurate to 
calculate a value of sensitivity from the standard data that was not corrected for 
attenuation correction using Chang’s technique. 
This was not the case for phantom work or patient work, as both of these 
volumes contain water and other attenuating medium. It important to apply an 
attenuation correction to both patient and phantom data as the counts from the 
various organs/structures in the torso will be affected by attenuation.  
Comparison of the attenuation corrected values with and without a background 
correction are described in Table 19. This shows that the value of activity 
calculated from the non-background corrected data more closely matches the 
value measured on the isotope calibrator. However, reproducibility 
measurements performed with the data from the phantom at 0Hr which included Chapter 2    78 
attenuation correction demonstrated that for the non-background corrected 
data a mean activity of 0.95MBq ± 0.04 and for the data with background 
correction, a mean activity of 0.55MBq ± 0.03. This would support the use of a 
background correction for patient data.  Chapter 2    79 
2.3.3 Assessment of updated reconstruction parameters 
All the image handling for this project was performed using software from 
Hermes Medical Solutions. The Hermes software system can be used to display 
and analyse various types of images including planar, dynamic, whole body and 
SPET.  This software can also perform image reconstruction of raw 3D data using 
either Filtered Back Projection techniques or Iterative techniques (OSEM) - these 
have been described previously in Chapter 1. When the software was first 
purchased, OSEM was relatively new to the commercial market and therefore 
Hermes provided basic advice as to the number of subsets and iterations 
required to achieve good quality reconstructed images. Having no experience of 
iterative reconstruction techniques, the department at GRI decided to follow the 
advice provided by Hermes. At the time data were compared with previous data 
which used filtered back projection and the data quality was assessed 
qualitatively to be consistent. During this project however, Hermes collaborated 
with Prof B Hutton of UCL, who provided advice on optimising the reconstruction 
parameters in terms of the number of subsets and iterations. This advice only 
became available after all the trial NeoSPECT data had been acquired and 
reconstructed and so there was some concern that the reconstructed data may 
not have been optimised, which might affect the quantitative analysis. Since this 
was a major part of the project, it was decided to compare the images 
reconstructed from a subset of the total patient population using the original 
parameters with those reconstructed using the new parameters proposed. 
2.3.3.1  Methods 
New advice from Hermes stated that the number of subsets should be dictated 
by the number of projections acquired, see Equation 9. 
4
Pr _ # ojections of
Subsets =  
Equation 9 
 
A total of 10 patients were selected to undertake this investigation, these being 
patients who took part in the NeoSPECT trial and had demonstrated abnormal 
uptake within the lungs on the NeoSPECT images. The data were reconstructed 
using the original and new suggested parameters as described in Table 20. Chapter 2    80 
  Iterative HOSEM – Hermes Ordered Subset Expectation Maximisation 
Reconstruction Method:  Original Parameters  New Advice 
Iterations:  4  4 
Subsets  6  30 
Zoom:  0  0 
Filter  Low Pass cut-off 1.5 cycles/cm  No advice (Low Pass cut-off 1.5 
cycles/cm used) 
Attenuation Correction  Yes  No advice (Yes used) 
Table 20 - Reconstruction Parameters 
 
To ensure a good comparison between the existing with the new parameters the 
volume reconstructed was exactly the same and this was defined by the start 
slice and total number of slices.   In addition where no advice was given with the 
new parameters, for example with the filter and attenuation correction, the 
original parameters were used. 
The abnormal area was analysed quantitatively via Tumour to Background ratios 
(T:B). The Hermes software allows up to 3 reconstructed volumes to be loaded, 
viewed and analysed simultaneously. The tumour and background areas were 
drawn on the transverse plane. The extent of disease was assessed using the 
sagittal and coronal planes also, allowing the volume and extent of disease to be 
accurately identified on the transverse plane.  
Using the original reconstruction, an ROI was drawn around the area of 
abnormality and an area of normal lung uptake, which were then applied to the 
same slice on the newly reconstructed data. The number of slices on which the 
abnormality/tumour was visible varied between patients but never between 
reconstruction techniques. 
From these regions, values of total counts and total number of pixels were 
extracted to allow a ratio to be calculated T:B. The tumour and the background 
ROI were often not equal in size and therefore the BKG region was normalised to 
the tumour region prior to calculating the ratio.  
2.3.3.2  Results 
From a qualitative perspective the image quality of those reconstructed using 30 
subsets appeared to contain more noise in comparison to those reconstructed 
using the original parameters advised- see Figure 27. There were, however, no Chapter 2    81 
instances where the ROI defined on the original reconstruction did not 
encompass the tumour volume on the new reconstruction. This was also true for 
the number of transverse slices over which the tumour was present.  
 
Figure 27 - Qualitative Comparison of transverse slices 
Images show a transverse slice of SPET data reconstructed with 6 subsets (on the left) and 
with 30 subsets (on the right). The transverse slices shown are through the thorax of patient 
with positive NeoSPECT uptake in the right lung.   
 
Results from the quantitative evaluation of the reconstruction techniques can be 
found on Table 21. 
Table 21 - Comparison of Reconstruction Parameters via T:B 
 
The maximum difference in ratios seen in any one volume was 0.34, whilst the 
mean of the maximum differences was 0.19. 
  Max T:B  Absolute Differences 
Patient  6 Sub  30 Sub  Max  Average 
1  1.60  1.57  0.17  0.07 
2  2.85  2.59  0.28  0.12 
3  1.85  1.91  0.26  0.08 
4  1.37  1.30  0.08  0.04 
5  1.98  1.95  0.14  0.07 
6  1.83  1.89  0.16  0.09 
7  1.71  1.56  0.19  0.09 
8  2.31  2.33  0.11  0.04 
9  1.52  1.76  0.34  0.16 
10  1.65  1.53  0.22  0.10 
6 Subsets  30 Subsets Chapter 2    82 
2.3.3.3  Discussion and Conclusion 
The difference between data reconstructed using the original Hermes settings 
and those using the new advice from Hermes was not considered significant as 
the reproducibility of the measurement assessed in section 2.3.2.2 
demonstrated differences in T:B ratios of up to 0.20, therefore it was considered 
unnecessary to reanalyse the previously reconstructed data using the new 
advice.  
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2.4 Patient Acquisitions & Image Quantification 
The main patient data group comprised those involved in the trial (see section 
2.2) to investigate the use of quantification to assess if dual time imaging could 
characterize tissue type in terms of washout rates. However, to increase sample 
size, data were also used from patients who had routine NeoSPECT imaging 
which consisted of SPET imaging at the 2 hours post injection time frame only.  
In addition to the clinical data for the trial, the data allowed improvements in 
reconstruction software (for example the commercial advent of iterative 
reconstruction) to be assessed in terms of its quantitative value. This was of 
great value as the majority of previously published data involved quantification 
of data reconstructed using Filtered Back Projection techniques. 
Data were used from 36 patients in total, of whom 19 had dual time imaging 
performed. The data were then grouped and analysed as follows:  
Investigation 1  Comparison between Filtered Back Projection and Iterative 
reconstruction techniques for all patients.  
Investigation 2  2hr  Acquisition  Tumour  to  Background  ratio  T:B,  versus 
histology findings. 
Investigation 3  2hr Versus 4hr Acquisition T:B and wash out versus histology 
findings in the main tumour. 
Investigation 4  2hr  Versus  4hr  Acquisition  Mediastinal  Uptake  Versus 
histology findings 
Investigation 5  2hr Acquisition percentage uptake versus histology findings. 
Investigation 6  2hr  Versus  4hr  Acquisition  percentage  uptake  wash  out 
versus histology findings in the main tumour. 
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2.4.1 Tumour to Background Ratio 
One of the most basic means of assessing the difference in uptake between two 
tissue types is simply a target tissue to background tissue ratio, T:B. In this 
context background tissue is in fact physiological uptake in equivalent non-
disease tissue. The target tissue is the tissue which is known or suspected to 
contain disease, characterized usually by a focal area of increased 
radiopharmaceutical uptake. Whilst the background tissue is merely tissue 
preferably of the same organ that demonstrates a more diffuse and notably 
physiological normal level of radiopharmaceutical uptake, in other words is 
disease free. In terms of NEOSPECT uptake this is best demonstrated by the 
example study shown in Figure 28.  
Figure 28 - NEOSPECT Uptake in Abnormal Patient 
Images shown are reconstructed coronal, transverse and sagittal slices as displayed by the 
Hermes system. This patient demonstrated increased uptake in the upper lobe of their right 
lung - as shown by red arrows on the coronal and transverse planes, the blue arrow shows 
normal lung tissue.   
 
In Figure 28 the red arrow highlights the area of abnormal uptake within the 
lung (right apex) and the blue shows normal lung uptake in the contralateral 
lung. 
2.4.1.1  Methods for Investigations 1 - 4  
The imaging protocol for routine NeoSPECT patients (the non-study patients), 
required each patient to have a SPET acquisition followed by a static planar 
image of the chest and the pelvis. This imaging was performed 2 hours post Chapter 2    85 
injection of the radiopharmaceutical. The SPET acquisition was of the thorax, 
including the entire lung field in the field of view (FoV) and (because of the 
proximity to the lungs) also including both axillae. An elliptical orbit was chosen 
for the SPET acquisition in order to reduce patient to detector distance and 
increase image quality. 
This orbit of rotation was optimised further by requesting the patient (when 
capable) to lie with their hands and arms behind their heads for the duration of 
the scan thus avoiding unnecessary attenuation from the patient’s arms. This 
helped to improve overall image quality by minimising scatter, improving 
sensitivity and thus improving image resolution whilst also helping to achieve 
good visualisation of the axillae. Aside from ensuring that the entire thorax 
(including the axillae) were in the FoV there was no other setup specifications. 
The setup for patients who had dual time imaging was slightly more controlled in 
that for these patients it was important to try and replicate the set up 
parameters and conditions of the first acquisition during the second acquisition.  
To aid this, a proforma had to be completed by imaging staff- see Appendix B. 
This allowed the parameters associated with the setup to be documented during 
the first study and the operator could then ensure both data volumes acquired 
were similar.  This also meant that variations in the count statistics caused by 
the orbit of rotation could be limited which was important since quantitative 
analysis would be performed. 
The proforma contained details including that of the bed height and transverse 
position. Each patient was positioned on the scanning bed ‘feet first’, their arms 
and shoulders were placed in a head and arm rest – see Figure 29 -  which was 
always placed at the end of the scanning bed. This meant that from a translation 
point of view the patient’s position could be replicated. Chapter 2    86 
 
Figure 29 - Patient Head and Arm Rest 
Image of the department’s arm and headrest used for NeoSPECT acquisitions. This aid is 
designed to assist the patient in maintaining the “arm up” position during the scan. The 
“arms up” position allows the detectors of the gamma camera to get closer to the thorax.   
 
The proforma also included details of the gamma camera head orbit. The 
elliptical orbit of rotation for the gamma camera heads was defined at four 
angles as shown in Figure 30. At these angles the heads were positioned as close 
as possible to the patient without being in actual contact. The detector positions 
at each angle were recorded. The orbit was then tested by rotating the heads 
around the patient to ensure clearance. Any amendments to the gamma camera 
head position were recorded. It was possible that the bed height could influence 
how close the detectors could get to the patient and the operator could vary this 
to aid optimisation of the orbit of rotation. The value of bed height was also 
recorded. 
Recently manufactured gamma cameras have sensors (usually infra red) 
positioned on each gamma camera head to detect the patient and as a result the 
orbit of rotation is able to mimic that of the actual patient allowing the 
detectors to get even closer to the patient. However, none of the gamma 
cameras used for this study had this facility. The orbit was computed from the 
four marked points as shown in Figure 30. Chapter 2    87 
 
Figure 30 - Detector Set - Up Configuration 
Image shown is a simplified diagram indicating the configuration of the dectectors used to 
set the orbit of rotation for NeoSPECT acquisitions. 
 
Limiting the positional differences at the acquisition stage meant less 
manipulation of the reconstructed data at later stages.  
A summary of the acquisition parameters for SPET imaging can be found in Table 
22.  The camera used was the Philips Forte as was used for the STD acquisitions. 
Orbit:  Elliptical 
Patient Position:  Supine and Feet First 
Collimators:  VXHR parallel hole, low energy, high resolution with long bore septa 
Frame Time:  30s 
Matrix size  128 x 128 
Number of Frames:  120 
Rotation:  360 (180 per head) 
Table 22 - Acquisition Parameters 
 
The raw data for each patient were reconstructed using the traditional Filtered 
Back Projection technique and then the Ordered Subset Expectation 
P1 - 90°  P2 - 270° 
P4 - 0° 
P3 - 180° Chapter 2    88 
Maximisation (OSEM) iterative technique
3. In both cases the full FoV was 
reconstructed to allow accurate slice by slice comparisons to be drawn.   
Reconstruction Method:  Iterative HOSEM – Hermes Ordered Subset Expectation Maximisation 
Protocol:  NeoSPECT 
Post Reconstruction  Filter:  Low Pass 1.5 
Iterations:  4 
Subsets  6 
Zoom:  No zoom (either on acquisition or following reconstruction) 
Table 23 - Iterative Reconstruction Parameters 
 
In  the  case  of  patients  who  had  2  and  4  hour  imaging,  despite  limiting  the 
variations  in  the  acquisition  setup,  there  were  slight  differences  in  the 
acquisition volumes. These were corrected by co-registering the reconstructed 
volumes using the purpose designed Hermes software. 
The Hermes registration software offered both automatic and manual options. 
There are a number of automatic techniques used for registration, the majority 
of these are iterative and are based on minimization techniques to match the 
volumes.  The  Hermes  system  uses  a  ‘multi-resolution  technique’.  This  option 
was  considered  initially  to  help  reduce  the  time  spent  during  the  image 
processing stage. However, visual evaluation of the volumes highlighted some 
notable differences between the volumes indicating that the volumes had not 
been matched successfully via the automatic process. Therefore it was decided 
that the semi automated form of image registration should be used - Landmark 
Registration. For more details on image registration refer to section 1.2.2.4 of 
Chapter 1.  
Once processing of the raw data was complete, the volume(s) were loaded into 
Hermes ‘Volume Fusion Display’ software, which displays the images in 24-bit 
colour depth (16,777,216 colours). Volume Fusion Display allowed two separate 
volumes to be displayed either separately or fused. ROI analysis could also be 
performed.  Since  ROI  analysis  was  being  used  to  try  to  identify  any  defining 
characteristics,  in  terms  of  tracer  uptake,  between  various  tissues,  it  was 
important  that  the  delineation  between  normal  and  abnormal  was  accurate. 
Consideration had therefore to be given to optimizing how these volumes were 
                                         
3 Refer to section 2.3 for optimisation of reconstruction parameters Chapter 2    89 
being displayed. Visual assessment was undertaken and it was realized that the 
images were more appropriately displayed in ‘absolute mode’. This means that 
the images were scaled to the maximum counts per pixel seen in the entire 
volume rather than ‘relative mode’ which scales a slice to the maximum counts 
in that particular slice. Secondly, with a wide range of colour schemes available 
it was important to choose a scheme that drew the eye to areas of increased 
uptake and could help delineate between normal and abnormal tissue. 
 
Figure 31 - Colour Schemes 
Images show transverse slices through a patient’s thorax with corresponding ROIs around 
the tumour and over an area of backround. The image on the left is displayed using colour 
scheme ‘Renal’ which has 256 colours and the image on the right using the ’17 point’ colour 
scheme.  
 
Whilst the scheme is subjective to the user, it was decided that 2 of the best 
schemes for viewing the data were ‘Renal’ shown on the left of Figure 31 and 
the ’17 point’ scheme on the right.  
For ROI analysis the ’17’ point scheme was chosen as there are only 17 actual 
colours within the colour scale. This is a discontinuous scale which unlike the 
‘Renal’ scale (256 different colours) means that changes in the counts per pixel 
appear more significant than they actually are, producing more discrete 
boundaries.   
To calculate tumour to background ratios an ROI was drawn around the area of 
abnormal or focal increased uptake on the transverse slice. A second ROI was 
then drawn around an area of normal lung uptake either in the same or the 
contralateral lung depending on the extent of the disease - an example is shown 
in Figure 32. Chapter 2    90 
 
Figure 32 - Lung ROIs  
Images shown are of the reconstructed coronal (top left), transverse (central) and sagittal 
(bottom right) slices through a NeoSPECT patient’s thorax. Example background and 
tumours ROIs are shown on the transverse slice; yellow and red ROIs respectively. The red 
dashed lines on the coronal and sagittal slice define the upper and lower limits of the 
tumour. 
 
From the ROIs, values were obtained of total and maximum counts. ROI sizes 
were also obtained. In most cases the tumour and background ROIs were equal in 
size, however, this was patient and specifically patient disease dependant and 
therefore  for  some  patients  the  size  of  these  two  ROIs  differed  to  allow 
appropriate tissue areas to be selected. To compare counts demonstrated in one 
ROI to another, the ROIs had to be either the same size or normalized to area 
i.e. the background ROI was normalised to the area of the tumour ROI. 
2.4.1.2  Investigation 1 Results - Iterative (IT) versus Filtered Back Projection 
(FBP) reconstruction of data acquired at 2 Hours 
Since iterative reconstruction techniques were available, one of the aims of this 
work was to determine if there were significant differences between the two 
reconstructed data sets that could affect or influence the results of image 
quantification. To investigate this 10 patient were selected ( 6 malignant and 4 
benign); each of these patients had an area of increased uptake demonstrated 
on their planar images at 2 Hours. Each patient’s tomographic data were Chapter 2    91 
reconstructed using both FBP and IT reconstruction techniques. Details of the 
reconstruction parameters are given in Table 24. 
Filter Back Projection  Iterative HOSEM  
# of Slices - Full Field of View  # of Slices - Full Field of View 
Post Recon  Filter - Low Pass 0.8  Post Recon Filter - Low Pass 1.5 
Iterations - NA  Iterations - 4 
Subsets - NA  Subsets - 6 
Zoom - 0  Zoom - 0 
Table 24 - Reconstruction Parameters 
 
Tumour and background regions of interest were drawn on the transverse slices 
and T:B ratios calculated. Figure 33 charts the difference in the total counts 
found in each Tumour region corrected for background, it should be noted that 
where the size of the region differed between reconstruction techniques the 
regions were normalised to those of the iterative technique.  
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Figure 33 - Graph of Variation in Total Counts 
The graph shown is a plot of the total counts demonstrated in a tumour volume for both 
iterative and FBP reconstruction techniques (red and blue data points and trendline 
respectively) 
 
A difference in the total number of counts in each tumour volume was noted 
between the iterative and FBP techniques, however, in terms of the ratios 
calculated the differences appeared less significant, see Figure 34. Chapter 2    92 
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Figure 34 - Graph of 2Hr Max T:B (Total Counts) 
Bar chart of the of the maximum T:B calculated using the total counts from the 2 hours 
acquisition only. Values calculated from data reconstructed with iterative techniques are 
shown in red and with FBP in blue.  
 
The largest difference in T:B noted between the two reconstruction techniques 
was 0.25, the maximum difference demonstrated when assessing the 
reproducibility of the T:B was found to be 0.19.  
To test for differences between the values from the two reconstruction 
techniques a wilcoxon signed rank test was performed. This test did not 
conclude a statistically significant difference between techniques, the p-value 
was p=0.359, estimated median of -0.04 and a 94.7 CI of (-0.155, 0.075). Since 
there is no trend in the differences, it is likely that differences seen are within 
the variation expected from the reproducibility of the techniques.  
From a quantitative perspective there was no significant difference between the 
two reconstruction techniques however it was decided that all subsequent data 
would be reconstructed using iterative techniques as there was a clear 
difference in the images from a qualitative perspective. Figure 35 is typical of 
the image quality seen using each technique. Chapter 2    93 
 
Figure 35 - Qualitative Comparison 
Images shown are coronal and transverse slices through a NeoSPECT patient, the upper 
images are of data reconstructed using iterative techniques whilst the bottom images are 
from data reconstructed using FBP. This patient has positive NeoSPECT uptake in the apex 
of the left lung. 
The upper row of Figure 35 demonstrates a coronal and transverse slice of data 
reconstructed using iterative techniques whilst the lower row shows the 
corresponding slices reconstructed using filtered back projection. The first 
notable feature when comparing these images is the clearer delineation of the 
cardiac cavity, where the iterative reconstruction technique appears to preserve 
resolution rather than reduce it. Secondly, when reviewing the corresponding 
transverse slices, the ‘starring or streak artifact’ associated with Filtered back 
projection is absent from the iterative techniques and so the natural contour of 
the body appears to be better delineated.  Chapter 2    94 
Section Summary – Investigation 1  
There are no significant quantitative differences seen between FBP and IT 
reconstructions however, it was felt that IT reconstruction provided a notable 
improvement qualitatively. IT reconstruction was therefore used in all 
subsequent sections. 
2.4.1.3  Investigation 2 Results - 2Hr Iterative (IT) Tumour to background 
ratio T:B versus Histology 
All NeoSPECT acquisitions undertaken between 2002 and 2006 at Glasgow Royal 
infirmary were reviewed. Areas of non-physiological uptake of NeoSPECT were 
identified and these classed as positive studies at 2 hours post injection. A total 
of 36 patients were identified as having positive NeoSPECT studies, some of 
whom had taken part in the pan-Glasgow trial. 
Of the 36 patients, more than half were from the trial (19), the remaining 17 
patients having been referred to the department for a NeoSPECT following an 
abnormality demonstrated on a chest x-ray. Case notes and electronic data 
bases (CRIS radiology system, National PACS system and the clinical portal) were 
all reviewed to obtain follow up details of each patient in order to determine if 
the disease demonstrating uptake on the NeoSPECT images was malignant or 
benign. 
Information was obtained for all patients apart from 1 patient who had been 
referred from another healthcare trust and therefore details such as histology or 
clinical/radiographic follow up could not be obtained .This patient was excluded 
from the group. Of the remaining 35 patients 13 were female and 22 were male, 
their ages ranged between 49 years and 86 years with the group’s mean age 
being 67.7 years.  
Images were reconstructed using iterative reconstruction with the parameters 
described in Table 23 in the previous section. From the 35 patients, a total of 36 
lesions/hot areas were identified. Of the 36 lesions, 28 were associated with 
malignant disease whilst the remaining 8 were associated with benign disease.  Chapter 2    95 
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Figure 36 - Graph of Malignant Versus Benign Disease 
Bar chart showing the values of T:B calculated for each patient. The red bars show values 
from the malignant group and the blue bars from the benign group. The solid balck line 
through each group is mean calculated for each group.  
 
From Figure 36 it can seen that values of the maximum (max) T:B calculated 
ranged between 1.50 to 4.23 with a mean of 2.26 for the malignant group (the 
mean is shown by a solid black trendline). For the benign group values of the 
max T:B calculated ranged between 1.49 to 3.30 with a mean of 2.17 and again 
this is shown using a solid black trendline. Considering that the reproducibility of 
the techniques has shown a variation of 0.2, there appears to be no significant 
difference in terms of T:B between these two groups.  
Statistical differences between the benign and malignant group were assessed 
using a Mann-Whitney test, results from this test giving a median for the 
malignant group of 2.01 and 2.21 for the benign group. The test found there to 
be no significant difference in the distribution of values when comparing the 
malignant and benign groups (p=0.90, 95.4% CI of (-0.5598, 0.5498)). 
In the Malignant group, 23 lesions were identified histologically as Non Small Cell 
Lung Cancer and 1 lesion as Small Cell Lung Cancer.  Histology and therefore 
classification was unavailable for 4 lesions but information retrieved from the Chapter 2    96 
case notes and/or radiology reports detailed the lesions to be of malignant 
origin.  
Figure 37 shows further histological breakdown of the lesion sub-types in the 
Non Small Cell group. 
 
 
Figure 37 - Lesion Type 
Image shown is the categorisation of the patient data groups based on histological findings. 
 
From Figure 37 it can be seen that 6 lesions fall into the ‘other/unknown’ 
category, of which 4 had no further information regarding the nature of their 
sub type histology. The distribution of T:B’s between the NSCLC sub groups can 
be seen in Figure 38, where the black bold trendline demonstrates the mean of 
each group.  
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Figure 38 - Graph of Characterisation of NSCLC Sub Type 
Bar chart showing the values of T:B calculated for each histological sub type of NSCLC, the 
blue bars represent the adenocarcinoma, the red bars the Squamous cells and the green 
bars the unknown. The mean is also shown for each group via a black solid trendline. 
 
The largest group was the Adenocarcinoma group followed by the Squamous cell 
group and finally was the Other/Unknown group, the range of T:B’s calculated 
for each group is given below:   
Adenocarcinoma Range: 1.59 - 4.23, mean = 2.49 
Squamous cell Range: 1.75 - 3.01, mean = 2.17 
Other/Unknown Range: 1.52 - 3.76, mean = 2.33 
The two highest values of T:Bs demonstrated in the Other/Unknown group were  
3.76 and 3.39 and were from patient 17 and 22 respectively. Both these patients 
had known histology, Patient 17 had a Pancoast tumour and Patient 22 had Large 
Cell Carcinoma. Whilst the majority of Pancoast tumours are Squamous Cell they 
can also be Adenocarcinomas or Large Cell and for this reason these have been 
included in the ‘other/unknown’ category (Guerrero, 2009).  
n = 9 
n = 8 
n = 6 Chapter 2    98 
Despite there being no clinical difference in the clinical management of patients 
in the different subgroups of NSCLC, statistical analysis was performed which 
looked for differences in the distribution of T:Bs between the Adenocarcinoma 
and Squamous cell group. The ‘other/unknown’ was excluded due to uncertainty 
of the nature of the tumour. 
Results from a Mann-Whitney test demonstrated medians of 2.06 and 2.00 for 
the Adenocarcinoma and Squamous cell groups respectively. A p-value of 0.88 
was calculated along with a 95.1% CI of (-0.460, 1.220) therefore there is no 
significant difference between the Adenocarcinoma and Squamous cell group. 
Section Summary – Investigation 2  
There is no significant difference demonstrated between the T:B ratio which 
would allow diagnosis of disease or disease sub-type. 
 
2.4.1.4  Investigation 3 Results - 2Hr and 4Hr tumour to background ratios 
T:B versus Histology. 
Based on the results demonstrated from section 2.4.1.2, analysis of the 2 v 4Hrs 
volumes was performed with data reconstructed using iterative techniques and 
not the tradition FBP methods. This group comprised 19 patients, imaged as 
described in previous sections. In this group, 7 were female and the remaining 
12 male. At the time of imaging, their ages ranged between 49 and 81 years, 
with a mean of 68 years. 
Pathology was obtained for 18 patients, while one patient did not have 
pathology performed and was diagnosed clinically based on growth of lesion over 
time. Of the 18 patients who had known pathology, 10 had the pathology of the 
lesion(s) confirmed following the NeoSPECT scan whilst the other 8 had some 
tissue removed from the lesion either via bronchoscopy or CT guided biopsy 
before the NeoSPECT image.  Chapter 2    99 
Table 25 summaries details of the mechanism of diagnosis of tumour type and 
duration between NeoSPECT scan and the pathology being determined. 
NeoSPECT 
# 
Age  Histology  Pathology Technique  #  of days prior/ post 
NeoSPECT Scan 
1  71  NSCLC - Adeno  Wedge resection  27 
2  58  NSCLC - Adeno  CT Biopsy  -23 
4  62  Unknown  Thoracotomy  34 
5  69  NSCLC - Squa  CT Biopsy  -22 
6  63  NSCLC - Squa  ( Attempted Thoracotomy)  - ?
4 
7  66  NSCLC  - Unknown  CT Biopsy  -15 
11  81  Negative  Wedge resection  7 
12  66  Negative  Lobectomy  8 
15  60  NSCLC  - Unknown  Wedge resection  12 
16  71  NSCLC  - Unknown  No Path (Diagnosed Clinically)  78 
19  76  +ve - Unknown  Thoracotomy  2 
21  49  NSCLC  - Unknown  Bronchial Biopsy  -21 
22  72  NSCLC - Squa  Lobectomy  22 
23  70  ?  CT Biopsy  -36 
26  65  NSCLC - Squa  Bronchial Biopsy  -11 
27  76  NSCLC - Adeno  Wedge resection  31 
28  74  NSCLC - Squa  No Path (Diagnosed Clinically)  NA 
31  77  NSCLC - Squa  Lobectomy  52 
32  66  SCLC  CT Biopsy  - ?
4 
Table 25 - Summary of NeoSPECT patient's pathology details 
 
The location of each area sampled was determined from the patient’s CT image. 
Firstly, a qualitative comparison was made between the CT findings and the 
NeoSPECT image to determine if there was correlation of tumour location. The 
CT reports for all patients were obtained and the location of the tumour noted 
and compared to the NeoSPECT scan. These findings are detailed in Table 26. 
This table also describes any other notable uptake demonstrated on the 
NeoSPECT scan, which unless stated otherwise would be in keeping with lymph 
node uptake and is noted in terms of location. 
 
 
 
                                         
4 The exact date is not known. Chapter 2    100 
NeoSPECT #  CT Location of Tumour  NeoSPECT 
Concordance(Y/N)  NeoSPECT - Other Uptake 
1  Right Mid Lung  Y 
Rt Upper Lobe 
Rt Lower Lobe 
Lt Mid Lobe 
2  Right Upper Lung  Y  Rt Mid Lobe 
Lt Mid Lobe 
3  Right Mid Lung  Y  Rt Mid Lobe 
4  Right Upper Lung  Y  Rt Mid Lobe 
Rt Lower Lobe 
5  Right Lower Lung  Y  Rt Mid Lobe 
6  Left Upper Lung  Y 
Rt Upper Lobe 
Trachea 
Lt Mid Lobe 
7  Left Upper Lung  Y  - 
8  Left Lower Lung    Rt Mid Lobe 
Lt Mid Lobe 
9  Right Upper Lung  Y  Trachea 
10  Right Lower Lung  Y  - 
11  Left Upper Lung  Y  Rt Mid Lobe (?Tumour) 
Trachea 
12  Right Upper Lung  Y  - 
13  Right Upper Lung  Y 
Rt Upper Lobe 
Rt Lower Lobe 
Lt Upper Lobe 
Lt Lower Lobe 
14  Right Lower Lung  Y  - 
15  Left Upper Lung  Y  Trachea 
16  Right Upper Lung  Y  Rt Mid Lobe 
17  Left Upper Lung  Y  RT Mid Lobe 
Trachea 
18  Left Lower Lung  Y  - 
19  Right Lower Lung  Y  - 
Table 26 - Correlation of CT & NeoSPECT findings 
 
Of particular note is that none of the areas of ‘Other Uptake’ lay within lung 
tissue but rather adjacent to or within the cardiac cavity. Analysis of this data is 
undertaken in section 2.4.1.5. 
Areas of abnormal uptake within the lung were identified on all 19 patients. The 
size of the abnormality varied between patients and was not thought to be 
characteristic of tumour type. 
As before ROI analysis was performed on the tumour volume. T:B ratios were 
calculated using both the total and max counts, results are detailed in Table 27.  
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  T:B using Total Counts in ROIs  T:B using Max Count per Pixel in ROIs 
NeoSPECT #  2Hr T:B  4Hr T:B  Diff   2Hr T:B  4Hr T:B  Diff  
1  2.06  2.17  0.11  3.01  3.56  0.55 
2  1.73  1.69  0.04  2.07  2.07  0.00 
3  1.96  2.40  0.43  2.91  3.10  0.20 
4  3.01  2.80  0.20  3.65  3.52  0.13 
5  2.43  2.85  0.42  2.63  2.69  0.06 
6  3.74  4.94  1.20  4.38  4.62  0.24 
7  1.49  2.26  0.77  1.69  2.42  0.73 
8  2.16  2.37  0.21  3.78  4.28  0.50 
9  1.59  1.53  0.06  1.97  1.72  0.25 
10  2.17  2.18  0.01  2.16  2.70  0.54 
11  2.11  2.37  0.26  3.32  3.81  0.50 
12  2.52  2.55  0.03  2.51  2.59  0.08 
13  3.39  3.62  0.23  3.82  3.30  0.51 
14  1.81  1.75  0.06  2.72  2.29  0.43 
15  3.02  3.22  0.20  4.51  3.89  0.63 
16  1.90  1.86  0.04  2.27  2.00  0.27 
17  1.50  1.14  0.35  2.40  2.11  0.29 
18  1.80  1.79  0.01  2.16  2.03  0.13 
19  1.75  1.72  0.03  2.17  2.50  0.33 
Table 27 Tumour to background ratios (T:Bs) at 2 & 4Hours calculated using total and  
maximum counts 
 
From the values calculated using the total counts found in each ROI, the max T:B 
at 2 Hrs was 3.74 and at 4Hrs was 4.94, with mean values of 2.22 and 2.38 
respectively. When calculating the T:B using the maximum counts per pixel the 
max value at 2Hrs was 4.51 and at 4Hrs 4.62, with mean values of 2.85 and 2.90.  
  Figure 39 demonstrates the distribution in T:B at 2 and 4Hours for the 
various histology’s. 
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  Figure 39 - Graph of 2Hr Versus 4Hr T:B 
Bar chart showing the values of T:B calculated at 2 and 4 hours post injection, indicated by 
the red and blue bars respectively.   
 
The maximum differences demonstrated between the 2 and 4hour T:B using the 
total counts was no greater than 1.2 and using the maximum counts per pixel 
0.73. 
Histology for these patients was attained via a number of methods as described 
in Table 25. Depending on the size of the tumour it was important to establish if 
sampling of the lesion before imaging had impacted on the any of the results. Of 
the 7 patients with pre-NeoSPECT histology, none had negative histology which 
indicates that the sample was taken of the true tumour site.  
Figure 40 shows the data split into histology sampled prior to and after the 
NeoSPECT imaging. 
Due to the sample size of the ‘+ve unknown’ and ‘-ve’ categories testing for 
difference between the values of T:B between 2 and 4 hours was not possible. 
However, a wilcoxon sign rank test could be used to asses the difference in dual 
time imaging for the ‘Adenocarcinoma’ and ‘Squamous Cell’ groups.  
The ‘Adenocarcinoma’ group failed to demonstrate any statistically significant 
difference in the values of T:B ratios calculated at 2 and 4 hours, the p-value 
-ve 
+ve: 
Unknown 
 
Squamous Cell 
Adenocarcinoma 
2Hr Versus 4Hr T:B Chapter 2    103 
calculated was 0.142, with an estimated median of -0.200 and 94.1% CI of (-
0.820, 0.050). Similarly the ‘Squamous Cell’ also failed to demonstrate and 
statistically significant differences in the T:B ratios calculated between 2 and 4 
hours, the p-value calculated was 1.00, with an estimated median of -0.002 and 
94.1% CI of (-0.205, 0.110).  
Pre Versus Post Histology T:B Results
0
1
2
3
4
5
6
P
a
t
i
e
n
t
 
1
P
a
t
i
e
n
t
 
4
P
a
t
i
e
n
t
 
7
P
a
t
i
e
n
t
 
1
1
P
a
t
i
e
n
t
 
1
2
P
a
t
i
e
n
t
 
1
5
P
a
t
i
e
n
t
 
1
6
P
a
t
i
e
n
t
 
1
9
P
a
t
i
e
n
t
 
2
2
P
a
t
i
e
n
t
 
2
7
P
a
t
i
e
n
t
 
2
8
P
a
t
i
e
n
t
 
3
1
P
a
t
i
e
n
t
 
2
P
a
t
i
e
n
t
 
5
P
a
t
i
e
n
t
 
6
P
a
t
i
e
n
t
 
2
1
P
a
t
i
e
n
t
 
2
3
P
a
t
i
e
n
t
 
2
6
P
a
t
i
e
n
t
 
3
2
T
:
B
2Hr T:B
4Hr T:B
 
Figure 40 – Graph of Pre versus Post Histology T:B Results  
Bar chart showing the values of T:B calculated at 2 and 4 hours post injection, indicated by 
the red and blue bars respectively. This data is grouped and presented based on whether 
tissue sampling was performed post or pre NeoSPECT imaging.     
 
Of the 7 patients who had their tumours sampled prior to having the NeoSPECT 
imaging 4 were via CT guided biopsy, 2 by bronchoscopy and 1 patient had a 
failed attempt at a thoracotomy. Of this ‘Pre NeoSPECT’ group only 3 (43%) of 
these patients had T:B less than the mean (2.27) of the group who had histology 
sampled after NeoSPECT (‘Post NeoSPECT Hist’ group). In the ‘Post NeoSPECT’ 
group 6 (50 %) patient had values of T:B less than the mean. 
Post NeoSPECT Hist 
Pre NeoSPECT Hist Chapter 2    104 
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Figure 41 - Graph of Difference in Total versus Max Counts in ROI 
Bar chart showing the difference in values of T:B calculated at 2 and 4 hours post injection, 
indicated by the red and blue bars respectively, using both the max and total counts. This 
data is grouped and presented based on the histological findings.   
 
When performing image subtraction in other areas of nuclear medicine, for 
example parathyroid subtraction analysis, there has never been any definitive 
approach as to the use of either total counts or maximum counts per pixel in a 
ROI to calculate the contrast index (ratio) used for the subtraction (Leslie, 2002; 
Hindie, 2009). This is likely because the appropriateness of its use is dependent 
upon the distribution of the radiopharmaceutical within a given organ or ROI i.e. 
an area of high counts in a ROI not representative of the overall distribution 
within a region resulting in either an under or over estimation of the index. 
Figure 41 charts the difference in T:Bs calculated between 2 and 4 Hrs using 
both the total ROI counts and the maximum counts per pixel to assess if the 
ratio of max counts per pixel is more characteristic of tumour type, these data 
are contained in Table 27.  
A wilcoxon signed rank test was performed to determine if there was a 
difference between the T:B difference calculated at 2 and 4 hours using the 
total count within the ROI and the T:B difference calculated using the maximum 
counts per pixel from the ROI. This test found there to be no statistically 
significant difference between the calculation techniques, a p-value of 0.469 
Adenocarcinoma 
Squamous Cell  +ve: 
Unknown 
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was calculated along with an estimated median of -0.08 and 94.9% CI of (-0.30, 
0.145). 
Section Summary – Investigation 3   
It can be seen that there is no clear pattern and no statistically significant 
difference of washout from 2h to 4h images which correlates with either disease 
type or when biopsy was performed. 
There appears to be no benefit in using two times frames for imaging with 
NeoSPECT. 
 
2.4.1.5  Investigation 4 Results - Tumour to background ratio T:B  in the 
mediastinum versus Histology 
Around two thirds of patients who had dual time imaging demonstrated uptake 
in the mediastinum which was thought likely to represent nodal uptake.  
Thirteen of the nineteen patients imaged demonstrated uptake in the 
mediastinum. For each patient the number of nodes identified was recorded 
along with the site of the node. The site of the node was defined relative to the 
lung containing tumour as ipsilateral to the tumour(‘side of Tum’), on the 
contralateral side from the tumour (‘Opp Side’) or as being either pretracheal or 
anterior mediastinal nodes (‘Mid’). Table 28 details the areas identified as being 
lymph nodes.  
 
 
 
 
 Chapter 2    106 
Patient ID  Pathology  # of Nodes  # Side of Tum  # Opp side  Mid 
Patient 1    3  2  1  /’ 
Patient 2    2  1  1  / 
Patient 4  Adenocarcinoma  1  1  /  / 
Patient 7    3  1  1  1 
Patient 15    1  /  /  1 
Patient 26    1  /  /  1 
Patient 5    2  2  /  / 
Patient 6    1  1  /  / 
Patient 19    1  /  /  1 
Patient 21    0  /  /  / 
Patient 23  Sqaumous Cell  0  /  /  / 
Patient 27    1  1  /  / 
Patient 31    0  /  /  / 
Patient 32    0  /  /  / 
Patient 16    0  /  /  / 
Patient 22  +ve  Unknown  4  2  2  / 
Patient 28    2  /  1  1 
Patient 11  - ve  0  /  /  / 
Patient 12    2  1  1  / 
Table 28 - Mediastinal Uptake 
 
T:B quantification undertaken on all lymph nodes detailed in Table 28.It should 
be noted that the patients are grouped in Table 28 in accordance with their 
associated main tumour histology as in  Figure 39 and Figure 41.  
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Figure 42 - Graph of T:B Mediastinal Nodes 
Bar chart showing the values of T:B calculated from sites considered to lymph nodes at 2 
and 4 hours post injection, indicated by the red and blue bars respectively.   Chapter 2    107 
At 2 hours the range of T:Bs calculated in the mediastinal nodes for all patients 
shown in Figure 42 was between 1.34 and 3.54, with a mean of 1.96. At 4 hours 
this range was 1.35 -3.43, with a mean of 2.07. The maximum absolute 
difference between nodes at 2 and 4 Hours was 0.72. 
Figure 42 demonstrates the difference in lymph node uptake between 2 and 4 
hours for patient with both positive and negative histology. Due to the 
difficulties in correlating nodes demonstrated using NeoSPECT imaging with 
those sampled histologically, differences between 2 and 4 hours could only be 
assessed by grouping the patients based on the primary tumour histology and not 
node histology. Due to sample size statistical analysis was only performed on the 
group of patients who had a positive primary tumour, a Wilcoxon signed rank 
test was performed to assess for differences in T:B between 2 and 4 hours. 
Results from this test concluded that there were no statistically significant 
difference between the difference in T:B ratio measured at the two time points, 
p-value was 0.108, with an estimated median of  -0.130 and an 95% CI of (-
0.295, 0.030). 
To investigate the trend in Depreotide uptake between tumour and lymph node 
tissue and how these both changed over time, the T:B were assigned a score of 1 
and -1. A score of 1 was assigned if the T:B at 4Hr was greater than that at 2Hr, 
and -1 was assigned if the T:B at 2Hr was greater than 4Hr. It should be noted 
that when the difference in T:B between 2 and 4Hrs was less than 0.1 a score of 
0 was assigned. This value was based on the previously measured differences 
during analysis of reproducibility - see Figure 43. Chapter 2    108 
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Figure 43 - Graph of Tumour Vs Lymph Tissue Uptake Over Time 
Bar chart indicating changes in tumour and lymph tissue uptake during dual time imagine, 
tumour is tissue is indicated by the red bars and lymph tissue by the blue bars.  
 
In the Adenocarcinoma group all 6 patients demonstrated nodal uptake 
compared with 4/8 patient in the Squamous cell group, 2/3 in the positive 
unknown group and 1/2 for the negative group. Three patients had their tumour 
ratio scored 0 (Patient 2, 15 and 27). Of the remaining patients, 7 demonstrated 
an increase in T:B values in both tumour and related lymph tissue between 2 and 
4 hours, whilst  1 patient demonstrated a reduction in T:B values between 2 and 
4 hours in both tumour and lymph tissue. Discordance in T:B values between the 
tumour and lymph tissue was seen in 2 patients (patient 6 and 28). In the case of 
patient 28 the lymph nodes were located on the contralateral lung to the tumour 
whilst for patient 6 the node was ipsilateral to the tumour.   
Section Summary – Investigation 4  
Images showed mediastinal nodal uptake, however again there seemed no clear 
trend in the washout rate based on changes to T:B ratio with respect to disease 
type. 
There was a slight trend to changes in tumour and lymph nodes over time to be 
similar in individual patients, however this was not completely the case. Chapter 2    109 
NeoSPECT imaging has clearly demonstrated nodal uptake, however, the nature 
of those nodes demonstrating cannot be assessed easily. This is because 
correlation between imaging and histological findings was impossible due to the 
lack of exact anatomical information available from the NeoSPECT imaging. 
 
2.4.2 Tracer percentage Uptake  
As discussed in the previous section an estimate of the amount of tracer within a 
tumour volume relative to normal tissue can be calculated using ratios. 
However, an alternative to this is to calculate the absolute uptake, in other 
words the proportion of the radiopharmaceutical injected which is subsequently 
absorbed/taken up by an area or organ of interest, in this case the suspected 
tumour. Unlike T:B ratios this method of quantification takes into account 
tumour size and therefore may provide a more information with respect tumour 
burden and how this changes over time.  
This technique has been used successfully in planar imaging over the years and is 
used regularly for example for thyroid gland function. The technique’s accuracy 
in SPET imaging and its value with regard to NeoSPECT is not clear. Its use in 
differentiating benign from malignant disease, is not known and would require 
investigation. It is therefore important to establish if there is a role for the 
uptake calculation in the characterization of tumour/tissue type and also if the 
uptake value can identify differences between 2 and 4 hour imaging.  
2.4.2.1  Methods for Investigations 5 - 6 
The majority of patients who had NeoSPECT (Depreotide) imaging performed 
between January 2004 and February 2006 at Glasgow Royal Infirmary had a 
standard volume study also acquired.  This allowed an absolute measurement of 
activity to be calculated. A total of 19 patients had a standard study volume 
acquired, of whom 12 were from the trial and therefore also had dual time 
imaging acquired. 
For all patients the standard study acquisition was acquired following either the 
2 or 4 Hr acquisition. This allowed for the setup conditions including detector Chapter 2    110 
distance and bed height used during the patient acquisition to be reproduced for 
the standard study. 
The standard volume consisted of a 5ml vial, which was filled with residual 
NeoSPECT and made up to 5ml using saline. The value of activity contained was 
measured using a radionuclide calibrator and was noted in MBq. This solution 
was then mixed thoroughly. The vial was then placed inside the phantom - see 
Figure 16 - between the lung inserts and secured to the vertebral column with 
tape. The standard acquisition data were reconstructed using the same 
parameters as the patient reconstructions but without the use of an attenuation 
correction for reasons investigated and detailed in section 2.3.2.3 
The reconstructed standard images were loaded into ‘Volume Fusion Display’ 
and ROIs were drawn around the standard and the background as described 
previously. Values of total counts and number of pixels were extracted from 
these and tabulated. The counts in each slice were area normalised and 
background corrected as described Equation 3.  
The total counts from each slice were then summed together and, since the 
standard was contained in a small volume, its activity was able to be measured 
prior to and after acquisition using the Capintec® well type radionuclide 
calibrator. Therefore the value of total counts, activity and acquisition length 
were used in Equation 6 to calculate the sensitivity of the system.  
The original ROI analysis used for the phantom analysis in section 2.3.2.1 
illustrated a ROI background region which encompassed the tumour volume. This 
technique was not used in the patient population as there was no discrete edges 
to the tumour volume and there was concern that the background region could 
encompass some low grade disease and therefore not be a true representation of 
normal lung.  Therefore the ROIs employed for the patient data set were more in 
keeping with those illustrated in Figure 32. 
The patient ROI data were handled in a similar manner to the phantom data, the 
number of counts found in each tumour region being corrected for normalised 
background counts as described in Equation 3. The tumour counts were summed Chapter 2    111 
over the depreotide avid tumour volume and used along with the value of 
sensitivity to calculate the activity in the tumour using Equation 8.  
2.4.2.2  Results for Investigation 5 - Correlation of 2Hr % Uptake with 
Histology   
The Administration of Radioactive Substance Advisory Committee (ARSAC) sets a 
diagnostic reference level (DRL) of 600MBq for NeoSPECT administrations, 
however, in the case of over or underweight patients the activity administered 
to the patient may be altered in order to optimise both the dose received and 
quality of the image (ARSAC, 2006). The activity injected into the patient was 
calculated from a measurement of syringe activity prior to injection and the 
residual activity in the syringe following injection.  These were measured using a 
calibrated radionuclide calibrator. Table 29 details the activities injected; for 
patients 13 and 16 there was no residual activity recorded. 
Patient ID  Syringe  Activity 
(MBq) 
Residual  
Activity (MBq) 
Injected Activity 
(MBq) 
Patient Activity 
@ 2Hrs (MBq) 
Patient Activity 
@ 4Hrs (MBq) 
Patient 1  622  35  587  452  347 
Patient 2  592  30  562  436  350 
Patient 3  603  85  518  389  - 
Patient 4  601  143  458  361  288 
Patient 5  626  29  597  471  367 
Patient 6  639  30  609  471  - 
Patient 7  555  74  481  354  - 
Patient 8  594  32  562  436  345 
Patient 9  579  50  529  408  324 
Patient 10  658  48  610  460  - 
Patient 11  486  32  454  330  - 
Patient 12  560  46  514  391  319 
Patient 13  526  -  526  397  - 
Patient 14  578  113  465  365  292 
Patient 15  608  35  573  402  346 
Patient 16  620  -  620  474  377 
Patient 17  610  126  484  353  291 
Patient 18  438  18  420  311  251 
Patient 19  666  165  501  364  - 
Table 29 - Injected NeoSPECT Activities (MBq) 
 
The mean of the activities injected was 528MBq and ranged between 420 - 
610MBq. Using Equation 4 and 5 along with the values of ‘injected activity’ in Chapter 2    112 
column 4 of Table 29, values of decay corrected activity at the time of imaging 
were calculated.  
With the exception of Patient 7, values of % uptake were calculated for all 
patients; Patient 7 did not demonstrate any abnormal uptake. Details of values 
of uptake calculated at 2 hours can be found in Table 30.  
Patient ID  Histology  Activity  Total Counts  Activity in Tumour 
Counts 
% Uptake 
Patient 1  NSCLC - Adeno  452  38306  0.48  0.11% 
Patient 2  NSCLC - Adeno  436  35187  0.22  0.05% 
Patient 3  Unknown  389  221619  1.76  0.45% 
Patient 4  NSCLC - Squa  361  379717  2.54  0.70% 
Patient 5  NSCLC - Squa  471  173696  0.85  0.18% 
Patient 6  NSCLC  - Unknown  471  46131  0.36  0.08% 
Patient 8  Negative  436  27192  0.25  0.06% 
Patient 9  Negative  408  217103  1.47  0.36% 
Patient 10  NSCLC  - Unknown  460  387019  3.07  0.67% 
Patient 11  NSCLC  - Unknown  330  79151  0.27  0.08% 
Patient 12  +ve - Unknown  391  104627  0.81  0.21% 
Patient 13  NSCLC  - Unknown  397  511204  7.89  1.99% 
Patient 14  NSCLC - Squa  365  21156  0.39  0.11% 
(Rt)  NSCLC - (unknown)  365  133058  2.48  0.68% 
Patient 15  NSCLC - Squa  402  275783  3.92  0.98% 
Patient 16  NSCLC - Adeno  474  249740  1.69  0.36% 
Patient 17  NSCLC - Squa  353  92951  0.59  0.17% 
Patient 18  NSCLC - Squa  311  66610  0.42  0.14% 
Patient 19  SCLC  364  556257  4.29  1.18% 
Table 30 - % Uptake calculated at 2 hours 
 
Table Key: NSCLC - Adeno: Non Small Cell Lung Cancer - Adenocarcinoma, NSCLC 
- Squa: Non Small Cell Lung Cancer - Squamous Cell, SCLC: Small Cell Lung 
Cancer, +ve: positive for lung cancer but no details regarding type available i.e. 
differentiation between NSCLC or SCLC. 
The range of activities found in areas associated with tumours ranged between 
0.22 and 7.79MBq with a mean of 1.78MBq (SD of 1.96). 
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Figure 44 - Graph of % Uptake @ 2Hrs 
Bar chart showing the values of % uptake calculated at 2 hours post injection, red bars 
indicate malignant group and blue bars benign group. 
 
The trend of % uptake values is shown in Figure 44; as with previous results the 
patients were grouped by their histological findings. Of the eighteen patients 
shown in Figure 44, 2 were found to have negative histology i.e. these were 
patients that were recruited to the study who were believed to have malignant 
disease. The uptake demonstrated in the 2 patients with negative histology 
ranged between 0.06 - 0.36%. Of the fifteen patients with positive histology, 
nine demonstrated uptake within this range, one patient demonstrated uptake 
less than this range and five patients demonstrated uptake that was greater than 
this range.  
The NSCLC group was categorised further by histology subtypes comprising of 
three patients with Adenocarcinoma, six patients with Squamous cell carcinoma 
and 4 patients whose case notes did not detail any information regarding 
histology subtype. The range of uptakes calculated for the subtypes are given: 
Adenocarcinoma: 0.05 - 0.36%, mean = 0.17% ± 0.002 
Squamous Cell Carcinoma: 0.14 - 0.98 %, mean = 0.38% ± 0.004  
No subtype: 0.08 - 1.99 %, mean = 0.71% ± 0.009  
+ ve - NSCLC  
-ve 
+ve - Unknown 
 
+ve - SCLC 
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There were no differences found in the values of percentage uptake which could 
differentiate between the histological subtypes in the NSCLC group. Incidentally, 
the value of percentage uptake for the SCLC was 1.18%. The sample size did not 
allow statistical analysis to be undertaken.  
Section Summary – Investigation 5  
Similar to the results found with T:B ratios , no clear difference between groups 
can be measured using absolute percentage uptake. 
2.4.2.3  Results for Investigation 6 - % Uptake Washout Versus Histology   
It is well known that different tissue types can washout radiopharmaceuticals at 
differing rates to adjacent tissues and this has been exploited in parathyroid 
imaging where the rate of washout is used to help differentiate parathyroid from 
thyroid tissue. It was considered important, therefore, to establish whether or 
not the tumour tissue had a different washout rate of NeoSPECT when compared 
with normal lung tissue and tissue from other disease processes.  
Of the 17 patients whose data were used to calculate percentage uptake in 
section 2.4.2.2 only 12 patients had dual time imaging along with a standard 
acquisition. Of these patients, 13 lesions were identified on NeoSPECT imaging 
with histological characterisation. If the tumour tissue had a different washout 
rate in comparison to normal tissue (background) then either a rise or fall in the 
uptake calculated at between 2 and 4 hours would be expected.  If there was no 
change in either it would be expected that the uptake would remain constant 
over the two time periods. Therefore based on the 2Hr results the 4Hr results 
could be predicted for no change and these could then be compared to the 
actual 4 hour results. Table 31 details these results. 
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Patient ID  2Hr Total Counts  4Hr Predicted Counts  4Hr Total Counts  Difference 
Patient 1  38306  29424  33853  -4429 
Patient 2  35187  28198  38093  -9895 
Patient 4  379717  303127  318571  -15443 
Patient 5  173696  135234  119595  15639 
Patient 8  27192  21541  24589  -3048 
Patient 9  217103  172647  175242  -2595 
Patient 12  104627  85476  73934  11542 
Patient 14(i)  21156  16889  19461  -2573 
Patient 14(ii)  133058  106220  109531  -3311 
Patient 15  275783  237325  195975  41350 
Patient 16  249740  198601  187197  11404 
Patient 17  92951  76671  71359  5312 
Patient 18  66610  53896  50701  3195 
Table 31 - Total tumour counts per patient at 2 and 4Hrs 
 
From section 2.3.2.3, for dual time acquisitions the phantom results 
demonstrated a minimum difference of 11428 in counts between the predicted 
and measured (13.46%). From Table 31 the percentage difference between 
predicted and actual at 4 hours ranged between 1.50% and 35.0%. Of the 13 
lesions only 5 demonstrated a difference greater than 13.5% but the phantom 
was acquired under absolute ideal conditions and so other factors such as 
reproducibility of the set-up and the use of attenuation correction for the 
patient may account for this. Figure 45 plots how the calculated values of 
uptake compare with the predicted value.  
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Figure 45 - Graph of Uptake @ 4Hrs Predicted Versus Actual 
Bar chart showing the values of % uptake calculated from the 4 hours SPET images (shown 
by solid coloured bars) versus the predicted values of % uptake (shown by the dashed 
bars). Red bars indicate malignant group nd blue bars the benign group. 
 
The solid red bars denotes % uptake calculated for the patients with positive 
histology and the solid blue bars are the patients with negative histology whilst 
their associated shaded bars represent the predicted values of % uptake 
calculated.  Despite some large differences noticed in the total counts this did 
not translate to into large differences in value of % uptake, Table 32 detail 
further the difference in % uptake demonstrated. 
Patient ID  Histology  4Hr Predicted  % Uptake  4Hr Actual % Uptake  Difference 
Patient 1  NSCLC (Adeno)  0.11%  0.12%  -0.01% 
Patient 2  NSCLC (Adeno)  0.05%  0.07%  -0.02% 
Patient 4  NSCLC (SQUA)  0.70%  0.74%  -0.04% 
Patient 5  NSCLC (SQUA)  0.18%  0.16%  0.02% 
Patient 8  NEGATIVE  0.06%  0.07%  -0.01% 
Patient 9  NEGATIVE  0.36%  0.37%  -0.01% 
Patient 12  POSITIVE (?)  0.21%  0.18%  0.03% 
Patient 14 (i)  NSCLC (SQUA)  0.11%  0.12%  -0.02% 
Patient 14(ii)  NSCLC  0.68%  0.70%  -0.02% 
Patient 15  NSCLC (SQUA)  0.98%  0.81%  0.17% 
Patient 16  NSCLC (Adeno)  0.36%  0.34%  0.02% 
Patient 17  NSCLC (SQUA)  0.20%  0.18%  0.02% 
Patient 18  NSCLC (SQUA)  0.14%  0.13%  0.01% 
Table 32 - Predicted Versus actual uptake at 4 hours 
 
-ve 
+ve - Unknown 
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Review of the imaging proforma and referral cards completed at the time of 
imaging drew a correlation between some of the more notable differences seen 
(Pat 4, 12, 15), these patients were noted as being non-compliant patients. 
These patients experienced difficulties with compliance as a result of physical 
condition, such as spondylitis, which caused difficulties in reproducing the 
positional set-up at acquisition for the second SPET acquisition. In addition to 
this some patients complained of ‘other’ conditions with associated pain, often 
resulting in movement during the acquisition. 
The differences between the ‘predicted’ and ‘actual’ values of % uptake at 4 
hours were assessed statistically via a Wilcoxon signed rank test which concluded 
there to be no significant difference between the ‘actual’ and ‘predicted’ 
values; p-value was 0.727, the estimated median was 0.005 and the 95% CI of (-
0.015, 0.020).  
The findings of no significant difference between the ‘predicted’ and ‘actual’ 
values of % uptake at 4 hours indicates that there was no significant change in 
the distribution and uptake of NeoSPECT between 2 and 4 hours.  
 
Section Summary – Investigation 6  
No significant difference in percentage uptake was demonstrated over the 
potential 2 hour washout time period which could be related to disease type.   
Whilst the T:B ratio data also demonstrated there to be no significant 
difference, this technique did not take into account variations in the extent of 
NeoSPECT distribution and tumour burden over time. The calculation of 
percentage uptake includes information from the whole tumour volume unlike 
the measure of T:B which only provides a measure from the maximum slice from 
the tumour volume. Therefore it was important for completeness to consider 
and assess all possible factors which could describe variations in tracer 
distribution over time.  
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2.5 NeoSPECT Discussion and Conclusion 
The numbers originally anticipated for the study were not achieved. When the 
pan-Glasgow NeoSPECT trial was first proposed, Nycomed Amersham agreed to 
fund fifty NeoSPECT doses resulting in dual time data for 50 patients i.e. 100 
SPET acquisitions. However, at the beginning of 2006 and halfway through the 
trial, Nycomed Amersham sold the NeoSPECT brand and product to IBA 
Molecular. At this stage only 19 of the intended 50 patients had been recruited. 
NeoSPECT was taken out of production until its re-launch in 2008 and thus, in 
addition to the lower than anticipated study numbers, the number of patients 
who would have had a routine NeoSPECT scan also dropped. This has meant that 
the data presented here is not as powerful as would have been expected had the 
trial recruitment reached completion. In an attempt to address this for at least 
some of the investigations, routine patient data was added. The data which 
looked at the two times points are therefore limited in the statistical 
significance which could be attached to it because of the small sample size. 
At the time of the study all the published data using NeoSPECT quantification 
involved data reconstruction using FBP reconstruction technique. One of the 
advantages of iterative reconstruction is that it may produce reconstructed 
images whose pixel data are a more accurate representation of the true image. 
The data presented here have allowed work to be undertaken to identify 
whether or not iterative reconstruction could improve the ability to firstly 
characterize the tumour and secondly quantitate tumour uptake. It was 
therefore important to re-evaluate the role of NeoSPECT Image quantification in 
light of the availability of better reconstruction algorithms. 
Comparison of the reconstruction data demonstrated a range of T:B ratios from 
1.49 - 4.32 for the iteratively reconstructed data and a range of 1.29 - 4.21 for 
the FBP reconstructions, with medians of 2.32 and 2.39 respectively. Since the 
data were not normally distributed, non-parametric analysis was undertaken in 
the form of a Wilcoxon Signed rank Test which demonstrated a p-value of 0.359, 
estimated median of -0.04 and a 94.7% CI of (-0.155, 0.075), indicating no 
difference between the groups in terms of the max T:B value calculated in each 
volume. Despite there being no proven statistical difference between Chapter 2    119 
reconstructions there was a significant difference qualitatively in that the FBP 
images were of a lower image quality. It was therefore considered appropriate 
to continue to analyse the data with only iterative reconstruction as there was 
concern that FBP reconstruction compromised accurate delineation of the 
tumour volume which in turn could result in an underestimation or 
overestimation of the total counts in the tumour volume. This is an important 
factor when considering percentage uptake values.  
In terms of the T:B ratios, review of the data qualitatively would have estimated 
the T:B ratio to be at least 2:1, however, these qualitative expectations did not 
translate quantitatively. The range in T:B ratios calculated lay between 1.50 to 
4.23 for the malignant group and 1.49 to 3.30 for benign group. The counts in 
the tumour regions of those patients who had lower than anticipated T:B ratios 
were not considered to be unusually low. However, the presence of active 
benign lung disease could have led to some low grade uptake, which would have 
caused a slight elevation of the counts in the background region. This would 
have resulted in the lower than anticipated values of T:B. Despite attempts to 
minimise this effect, by placement of the background ROI on the contralateral 
lung, it remained impossible to determine a difference between widespread 
active benign lung disease and low grade tumour uptake. A possible solution to 
identifying the presence of active benign lung disease may be achieved by 
grading lung uptake against another organ such as the liver i.e. measuring a Lung 
to Liver ratio. 
A Mann-Whitney test was undertaken to determine if there was any statistically 
significant differences between the benign and malignant group. This test gave a 
p-value of 0.90 and 95.4% CI of (-0.5598, 0.5498), concluding there to be no 
statistically significant difference in the T:B ratios calculated at 2 hours between 
the malignant and the benign group. A Mann-Whitney was performed to try and 
determine if the malignant group could be characterised further by determining 
if there were any differences between the diseases process within the 
malignant. This test found there to be no statistically significant differences 
between the larger of the groups, Adenocarcinoma and Squamous cell group (p-
value 0.88). Chapter 2    120 
The T:B ratios were assessed further by trying to establish if there was a 
difference between values calculated at 2 hours to those calculated at 4 hours in 
the malignant group. Statistical comparison between the 2Hr and 4Hr group was 
achieved by a Wilcoxon signed rank test. The outcome of this demonstrated no 
significant difference in T:B ratio between 2 and 4 hours between the 
Adenocarcinoma and Squamous cell groups (p-value 0.142 and 1.00 
respectively). 
As demonstrated, the T:B ratio form of quantification failed to identify any 
difference between the benign and malignant groups. This technique, however, 
may be inhibited by the presence of benign lung disease and particularly so 
when both lungs are involved. Calculating a percentage uptake, however, should 
be a more sensitive form of characterisation for dual time imaging, as this 
doesn’t rely on the use of a background correction and takes into account 
factors such as tumour size. 
The first assessment of the percentage uptake values tried to determine 
whether or not the percentage uptake demonstrated at 2 hours was typical of 
the tumour histology. Due to the small sample numbers between the groups no 
statistical analysis could be undertaken, however, comparison of the ranges of 
values between histologies proved useful. Two of the eighteen patients found to 
have negative histology demonstrated uptake which ranged between 0.06 - 
0.36%. Of the remaining patients with a positive histology, nine demonstrated 
uptake within this range, one patient demonstrated uptake less than this range 
and five patients demonstrated uptake that was greater than this range.  
The NSCLC group was categorised further by histology subtypes comprising of 
three patients with Adenocarcinoma, six patients with Squamous cell carcinoma 
and 4 patients whose case notes did not detail any information regarding 
histology subtype. No differences were found between the ranges of values of 
percentage uptake which could help to differentiate between the histological 
subtypes in the NSCLC group.  
 Chapter 2    121 
Finally, the difference in percentage uptake calculated between 2 and 4 hours 
was assessed via a Wilcoxon signed rank test. This test concluded there to be no 
significant difference in uptake between the two acquisitions for the malignant 
group; p-value was 0.727, the estimated median was 0.005 and the 95% CI of (-
0.015, 0.020).  
The ability to reproduce the set-up conditions of the first acquisition proved 
more challenging for those patients who demonstrated a large BMI. These 
patients were often less compliant with the procedure and there was more 
variation with regards to the orbit of rotation. Increased orbits of rotation 
and/or scatter and attenuation within the patient compromised the ability to 
resolve and delineate the tumour volume accurately. To try to reduce the 
effects of attenuation, a Changs attenuation correction was applied. This form 
of attenuation correction, however, transforms the data linearly across its 
volume independent of the material that the photon traverses through which 
depending on the sex and BMI of the patient could be breast/fatty tissue or 
simply lung. Therefore counts in the lungs are over-corrected, which would have 
contributed to increased uptake in lung background regions. With this in mind, 
where accuracy is important, this form of attenuation correction may not be the 
best tool when considering image quantification. 
Work with the in-house designed and manufactured phantom was undertaken to 
validate the results and characterise changes but the phantom is a static 
geometric volume with components that have discrete boundaries and is 
acquired under ideal conditions including no repositioning. These factors should 
be taken into consideration when comparing the patient data to the phantom as 
the patient volume is a dynamic volume as a result of breathing, it often has 
non-discreet tumour boundaries, none of which the phantom could replicate. 
However, what the phantom work does provide is a threshold for the minimum 
differences able to be measured. 
Quantification in the mediastinum was subject to the same drawbacks 
demonstrated by tumour quantification. However, in addition to this on the SPET 
imaging, nodes could only be characterized purely based on their size and shape 
which could not be confirmed. This combined with a lack of anatomical Chapter 2    122 
information meant that comparison with any histology could not be undertaken 
accurately.  
Due to Depreotide’s high binding affinity to NSCLC tumours, consideration has 
been given to its use as an agent for radionuclide targeted therapy. The top row 
of Figure 46 demonstrates an area of focal uptake in the right lung with proven 
positive histology whilst the bottom row is from a patient who also demonstrates 
focal uptake in the left lung which is similar in size and shape but whose 
histology demonstrated benign disease. 
 
 
Figure 46 - Spot the difference 
Image showing a coronal and transverse slice from a patient with positive NeoSPECT 
uptake with histologically proven malignancy - top row. The coronal and transverse slices 
on the bottom row are from a patient who has histologically proven benign disease.  
 
Although NeoSPECT imaging was unable to differentiate between benign and 
malignant groups, work undertaken in section 2.4 does provide a quantitative 
indication of this binding affinity. Results demonstrated lower than anticipated 
T:B ratios which may be partly due to difficulties in identification of true 
background lung tissue as many patients also had uptake which was related to 
benign processes in addition to the tumour. If characterisation of the tumour 
tissue could be achieved by some other method and Depreotide was to be used Chapter 2    123 
as a targeted therapy agent then identification of additional benign processes in 
the lungs must be considered as there is the potential to damage non-malignant 
tissue and therefore reduce capacity and function. The fact that significant 
uptake exists in benign disease make it unlikely that a therapy agent based on 
NeoSPECT would be of any value.  
In addition to there being no significant difference between the malignant and 
benign groups using T:B ratios from both standard and dual time imaging, there 
was also a failure to successfully calculate uptake from SPET data. A major 
reason for the failure of SPET to calculate uptake accurately lay with the 
accuracy of the sensitivity measurement and the use of an attenuation 
correction. The accuracy was dependent upon replicating the attenuating 
conditions of the patient acquisition in the standard acquisition as these 
conditions influenced the value of sensitivity calculated. This is easily achieved 
in some other forms of image quantification, namely thyroid uptake 
measurements, as the amount of attenuating tissue is limited by the anatomical 
position of the thyroid gland, where the average amount of attenuating tissue is 
easily estimated and incorporated into a standard phantom providing a more 
accurate measure of sensitivity. However, depth is a factor when considering 
uptake within the thorax as the depth of the tumour between patients varied, a 
factor which is compounded further by BMI and breast tissue therefore the 
amount of attenuation was difficult to estimate and standardise for the purpose 
of the standard acquisition.  
The standard acquisition was not the only difficulty realised. There were a 
number of issues that impacted on the quality of the data. These included 
patient compliance and movement, repositioning, patient size and sex which had 
an obvious impact on the amount of attenuating and scatter material and its 
position within the patient volume.  
Recent advances in Gamma Camera hardware and software may help to 
eliminate some of the problems experienced. Firstly, there were a number of 
physical difficulties which simply could not be overcome such as the patient’s 
flexibility and general compliance. These often led to large orbits of rotation 
i.e. large distance between the detector and the thorax of the patient. This led 
to subsequent degradation in image quality in other words resolution. It then Chapter 2    124 
became difficult to accurately delineate the tumour boundaries. For the patients 
detailed, the orbit of rotation was limited by the gamma camera system itself as 
the heads were only capable of undertaking a circular or elliptical orbit with a 
fixed maximum radius. However, nowadays almost all gamma cameras are able 
to closely contour the patient’s diameter via motion sensors and are also able to 
correct for increased patient to detector distance by storing information about 
the orbit of rotation in the acquisition header files and by the use of resolution 
recovery. Another change to the way images are acquired is the addition of a 
scatter window, which allows the peak window data to be corrected for a 
contribution due to scatter during the reconstruction process. 
Probably the biggest advance in gamma camera technology which could 
potentially have a massive impact on the data presented is the advent of Hybrid 
Imaging. SPET-CT systems are now widely available and are simply a double 
headed gamma camera with a CT unit bolted onto the gantry. These systems 
allow a SPET acquisition to be performed followed by a low dose CT which in 
turn is used to create an attenuation map for the patient. The attenuation map 
allows for a truer attenuation correction to be performed. If this correction 
could be used to provide a more accurate calculation of percentage uptake then 
it may be that this value would prove useful in optimizing the dose of NeoSPECT 
for target therapy. Chapter 4 - Octreotide, details further investigation of the 
influence and effect of an attenuation correction on SSR images.  
All of these new features could have potentially impacted on the quality of the 
data and results both qualitatively and quantitatively, in particular the 
estimation of sensitivity derived from the standard acquisition. If the 
attenuation and scatter in the patient could be accounted and corrected for, it 
raises the question of whether or not the standard acquisition requires to mimic 
that of the patient in terms of its attenuation and depth characteristics. The 
standard acquisition could simply be the acquisition of a vial of known activity 
and volume and therefore a more accurate measure and calculation of 
sensitivity. This would have to be investigated further, see Chapter 4. 
In terms of its localisation ability, SPET-CT would have no doubt proved a 
powerful tool in the identification of tumour volume. Correlative imaging could 
have allowed for the tumour ROI volume to be defined on the CT images and the Chapter 2    125 
ROIs copied to the SPET volume which could have simplified the ROI analysis 
process and reduced any delineation inaccuracies caused by the partial volume 
effect and scatter in the SPET image. Review of some of the patients’ CT data 
showed tumour volumes that were very discrete on the CT images but on the 
SPET data demonstrated multiple focal areas rather than one large diffuse 
volume. This additional anatomical information could also have helped improve 
the identification of normal/disease free lung required as part of the T:B 
analysis.   
When assessing uptake in the mediastinum, one of the other major difficulties 
with the SPET only data was the characterisation of this uptake, as uptake was 
considered to be nodal based on its size, shape and location. The actual source 
of this type of uptake could not be confirmed and therefore SPET-CT would have 
helped identify whether the uptake corresponded to that of a lymph node.  
Another equally difficult problem was in identifying which nodes actually had 
uptake and these suspected areas of nodal uptake could only be regionalized in 
terms of their gross location in the thorax. This made correlation with the 
histological findings and/or any other imaging difficult if not impossible. Again  
SPET-CT could have provided the additional localisation information required, 
and confirmed if uptake demonstrated was that of a lymph node or not. In 
addition SPET-Ct would have improved the confidence in the identification of 
any potential additional nodes with low grade uptake. 
The quantitative results detailed in the thesis did not discover any statistically 
significant differences between the benign and malignant group. “Neo SPET-CT” 
could possibly lead to a clearer differentiation between the groups through its 
ability to identify and compare large differences in the tumour volume based on 
the CT and compare these with the SPET distribution. This imaging technique 
could also potentially help indicate early infiltration of disease to surrounding 
tissue, allowing disease progression or response to treatment to be monitored 
more accurately. This could also be true for lymph node involvement.  
Whilst it could be argued that a diagnostic CT data would be obtained for these 
patients the reality is that there is often a notable time difference between both 
forms of imaging during which time there could be disease progression in the 
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defined using previous CT imaging may not prove to be reliable. In addition 
breath hold diagnostic CT images are often very different from the SPET studies 
where a breath hold image would be impossible. 
In spite of the small sample sizes, the data show no clear message that 
NeoSPECT could be used to differentially diagnose malignant from benign 
disease, or to sub-categorise tumour type. The image data however does 
demonstrate clearly that these images can show disease tissue both in the main 
lung tumour sites and uptake in lymph nodes within the mediastinum. Although 
this had been previously reported by Waxman, 2002, this had not been 
previously quantified. Quantitative work undertaken in this thesis failed to 
provide any additional value to previous findings as a result of being unable to 
successfully correlate the lymph node uptake with the node sampled 
histologically. 
Further work 
In order to determine whether or not “NeoSPECT-CT” could have improved the 
quality of image data significantly enough to lead to an improvement in the 
sensitivity of the quantification measurements the natural step would be to 
assess future NeoSPECT and SPET studies with SPET-CT. Unfortunately timing 
made this impossible but in order to investigate this work will be presented in 
chapter 4 looking at the use of SPET-CT with another type of SSR imaging agent, 
octreotide. 127 
Chapter 3 - Hybrid Imaging 
3.1 SIEMENS Symbia T 
The first SPET-CT unit was developed during the 1980s and 1990s at the 
University College of San Francisco. The development of this type of system 
stemmed from a desire to add anatomical information to the excellent 
functional imaging of nuclear medicine. In addition the CT component could be 
used to correct for image degradation caused by soft tissue absorption 
(attenuation) which is a problem with all nuclear medicine imaging. 
The first commercial system using a CT tube became available in 1999 and was 
manufactured by GE Healthcare as the GE Millennium VG Hawkeye
TM. This 
comprised a standard double headed VG gamma camera and a CT component. 
The CT component of the Hawkeye system was designed with cardiac imaging 
and attenuation correction specifically in mind and, because of this, was 
designed specifically to produce low dose, single slice CT images. The CT tube 
was designed for slow tube rotation - this was a considered and deliberate 
feature of the design in an attempt to produce a CT image that better matched 
the nuclear medicine component in terms of patient movement, caused 
primarily by patient breathing. 
During 2006, Glasgow Royal Infirmary (GRI) were inviting manufacturers to 
complete a tender application for a SPET CT system. At this time there were 
three major manufactures of SPET-CT units involved; GE Healthcare, Phillips 
Medical Systems and Siemens Medical Systems. In January 2007, following the 
tendering process, GRI installed and commissioned a Siemens Symbia T SPET-CT 
unit as shown in Figure 47. 
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Figure 47 - Symbia T 
Image of the Symbia T Hybrid Imager at GRI.  
 
There were a number of small differences between these units, most of which 
were subtle and software based, but the largest and most important (to GRI) 
difference between these units was the CT component. The Siemens Symbia T 
offered a fully diagnostic 2 slice tube optimized to produce low dose CT images 
meaning the functionality and image parameters were limited only by 
preprogrammed software rather than hardware. Since the CT tube was a 
diagnostic tube, images could be acquired at a much faster rate, leading to less 
movement artifact in the CT image and thus, when compared to the GE unit, a 
better quality CT dataset. The software however limited this tube to work at low 
dose. The Phillips Medical system incorporated a high dose fully diagnostic 6 
slice CT tube which made the unit very expensive and as our tender and 
requirement for imaging was primarily for the SPET component of the machine, 
the Phillips system was not considered as a result of cost and the high CT dose. 
 
 
CT Component 
Nuclear Medicine  
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3.1.1 CT Technology 
The first ever commercial CT scanner was the EMI scanner, which was installed 
in 1970 at the Atkinson Morley Hospital in Wimbledon, England. This was as a 
result of work undertaken by Godfrey Hounsfield, a British Electrical Engineer 
who was working for EMI Central Research laboratories in England.  
In 1979 both Hounsfield and a South African born American Physicist Allan 
McLeod Cormack shared the Nobel Prize in Medicine. Both scientists had worked 
independently of one another, Cormack being recognised for developing the 
associated mathematical theory and Hounsfield for applying this theory and 
creating the first ever CT scanner, (Wiki-CT, 2011). 
Of the two scientists, Hounsfield is probably the more recognisable as his name 
was given to the unit used to quantify the radiodensity of structures. The 
Hounsfield Unit, HU, is defined in Equation 10. 
water
water material HU
m
m m -
= * 1000    
Equation 10  
(Delbeke & Israel, 2010) 
 
where µ is the linear attenuation coefficient and HU the hounsfield unit. Typical 
values of HU for common substances are given in Table 33. 
Substance  Hounsfield Unit, HU 
Air  - 1000 
Fat  - 120 
Water  0 
Muscle  + 40 
Contrast  + 130 
Bone  + 400 or more 
Table 33 - Typical Hounsfield Units  
(Wiki-Hounsfield, 2011) 
 
In terms of its hardware, the CT component of the Symbia T comprises a 
diagnostic tube and two rows of detectors (known as slices). These are optimised 
via the system’s software to acquire only low dose CT volumes.  Chapter 3    130 
Despite the Symbia having a diagnostic tube the images, in comparison with 
current day CT scanners, are considered of low quality and ‘non-diagnostic’. This 
is due to the acquisition properties including lower mAs (tube current) although 
the image quality is also related to the system’s default smoothing kernel used 
to reconstruct the raw CT data (Siemens, 2005).  
In a bid to optimise the resolution of CT images acquired, the size of the 
acquisition matrix was considered. Although this parameter could be modified it 
could only be achieved through a very indirect manner. The matrix of the 
Symbia T’s CT is dictated by the matrix size of the SPET acquisition, that is the 
matrix size of the CT will always be double the matrix size of the SPET 
acquisition. Typically, SPET acquisitions are acquired using a 128x128 matrix to 
achieve good count statistics per pixel, which would result in a CT with a 
256x256 matrix. Careful consideration was given to what size of SPET acquisition 
matrix would produce the best possible resolution of the CT without 
compromising the SPET image quality. Within the limitations, the preference 
was to produce a CT with 512 x 512 matrix from a SPET acquisition acquired 
using a 256 x 256 matrix. However, software on the Symbia allowed for rebinning 
of the raw SPET acquisition data following the CT acquisition which meant that 
the raw SPET data could be folded back down to a 128 x 128 matrix. All SPET-
CT’s were undertaken by acquiring 256 x256 SPET with a 512 x512 CT.  
The Symbia’s default smoothing kernel used for reconstruction is the B08s which 
must be applied if the CT is to be used to perform an attenuation correction. 
However the Symbia T offers 3 smoothing kernels to reconstruct the raw data; 
B08s, B30s and B60s, B08s being the lowest in terms of resolution, because it has 
the highest smoothing and the B60s the highest resolution (less smoothing). 
Whilst B08s must be used when performing attenuation correction, the senior 
radiologist decided that the B60s was the most suitable smoothing kernel for CT 
images as part of SPET-CT localisation as this kernel produced sharper images.  
In addition to the aforementioned parameters, the Symbia software also has the 
option of working in ‘CareDose4D’ mode which is used to ensure the lowest dose 
to the patient. The ‘CareDose4D’ mode uses Automatic Exposure Control, AEC, 
techniques and is achieved by firstly acquiring a topogram/scout view. This 2D 
acquisition is able to determine the radiographic density of the patient. The Chapter 3    131 
density profile, along with a fixed tube voltage of 130kVp, is used to modify 
other CT parameters according to the patient’s size. In this way, the system 
ensures that the parameters for a thin patient are not equal to those of heavier 
patients (Siemens, 2006). 
The dose is therefore optimised on a patient by patient basis. If a patient is 
larger than average, the dose modulation system adjusts the acquisition 
parameters to ensure the best image quality with a specifically set reference 
mAs. The system employed at GRI aims for a reference current of 17mAs.  
 
3.1.2 New SPET Reconstruction Algorithms 
Section 1.2.2 of Chapter 1 details two very different approaches to 
tomographic image reconstruction. As discussed, originally tomographic 
reconstruction took an analytical (FBP) approach but has since moved onto an 
iterative approach in the form of OSEM algorithms, as used for the 
reconstruction of the NeoSPECT patient data. These algorithms have been 
improved further by the addition of resolution recovery.  
The Symbia T software, Syngo, provides both analytical and iterative techniques 
for SPET data reconstruction. Of the iterative reconstructions, there were 2 
techniques available; the standard 2D OSEM as described in previous chapters 
and Flash 3D.  
Flash 3D reconstruction is a Siemens OSEM algorithm with resolution recovery. 
The resolution recovery component of the algorithm compensates for 
degradation to image resolution caused by the increased distance placed 
between the source, in this case the organ within the patient, and the detector. 
There are two main causes for increased source to detector distance: 
1.  Collimator depth. 
2.  Radius of rotation, which is dictated by patient circumference and/or 
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Loss of resolution with increasing distance is illustrated in Figure 48. The ‘True’ 
line for collection of projection data is shown along with the ‘reality’ which has 
been shown as a fan beam for the purpose of illustration. This means that the 
area of acceptance for gamma rays increases with distance from the detector 
therefore gamma rays from outside the ‘True’ projection will be accepted by 
the detector and this causes blurring of the projection image.  
 
 
Figure 48 - Loss in resolution with increasing distance 
Image demonstrating the loss in resolution with depth, the blue circle represents a focus of 
activity and the long grey rectangle, the detector. 
 
The fan beam model can be incorporated into the OSEM algorithm and on the 
Symbia this is known as OSEM 2D reconstruction but resolution recovery is a 3D 
problem and therefore a cone beam provides a true representation of the 
collection of gamma rays out with the ‘True’ projection. The Siemens Flash 3D 
algorithm uses a cone beam model and is therefore able to correct for the 
acceptance of gamma rays out with the true projection in 3 dimensions. Siemens 
use detailed information of the collimator and orbit of rotation to model this 
effect and include this correction to the iterative reconstruction (Lawson, 2011) 
3.1.2.1  Scatter and CT attenuation Corrections  
All Nuclear Medicine imaging is susceptible to the effects of attenuation and the 
scatter of gamma rays within the body. Image degradation due to scatter occurs 
when gamma rays from elsewhere in the body are deflected from their original 
path (true projection), during this process they lose only a small quantity of 
their energy, and are subsequently detected in the photo-peak of another 
Projection 
True 
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projection. It is the summation of all of these reduced energy gamma rays which 
broaden the base of the photo-peak when detected and cause image degradation 
by image blurring.  
In addition to reducing image quality, the inclusion of scattered gamma rays 
within the photo peak will also have an impact on any image quantification 
undertaken.  
It is important to attempt to correct the images for these scattered photons and 
there are two methods that can be used. The first method involves measuring 
the scatter, which is achieved via either Dual Energy Windows (DEW, 
99mTc 
acquisitions) or Triple Energy Windows (TEW, 
111In acquisitions). Alternatively, 
the scatter correction can be corrected for by modeling the scatter using, for 
example, Monte Carlo Modeling.  
Siemens Flash3D corrects for scatter using the DEW or TEW method by directly 
measuring the scatter windows. This estimated measure of scatter is applied to 
the estimated slice created in the ‘expectation’ stage of the OSEM algorithm and 
to back projection of the raw data.  Figure 49 is a screen capture from a SPET 
acquisition performed on the Symbia T. It shows two energy windows which are 
preset by Siemens for Tc99m scatter correction. Window A is the photo-peak and 
window B is the scatter window.  
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Figure 49 - Symbia SPET Example of Scatter Windows, DEW 
Image showing a screen capture of the energy spectrum taken from the Symbia of a Tc99m 
SPET acquisition. The dual energy windows A and B are shown, Window A (in red) is the 
main Tc99m photopeak centred on 140keV and Window B (in blue) is the scatter window 
used.  
 
In addition to being able to correct for scatter, both the Siemens Flash3D and 
OSEM2D algorithms also allow for an attenuation correction to be applied.  
In Chapter 2, attenuation was corrected for by using a uniform geometric 
technique. The Symbia T, however, utilises the data from the low dose CT to 
convert HU’s into attenuation coefficients (MU) and is therefore able to produce 
a map of these, an MU map. An example of an MU map is shown in Figure 50.  
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Figure 50 - Symbia MU Map 
Images show a low dose CT transverse slice through a patients abdomen (Image to the left) 
and the corresponding screen capture from the Symbia of the MU Map (Image to the right). 
 
The standard conversion from CT HU to MU is usually in the form of a ‘piece-
wise’ bilinear fit model as firstly described by Blankespoor et al in 1996 (Brown, 
2008). The bilinear model makes a distinction between materials which are 
comprised of air-water and water-bone. Therefore there are two HU dependant 
equations that must be used to perform the conversion. The first equation is 
used for HU values less than 0, refer to Equation 11. 
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The second equation is used for HU values greater than 0, refer to Equation 12. 
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Recent work undertaken by Brown et al (Brown, 2008) described an adaptation 
of this model which aimed to provide a simpler approach in that instead of using 
two equations to perform the conversion a single equation could be used, as 
described using Equation 13.  
) ( 0 HU a y ´ + = m  
Equation 13 
 
where µ is the attenuation coefficient, y0 is the attenuation coefficient of water 
(when HU = 0,), a is a material scaling factor and HU is the Hounsfield unit.  
However, to maintain the bilinear model approach a scaling factor, a, was 
introduced which differentiated between the two distinct types of material 
used, with HU <0 and HU >= 0. To convert HU into attenuation coefficients using 
a 120 kVp CT and for a radionuclide with energy of 140 keV the following values 
should be inserted into Equation 13: 
1.  y0 = 0.149cm
-1. 
2.  For HU values less than 0, a = 0.15x10
-3.  
3.  For HU values greater are than or equal to 0, a = 0.14x10
-3.  Chapter 3    137 
Using these values the conversion can be calculated and is shown as in Figure 
51.
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Figure 51 - Bilinear Response  
The relationship between the attenuation coefficient and the Hounsfield unit for a 140keV x-
ray as described by Brown et al. 2008. 
 
The various values of MU’s for specific radioisotopes along with values of 
effective energy of the CT are stored in ‘look up’ tables within the 
reconstruction algorithm. Despite information regarding the exact method 
employed by Siemens being unavailable, the conversion will take the form of a 
bilinear model and will be accessed via lookup tables.  
Similar to the treatment of scatter, the OSEM algorithm applies these factors to 
both the estimated and measured data sets. However, it is important to note 
that the relationship described by Brown et al assumes a narrow beam, meaning 
data which have been corrected for scatter. 
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3.2  Influence on Bone Imaging 
Since its installation, the department at GRI has undertaken over 2500 SPET CT 
acquisitions, a large proportion of these having been undertaken following 
review of the planar whole body bone images. The added CT information has 
been particularly useful in differentiating between benign or traumatic disease 
and that which is malignant in origin.  
 
3.2.1 Characterisation of indeterminate Bone Scan Findings 
Figure 52 highlights the importance of the SPET-CT’s ability to differentiate 
between benign and malignant processes.  
 
Figure 52 - Benign Versus Malignant 
Images shown are of a whole body planar bone scan with several areas of increased Tc99m-
MDP uptake, indicated by red arrows. The corresponding transverse and sagittal slices from 
fused SPET-CT demonstrating benign bone disease are shown on the right.  
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The whole body planar image is from a patient with known prostate cancer with 
a general deterioration in overall health and left sided leg weakness. The 
appearances seen on the bone scan were in keeping with the patient’s symptoms 
and raised the suspicion of bone metastases. SPET-CT of these areas, however, 
demonstrated degenerative disease with no evidence of bone metastases. 
 
3.2.2 Incidental Findings 
In addition to improving the diagnostic accuracy (Han 2010) of the bone scan, 
the CT component of the acquisition has also been useful in displaying other 
incidental findings. 
A whole body bone scan was performed on a 63 year old woman who was newly 
diagnosed with breast cancer and complained of back pain. A whole body scan 
was undertaken to stage the disease before the appropriate management could 
be decided.  The bone scan showed multiple areas of increased uptake which, 
although suspicious of metastases, could also have represented degenerative 
(benign disease). This patient went on to have SPET-CT of the mid thoracic 
spine.  
 
Figure 53 - SPET CT; Invasion of Spinal Cord 
Image shown are transverse slices of a patient with spinal cord invasion; CT image on the 
left, Tc99m MDP bone SPET image centrally and the fused SPET-CT images on the right. 
 
The SPET CT confirmed the multiple areas of increased uptake to be metastatic 
disease caused by multiple sclerotic lesions. In addition to these the scan also 
demonstrated a large destructive lesion in the T10 vertebra which was invading 
the spinal canal and therefore had the potential to compromise the integrity of 
the spinal cord as shown in Figure 53. As a direct result from the SPET CT, the Chapter 3    140 
patient went on to have an urgent MRI of the thoracic spine and was treated 
with radiotherapy for impending cord compression.  
Figure 54 demonstrates another example of a suspicious area of uptake, this 
time the area of abnormality appears to involve the right side of sacrum as 
shown by the red arrows.   
 
Figure 54 - Calcified Fibroid 
Images shown are of a whole body planar bone scan with an area of increased Tc99m-MDP 
uptake overlying the right side of sacrum, indicated by red arrows. The corresponding 
transverse CT, SPECT and SPET-CT Fused slices, on the right, demonstrated a calcified 
fibroid.  
 
As can be seen in Figure 54 the area of abnormality did not actually lie within 
the bone but out with. Without SPET CT imaging, the reporter would have had to 
rely on either interval bone imaging or imaging using another modality to 
confirm or exclude bone metastases as the diagnosis.  
In the department at Glasgow Royal Infirmary, it has certainly been the case 
that SPET-CT has demonstrated a large reduction in the number of 
indeterminate bone scan reports being issued and subsequently reduced the 
number of patients for whom in the past a repeat bone scan after a reasonable 
period of time may have been required. It has also reduced the number of 
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form a definitive diagnosis (Han et al, 2011).  However, despite aiding the 
diagnostic value of planar whole body bone scans, when the unit was installed 
there was very little published information regarding the use of SPET- CT in 
quantitative imaging other than in the area of cardiac imaging. Work undertaken 
in the remaining and following chapters was undertaken to investigate whether 
or not the accuracy of NeoSPECT quantification could have been improved with 
the use of SPET CT imaging. This involved careful assessment of the associated 
reconstruction algorithms and an evaluation of the qualitative differences in 
uptake in the abdomen, pelvis and (to a lesser extent) the chest demonstrated 
between the existing and new SPET imaging techniques.  
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3.3 Customised Phantoms for SPET-CT 
The size, shape and function of individual organs can vary greatly between 
patients, leading to variations in the distribution of radiopharmaceutical within 
the patient. Identification and understanding of normal, abnormal and 
physiological uptake of the radiopharmaceutical is paramount in assessing the 
parameters for the reconstruction technique. In order to allow the accuracy of 
the image processing to be measured and to achieve a more in depth 
understanding of the reconstruction processes in particular the processing 
involved in the CT attenuation correction, a phantom was essential. Phantoms 
allow a known activity and distribution of radiopharmaceutical to be imaged in 
idealised circumstances and this means that the reconstructed data set and any 
measured parameters can be compared with this known distribution. 
There are few anthropomorphic phantoms currently available commercially 
which are suitable for nuclear medicine purposes. There are even fewer that are 
suitable for new hybrid nuclear medicine SPET-CT units.  
To overcome this problem, a bespoke phantom that met the needs of the 
research project and that could be designed and manufactured in-house was 
required. This phantom had to mimic a patient and therefore had to contain 
components which represented bone, lung and liver, the properties of which had 
to be applicable to both the Nuclear Medicine and the CT aspects of imaging.    
Designing a phantom with known dimensions of vessels and compartments, also 
allowed the accuracy of SPET quantification to be assessed. This is achievable as 
known activities of radiopharmaceuticals can be introduced to the individual 
compartments of the phantom allowing a comparison of calculated activity to be 
made with actual activity. This also allowed the phantom to be used to 
determine the effect of both reconstruction techniques and filter parameters.  
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3.3.1 Requirements 
The main purpose of the phantom was to mimic some of the different 
attenuating volumes and structures found within the thorax of a patient. It had 
to include therefore a volume representative of lung, bone, liver and general 
tissue. The design brief for this phantom raised the following questions: 
1.  What is the purpose of the phantom? -  The phantom will be used to 
assess the accuracy of reconstruction techniques and post processing 
activities. 
2.  Physical Size? - Approximate dimensions, in mm, 250-300 diameter x 300 
high. 
3.  Weight? - As light as possible for easy handling, when filled with liquid. 
4.  Materials? - Mainly perspex and no metals. 
5.  Compartment Contents? - Saline solution, water, polystyrene beads to 
represent air in the lungs, and liquid bone solution. 
6.  Adaptability? - If designed to include bone, liver, lung and tumour 
compartments this should cover any future requirements. 
A number of features had to be considered for this phantom. Firstly, the volume 
had to be large enough to house additional smaller volumes within it. Two of 
these volumes would have to simulate lung compartments. These compartments 
would contain both polystyrene beads and liquid solution (radioactive). The 
polystyrene beads to simulate an air component to the compartment in keeping 
with the actual lung. This is the same approach used by RDS phantoms for their 
lung component in their anthropomorphic phantom (RSD Phantom). Additional 
objects may be placed inside either or both of the lung compartments to mimic 
tumour volume. These compartments must be easy to fill and evacuate.  
The liver compartment required to be a simple volume not requiring any 
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liquid filled (not necessarily radioactive) and must be filled and evacuated 
easily.  
The spinal cord compartment, surrounded by material mimicking bone, also 
required to be filled and evacuated easily with liquid (radioactive solution). 
The distribution of the compartments within the main compartment of the 
phantom should mirror the distribution of organs and structures normally found 
within the thorax; refer to Figure 55. 
 
Figure 55 - Guide to compartment distribution within phantom 
Image showing the basic distribution of compartments required for the SPET-CT phantom.   
 
All compartments including the main vessel required a system which allows the 
phantom to be filled and vented easily to avoid air bubbles.  
 
3.3.2 Phantom Design 
Throughout the manufacturing process of the phantom, the design went through 
a number of transformations to accommodate the limitations of the materials 
used and to keep the size and weight of the phantom to a minimum.  
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Firstly, the overall size of the phantom had to be reconsidered, as the weight of 
the phantom when filled with liquid solution made it too heavy to transfer and 
therefore impractical. In addition to this, the weight of the phantom when filled 
with liquid was stressing the joins/joints, compromising the water seal and long 
term durability of the phantom.  
A compromise had to be achieved that would allow the phantom to be filled with 
liquid whilst still being able to meet the requirements described in Section 
3.3.1. This was achieved by removing one of the lung components, therefore 
reducing the overall radius of the main body of the phantom - see Figure 56. 
 
Figure 56 - Schematic of Phantom (including actual dimensions) 
Image showing the detailed design schematic of the SPET-CT phantom produced in-house 
by the mechanical workshop. 
 
Figure 56 is the actual schematic that was approved for in-house manufacture. 
This schematic shows a bone, lung and a liver component with a tumour volume 
within it.  Chapter 3    146 
The main body of the phantom was made from perspex moulded into a 
cylindrical shape. The base and lid of the main volume were then fixed to the 
moulded cylinder via an adhesive. 
In order to create two separate compartments that lay one directly above the 
other, i.e. to emulate the anatomical distribution of liver and lung, a solid 
cylinder of perspex had to be drilled out. Two cavities were therefore created 
that were separated by a small layer of perspex. The bone compartment was 
fashioned in a similar manner to the lung/liver components and this cylindrical 
compartment contained another cylindrical compartment that would essentially 
act as the spinal cord.  The spinal compartment was the only volume within the 
main body of the phantom that extended over the entire inside length of the 
phantom. The final in-house manufactured phantom is shown in Figure 57. 
 
Figure 57 - In-house manufactured SPET-CT Phantom 
Image of the actual phantom produced by the in-house mechanical workshop. The red 
arrows indicating the compartments included in the original basic design. 
 
In terms of the thickness of perspex, either drilled or moulded, there was only 
one real specification and that was for it to be as thin as practicable but no 
thicker than 10mm as nuclear medicine imaging is unable to resolve structures 
less than approximately 10mm. The most challenging aspect of the phantom was 
the bone component, as this compartment was required to have similar 
properties to bone in terms of electron density. 
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3.3.2.1  Bone Substance 
Bone is composed of 2 discrete components: cortical and trabecular bone, the 
abundance of these components being dependent on the type of bone. There are 
5 bone types in the human body each of which have varying densities (Stalheim-
Smith, 1993): 
1.  Long Bones - These are bones which are longer than they are wide. They 
have a strong layer of cortical bone encapsulating trabecular bone 
(examples include the femur and humerus). 
2.  Short Bones – These are bone that are as wide as they are long. They are 
comprised of a thin layer of cortical bone encapsulating trabecular bone, 
(examples include the wrists and ankle bones). 
3.  Flat Bones – 2 thin parallel layers of cortical bone surrounding a thin layer 
of trabecular bone (examples include the skull). 
4.  Irregular Bones – mixture of thin layers of cortical bone surrounding 
trabecular bone (example include the spine and hips). 
5.  Sesamoid Bones – mostly cortical bone (examples include the patella). 
The bone component of the phantom needed to simulate bone within the thorax 
and abdomen. A material/substance similar to vertebral bone, in other words 
irregular bone, was required. Sourcing such a solid material proved difficult and 
equally any materials found were expensive and the ease of the subsequent in-
house manufacturing process was difficult to assess. 
An alternative approach to a solid piece of material was to consider a liquid 
solution that could emulate vertebral bone. This option provided the phantom 
with a greater degree of flexibility in terms of its use i.e. if a bone component 
was not required it could easily be removed, it also gave rise to the possibility of 
varying the concentration of bone solution depending on which type of bone was 
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The use of liquid solution to emulate bone has been used in the past (Hosie, 
1993), by dissolving various weights of Potassium Hydrophosphate (K2HPO4) in 
water to achieve varying concentrations that could mimic different bone types 
i.e. liquid bone. It was decided that a K2HPO4 solution was ideal for use in the 
phantom as it could be sourced in-house, was relatively inexpensive and varying 
concentrations could be made up to meet the requirements of use. 
3.3.2.2  Identification of correct bone solution concentration 
From Hosie’s paper, a concentration 150mg/ml was deemed an appropriate 
K2HPO4 solution. However, this had to be tested therefore the solution was 
added to the long bone cylinder as shown in Figure 57. To assess the 
appropriateness of the solution, it was necessary to establish whether it 
mimicked true trabecular vertebral bone in terms of its electron density. To 
determine this, region of interest analysis was performed on a number of patient 
CT’s. Table 34 details typical demographics of bone scan patients seen in the 
department.  
  Total Number  Average Age (Years), Standard Deviation 
All  2051  65.1 Yrs, 14.3 
Female  1132  63.3 Yrs, 14.5 
Male  919  67.3 Yrs, 13.8 
Table 34 - Bone Scan Performed January 08 - December 2008 
 
In total 10 patients were selected at random, whose age ranged between 62 – 89 
years; 6 patient were female and 4 male. Two of the 10 patients were known to 
have osteoporosis. Chapter 3    149 
 
Figure 58 - Standard ROI for Patient CT 
Image of a CT sagittal slice from a patient though the lower abdomen and pelvis, including 
an example of ROI placements within the vertebrae.   
 
In each case, the vertebrae selected demonstrated no visual abnormalities and 
ROI analysis was performed over 10 slices on both the coronal and sagittal 
planes. From the ROI’s, values of Hounsfield Units (max) were obtained. Figure 
58 demonstrates the standard ROI used to obtain values. 
An average was taken and over the 10 slices for each plane, these are given in 
Table 35. ROI analysis was also performed on the phantom - as shown in Figure 
59 and average values are also given in Table 35.  
Patient  Average HU from Coronal Slices  Average HU from Sagittal Slices  
Patient 1  186  182 
Patient 2  259  252 
Patient 3  350  313 
Patient 4  241  237 
Patient 5  360  320 
Patient 6  284  247 
Patient 7  289  263 
Patient 8  165  137 
Patient 9  237  210 
Patient 10  244  239 
Phantom  234  243 
Table 35 - Patient Trabecular Bone Values and Phantom Values 
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Figure 59 - SPET CT Phantom ROIs 
Image shown is a transverse CT slice through the in-house SPET-CT phantom and the 
placement of the ROIS used to measure the Hounsfield units. 
 
Hounsfield Units for patient data of normal trabecular bone ranged between 
137HU and 360HU with a mean of 250, the phantom gave an average value of 
238 HU which lies within the patient range. The bone component solution 
concentration was thus considered a suitable solution to mimic trabecular bone 
found in the normal vertebrae.  
 
Summary/Conclusion: 
Production of the phantom proved to be a lengthy process; this was principally 
due to the continuously evolving design of the phantom as a direct result of 
material and manufacturing limitations. In addition to this, the correct 
identification, suitability, and sourcing of a material which could mimic 
trabecular vertebral bone in terms of its electron density proved challenging. 
For the most part, the 150mg/ml K2HPO4 solution provided HU values that were 
comparable to those demonstrated in actual patient CTs with normal bone, 
therefore this concentration of solution was used to fill the bone component for 
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The manufacture of this phantom including the bone component allowed 
accurate quantification to be undertaken using SPET-CT imaging including 
reconstructions with non-uniform attenuation corrections. Quantifications in 
chapter 2 showed that there were often inaccuracies in the measurement of 
acquired activity and it would seem reasonable to suppose that the application 
of attenuation correction (and to some degree scatter correction and resolution 
recovery) should improve these values. Work using this phantom to calculate 
measured activity will be discussed in Chapter 4. 
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Chapter 4 - OctreoScan Imaging  
4.1 Introduction 
The work undertaken in Chapter 2 raised two specific questions of whether or 
not hybrid imaging could improve firstly, the accuracy of the quantification 
achieved from SPET data as a result of using resolution recovery, scatter and CT 
- attenuation correction and, secondly, improve tumour delineation with the 
addition of anatomical information to the NeoSPECT data.  
As the Symbia-T SPET-CT was not installed until 2007, there was no scope to 
investigate these inferences with NeoSPECT as the department was no longer 
using this agent by then. However, another commonly used radiopharmaceutical 
which shares many properties with NeoSPECT is OctreoScan. Like NeoSPECT, 
OctreoScan is a somatostatin analogue, pentetreotide, which when Iabeled with 
In-111 is used to locate neuroendocrine tumours(NET) - see section 1.1.2.2 of 
Chapter 1 for more details.  
Since the mechanism of uptake for OctreoScan is thought to be similar to that of 
NeoSPECT, it was considered appropriate to undertake a retrospective review of 
32 patients who had an OctreoScan scan with SPET-CT as part of their normal 
management, and to assess and compare the corrections available with SPET-CT 
and the influence of the additional information on image quality.  
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4.2 Literature Review 
A literature review of SPET-CT OctreoScan was undertaken prior to the start of 
this study, but it was found that, as a result of the infancy of SPET-CT and 
resolution recovery reconstructions, there was a lack of published information 
available. This work stands on its own as there is little published work looking at 
OctreoScan specifically or even data specifically relating to indium-111. In 
addition to this, in the absence of data being available with depreotide, it 
allowed postulation of any improvements which might have been possible had 
SPET-CT been available. The work in this chapter sets out to investigate the 
claims set out in Chapter 2 relating to improvements which might have been 
possible while also aiming to establish if SPET-CT OctreoScan improved the 
detection of NET. In addition it was possible to use this data to investigate if the 
current standard imaging protocols should be amended in response to the 
availability of hybrid imaging.  
Since its installation at Glasgow Royal Infirmary, and following the time frame in 
which this work was carried out there has been an increase in the availability of 
SPET-CT systems throughout the UK and Europe. As a result there is now more 
work being published using these systems, including work using their 
commercially available reconstruction algorithms that allow factors such as 
scatter, non-linear attenuation and resolution recovery to be considered and 
corrected for.  
A comprehensive review of the clinical uses of SPET-CT was published in 2010 
(Mariani, 2010). This review identified a number of nuclear medicine 
investigations where SPET-CT imaging improved the overall specificity of the 
study in comparison with traditional planar or SPET only imaging.  
In terms of OctreoScan, in 2008 a study was carried out by Perri et al. (2008) 
looking specifically at whether or not the accuracy of detection and localisation 
of suspected NET  neuroendocrine tumour) in OctreoSCAN imaging could be 
improved with SPET-CT in comparison to SPET only imaging. A total of 81 
patients with known or suspected neuroendocrine tumours had SPET-CT 
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nature of lesions identified were validated with either histopathology or 
clinical/imaging follow up. In terms of patients, 92.6% were correctly classified 
using SPET-CT in comparison to 79% using SPET alone. Improvement in the 
localisation of lesions using SPET-CT was also demonstrated, 94.7% in comparison 
45.6% for SPET alone.    
The main motivation for the application of SPET image quantification is 
treatment dosimetry and monitoring treatment response. Cremonesi et al. 
(2006) identified OctreoSCAN as a suitable imaging substitute for mapping the 
bio-distribution of 
90Y, which can be labeled to a number of somatostatin 
analogues to be used as a form of treatment for somatostatin receptor positive 
neuroendocrine tumours. 
In a recent review of some of the literature available for absolute quantification 
in SPET published by Ritt et al. (2011), it was concluded that absolute 
quantification of activity using low energy radionuclides was achievable within a  
10% error.  
The review discussed the key elements affecting absolute quantification in SPET, 
such as attenuation, scatter and partial volume. There were a total of eight 
publications which specifically investigated absolute quantification using hybrid 
systems. Of note were in-vitro (phantom) work carried out by Shcherbinin et al. 
(2008) and in-vivo work by DaSilva et al. (2001), Willowson et al. (2008) and 
Zeintl et al. (2010).  
Shcherbinin et al. (2008) assessed the accuracy of absolute uptake of a number 
of radioisotopes (
99mTc, 
111In, 
123I and 
131I) using an anthropometric thorax 
phantom and a hybrid system. Results from which demonstrated activity 
estimations with errors which lay between 3% and 5% for all isotopes.   
All of the in-vivo work undertaken by DaSilva et al. (2001), Willowson et al. 
(2008) and Zeintl et al. (2010) were performed using hybrid systems and not 
independent CT system. DaSilva et al. (2001) investigated the accuracy of 
absolute quantification by quantifying uptake in the myocardium of adult pigs. 
Each pig was administered with 99mTc-Sestimibi, the animals were then killed 
after a short period of time and subsequently imaged with SPET-CT. Following Chapter 4    155 
imaging the heart was removed and activity within the myocardium measured. 
DaSilva et al. (2001) were able to demonstrate quantitative errors in the order 
of 10% regarding absolute quantification between the measured activity and that 
calculated from the SPET images.   
Quantitative accuracy of absolute uptake was assessed by Willowson et al. 
(2008) in lung V/Q SPET-CT imaging; quantification was undertaken of the 
perfusion phase (Q) of the study. This was not a dual isotope study, both the 
ventilation and perfusion were performed with 
99mTc, therefore the perfusion 
scan was corrected for background ventilation agent before quantification. This 
study demonstrated a difference between the measured activity injected and 
that calculated to fall between -7.4% to 2.1%, with an average error calculated 
at 2.6%.  
Zeintl et al. (2010), quantified the activity present in the bladder from patients 
undergoing 99mTc -diphosponate bone imaging. Urine was collected from the 
patient following SPET-CT imaging and activity measured using a well counter.  
Corrections were applied that accounted for the changes in concentration of 
activity within the bladder between the acquisition start time and the time at 
which the urine was collected. This investigation demonstrated errors which 
ranged between -7.8% and 16.9% with an average error of 6.5% in the estimation 
of activity. 
Of the validation studies reviewed by Ritt et al. (2011), either in-vivo (phantom) 
or in-vitro, the majority were performed using 
99mTc and there remains few 
published data on other isotopes, in particular 
111In. One recently published 
study by Assie et al. (2010), not included in Ritt et al. (2011) review, 
investigated the accuracy of 
111In quantification via phantom and monte carlo 
simulation data. SPET data was corrected for factors affecting image quality 
such as scatter, attenuation and partial volume effects. This work was not 
performed using a hybrid imaging system but a separate CT was acquired on 
independent system and used for non-uniform attenuation correction. VOI 
analysis was undertaken, where the VOIs were delineated by the CT. Assie et al. 
(2010) concluded accurate absolute quantification of 
111In from SPET acquisitions 
was possible using OSEM reconstructions algorithms that incorporated scatter, 
non-uniform attenuation and partial volume corrections. A less than 20% error Chapter 4    156 
was achieved in estimating activities of organs and tumours that were greater 
than 20mm in diameter.  
Despite a maximum error in estimating activity of 10% for 
99mTc, Ritt et al. 
(2011) acknowledged that the techniques to perform SPET-CT quantification 
requires strict reproducible patient set-up conditions along with the appropriate 
application of various corrections incorporated into the iterative reconstruction 
techniques. Based on the lack of autonomy in the patient set-up and image 
processing  Ritt et al. (2011) described the techniques used to date not entirely 
suitable for the clinical environment due to large time constraints required.   
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4.3 Patient Acquisition Data  
Patients attending Nuclear Medicine at Glasgow Royal Infirmary for diagnostic 
procedures are always asked to consent to the use of their images/data for 
teaching purposes and/or clinical audit. In addition to this the department was 
issued with a letter from the local research ethics committee, LREC, which 
stated that the use of SPET-CT could be considered as a service development 
and therefore ethics was not needed. Hence no application to LREC was required 
for this section of work. 
The standard activity of OctreoScan administered is 220MBq of Indium-111 
labelled octreotide in 2ml, it is administrated intravenously. OctreoScan studies 
include a whole body image and a SPET-CT image of abdomen/pelvis at 24 hours 
post injection. 
 
Figure 60 - Standard Images Acquired 
Images shown are of standard whole body planar OctreoSCAN images acquired at 24 and 
48 hours post injection (on the left) and transverse SPET, CT and Fused SPET-CT (on the 
right) of an area over the abdomen performed at 24 hours. Chapter 4    158 
24 hour imaging is followed by a whole body image at 48 hours post injection +/- 
a SPET-CT of any additional areas of interest if these have not been previously 
included in the 24 hour SPET field of view - see Figure 60.  
Acquisition parameters for the whole body images are detailed in Table 36.  
Collimator:  MELP 
Frame time:  10 cm / min  
Energy Windows (keV):  10% window on 172 and 10% window on 247 
Matrix:  1024 x 256 
Orbit:  Auto Body Contour  
Table 36 - OctreoScan Whole Body Acquisition Parameters 
 
In 2010 the European Association of Nuclear Medicine, EANM, published 
guidelines on OctreoScan imaging procedures, (Bombardieri, 2010). These 
guidelines suggest whole body imaging is undertaken at 3cm/min, however, our 
institution acquires whole body images using 10cm/min. 
For SPET imaging these guidelines suggest 45s per angle, whereas, the standard 
practice at our institution is 30s per angle. These guidelines also stipulated a 
64x64 matrix to be used for the SPET acquisition. Our institution performs SPET-
CT imaging, on the Symbia-T system and the quality of the CT images acquired 
are influenced by the SPET acquisition parameters. To produce a high quality CT 
the SPET data is acquired in a 256x256 matrix. The SPET 256x256 data is then 
binned down to 128x128 for reconstruction and display as discussed previously. 
Acquisition parameters of the SPET component are detailed in Table 37. 
Collimator:  MELP 
Degrees of Rotation:  360 degrees (180 each head) 
Frame time:  30 seconds  
Interval:  3 degrees 
Energy Windows:  5 Windows;  2 x Peak,  3x Scatter 
Matrix:  256 x 256 
Orbit:  Auto Contour  
Table 37 - OctreoScan SPET Acquisition Parameters 
 
From Table 37 it can be seen that aside from the peak data acquired for In-111, 
additional energy windows were also acquired. The Symbia T software was able 
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used as opposed to a fixed orbit of rotation as this ensures the orbit is as close 
to the patient as possible. 
Despite the fact that the application of a scatter correction had never been 
investigated locally, all SPET acquisitions acquired on the Symbia T were 
acquired with both peak and scatter energy windows. This approach was taken 
to allow data to be reviewed retrospectively and make a decision based on the 
data if the correction was deemed appropriate at a later stage.  
 
Figure 61 - Peak and Scatter Windows 
Image showing a screen capture taken of the energy spectrum from the Symbia of an In111 
SPET acquisition, the various peak and scatter windows acquired are shown. Windows A 
and B are the photopeak energies for In
111 while windows C, D and E are the relevant scatter 
windows. 
 
For In-111, scatter data was acquired below and above the first peak, and a 
scatter window was acquired below the second peak as illustrated in Figure 61. 
Prior to the Symbia-T’s installation reconstructions of OctreoScan SPET studies 
were undertaken on the Hermes system. These reconstructions did not include 
any scatter corrections. The software on the Symbia-T was capable of 
performing 3 different reconstruction techniques for SPET: 
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1.  Filtered Back Projection 
2.  OSEM2D- Siemens version of the Hermes OSEM (HOSEM). 
3.  Flash3D - This is an Iterative Reconstruction algorithm with Resolution 
Recovery which has the option of employing scatter and CT-attenuation 
corrections (SAC). 
The details of each technique have been discussed in previous chapters.  
Reconstruction Method:  OSEM – Ordered Subset Expectation Maximisation 
Subsets:  4 
Iterations:  8 
Number of slices:  Full Field of View  
Low Pass Filter Setting:  Gaussian FWHM  8.4mm (default settings) 
Zoom:  No Zoom 
Table 38 - OctreoScan OSEM Reconstruction Parametes 
 
To allow a direct comparison, the standard OSEM reconstruction parameters for 
OctreoScan studies used on the Hermes system were translated to the Symbia T, 
these are given in Table 38.   The post filter applied on the Hermes system for 
Octreotide  studies was a Butterworth filter with cut-off 0.8 cycles/cm and order 
5.  The shape of a Butterworth filter is shown in Figure 11.   On the Symbia T the 
post filter applied was a Gaussian.  Although the shape of this filter is different 
from that of a Butterworth (as it’s name implies it is shaped like a Gaussian), the 
effect on the image is similar.   This Gaussian filter is described by it’s full width 
at half maximum (FWHM) and on applying Siemens default setting (FWHM 
8.4mm) to the data, the reconstructions were judged by the clinicians at 
Glasgow Royal Infirmary to be comparable to those reconstructions from the 
legacy Hermes system.  For a Gaussian filter as the FWHM increases so does the 
amount of smoothing. 
 
4.3.1 Pilot Review of Flash3D Reconstruction 
Siemens heavily promote the use of resolution recovery, Flash3D, in all SPET 
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differences between the standard reconstruction (OSEM 2D) and the new 
reconstruction technique (Flash 3D with and without corrections), it was 
important to become familiar visually with the basic Flash3D technique that is 
with no corrections, and to establish if there were any qualitative differences in 
image quality between the standard reconstruction and the basic Flash 3D 
technique. 
SPET acquisition data from 15 patients were selected at random. Since the data 
acquired were in a 256x256 matrix the data had to be binned down into a 
128x128 matrix prior to reconstruction. The data were reconstructed using both 
the OSEM 2D and the basic Flash 3D techniques, the parameters described in 
Table 38 for the OSEM2D were replicated for the basic Flash3D reconstruction. 
Both reconstructed SPET volumes were visually interpreted simultaneously using 
Hermes Multi-Modality Display protocol, this protocol allowed a slice by slice 
comparison of each technique. Two experienced observers recorded which 
organs were demonstrated and if any areas of increased focal uptake were 
demonstrated.  
Flash 3D did not identify any new lesions when compared with OSEM2D, 
however, in 2 of 15 patients the lesions appeared more resolved. In terms of the 
OSEM, 3 out of the 15 patients demonstrated additional lesions in the OSEM 
reconstruction that were apparently not seen using Flash 3D. This would 
therefore suggest that the Flash 3D method of image reconstruction possibly 
removed lesions when compared with the OSEM 2D method. However, further 
review of the SPET volumes with the associated CT demonstrated the discordant 
areas to be part of an existing lesion which was demonstrated on the Flash 3D 
volume but which appeared over a smaller number of slices. Of the 3 volumes all 
the discordant areas were located in the abdomen and within areas of very low 
counts, therefore these very subtle differences are most likely an indication of 
improved image resolution as a direct result of using Flash 3D.  
It was clear from this pilot review of the images that there were no major 
differences in terms of clinical diagnosis when adding Flash 3D to the 
reconstruction algorithm but that there was a difference in the image quality 
and because of this there was a potential for a difference in the quantification Chapter 4    162 
as a result of the improved resolution.  It was therefore decided that it was 
worthwhile to proceed to a more in-depth analysis of this using the larger 
patient data set. 
 
4.3.2 Methods - Corrected Versus Uncorrected 
Until hybrid imaging was introduced to the department at GRI, OctreoScan SPET 
studies had always been reconstructed using standard OSEM techniques. Whilst, 
for the most part, this reconstruction was deemed suitable, there were 
instances where confidence was low in terms of the true nature of the origin of 
uptake. This was either because the area of uptake lay within an area of low 
counts or in an area of bowel where there remained increased physiological 
uptake despite the use of a bowel preparation prior to imaging. 
Hybrid imaging proposed a solution to the identification of low grade uptake 
within these areas via the various corrections which could be included in the 
reconstruction algorithm. In addition the anatomical information provided by the 
CT volume allowed better localisation of these areas and some characterisation. 
To investigate fully whether or not the corrections and additional anatomical 
information might lead to an improvement in image quality and accuracy of NET 
lesion detection an assessment using a comparison of the standard 
reconstruction with the new reconstruction techniques was undertaken. 
For this investigation 32 OctreoScan consecutive patients were selected from the 
department’s image archive. These patients all had routine imaging performed 
between April 2007 and May 2010. The anonymised demographics of the patients 
selected are detailed in Table 39, this table also details the clinical question.  
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OctreoScan #:  Age  Sex   Query  
Oct Pat 1  80  F  ? Active avid SSTR Tumour 
Oct Pat 2  53  F  Pancreatic Carcinoma, staging scan 
Oct Pat 3  67  M  Wegners granulomatosis, pre-treatment scan 
Oct Pat 4   71  M  Liver Mets. ? Site of primary 
Oct Pat 5  44  M  Kidney Carcinoma. ? Mets 
Oct Pat 6  84  F  RUQ mass ?Carcinoid 
Oct Pat 7   65  M  Liver Mets. ? Primary 
Oct Pat 8  58  M  ? Malignant ascites 
Oct Pat 9  44  F  Mass ? NET (Gastrinoma) 
Oct Pat 10  83  M  Mass ? NET 
Oct Pat 11  83  F  Gastrinoma, ?Mets 
Oct Pat 12  77  F  ? Recurrent carcinoid tumour 
Oct Pat 13  64  M  Large left side abdominal mass. ? NET 
Oct Pat 14  63  F  ? Carcinoid mets 
Oct Pat 15  77  M  ? Gastrinoma 
Oct Pat 16  41  F  Known carcinoid tumour. ? Mets 
Oct Pat 17  64  M  Pancreatic mass. ? NET 
Oct Pat 18  62  F  Metastatic carcinoid lymph node. ? Primary 
Oct Pat 19  51  M  Duodenal polyp carcinoid. ? Mets 
Oct Pat 20  74  M  Carcinoid syndrome. ? Primary 
Oct Pat 21  53  F  Mass pancreatic tail. ? NET 
Oct Pat 22  61  M  NET Lung. ? Mets 
Oct Pat 23  40  M  Resection of primary carcinoid tumour. ? residual disease 
Oct Pat 24  38  F  ? Mesenteric carcinoid mass 
Oct Pat 25  60  F  NET Liver. ? Mets, staging scan 
Oct Pat 26  56  M  Carcinoid prostate ? Mets 
Oct Pat 27  41  M  ? Gastrointestinal carcinoid tumour 
Oct Pat 28  49  M  Metastatic carcinoid tumour bowel? Extent 
Oct Pat 29  57  M  Mass head of pancreas. ?NET 
Oct Pat 30  69  F  Mass body of pancreas. ? NET 
Oct Pat 31  65  F  ? Recurrent carcinoid. 
Oct Pat 32  39  F  Carcinoid tumour appendix. ?Mets 
Table 39 - OctreoScan Patient Demographics 
 
Each of the patients detailed above had the following SPET reconstructions 
performed on the Symbia-T: 
1.  Reconstruction 1 - OSEM basic (O2D) 
2.  Reconstruction 2 - Flash3D basic (F3D) 
3.  Reconstruction 3 - Flash3D with Corrections (F3D SAC) Chapter 4    164 
The parameters outlined previously in Table 38 were used for all 3 
reconstructions, however, as suggested, reconstruction 3 also included a scatter 
and CT-attenuation correction.  
All reconstructions were registered to their associated CT. There were 2 
reconstructed CT volumes available, the first used a smooth kernel (B08s) to 
reconstruct. The B08s CT was used for attenuation correction and was of limited 
diagnostic use. The second CT was reconstructed using a sharp CT kernel (B60s), 
this reconstructed CT was higher in resolution in comparison to the B08s and was 
better for localisation and characterisation of organs and lesions, all SPET data 
was therefore registered with B60s CT.  
To ensure the observers were blinded to the reconstruction technique and the 
patient, the data was anonymised. To do this each registered SPET 
reconstruction and CT were selected together and assigned new demographics. 
It should be noted that this process did not overwrite any of the original patient 
demographics but simply created duplicate image files, only the header files of 
the duplicate images were amended. Each file took the format shown in Figure 
62.  
 
Figure 62 - Anonymised Data Format 
Image showing how the patient data was anonymised. 
 
Each anonymised data set contained only 1 SPET and 1 CT volume. This meant 
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a different number assigned. The process of anonymising data was randomised to 
avoid assigning numbers in successive order to the data sets. To allow ease in 
accessing these files a separate folder in the database was created to store the 
files in, this was called “Pentetreotide Study”. In addition, to estimate intra-
observer reproducibility multiple copies of several images were included within 
the randomisation. 
4.3.2.1  Investigation 1: Qualitative Assessment 
Four observers were chosen to score the images, each observer was experienced 
in the interpretation and/or reporting of OctreoScan studies. Observers were 
asked to review each data set using the Hybrid Imaging Viewer on the Hermes 
system.  
The observers were asked to score each SPET volume in terms of image quality 
and assign each volume a score between 1 and 5; 1 being the poorest and 5 best. 
When assigning a score the observers were asked to consider the following 
points: 
1.  Delineation of patient habitus or in other words does the edge of the 
patient on the SPET image match that seen on the CT or is there scatter 
outside the patient’s body. 
2.  Delineation of the lungs as air. 
3.  Uniformity of uptake across solid organs e.g. liver, spleen, kidneys, 
bladder. 
4.  Delineation of any abnormalities and/or loops of gut. 
Each observer was asked to score the total SPET volume, this was usually the 
abdomen. Where the lungs were included in the FoV the observers were asked to 
score this separately in addition to a score for the entire volume. This was in an 
attempt to determine improvements which would have been made to the 
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The purpose of the CT was to act as a reference for the SPET data and allowed 
the observer to ensure areas of uptake demonstrated on the SPET images 
corresponded to areas of abnormality or areas of expected physiological uptake. 
The CT was also important when assessing the distribution of the uptake within 
an organ for example, the liver, as it was important to exclude the presence of 
disease processes which would result in a non-uniform distribution of uptake. 
Figure 63 provides some example cases. Observers were informed that when 
disease or other abnormality was present this should not be reflected in a poorer 
score, that is the quality of the distribution of uptake in the SPET data should 
not be scored low as a result of an existing process for example liver metastases.  
     
          
Figure 63 - Example of Varying Quality of SPET Images 
Images shown are SPET and CT transverse slices of two patients showing upper abdomen 
and highlighting the difference in distribution across the liver. The top row images 
demonstrate a liver with uniform distribution on the SPET (image on the left) and the 
corresponding CT (image on the right). The bottom row images demonstrate a liver with 
non-uniform distribution on the SPET (image on the left) and the corresponding CT (image 
on the right). 
 
SPET Poor Quality  Corresponding CT 
 
SPET Good Quality  Corresponding CT 
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The top row in Figure 63 demonstrates uptake that was uniformly distributed 
across the liver whilst the bottom row demonstrates how disease processes could 
affect the distribution of uptake across an organ. Review of the diseased liver in 
isolation of the CT may have resulted in a poorer score being assigned. A copy of 
the score sheet issued can be found in Appendix C -.  
In addition to image quality, the reproducibility of each observer was also 
assessed. This was achieved by incorporating 10 duplicate images. These were 
also anonymised and included in the randomisation.  
4.3.2.2  Investigation 2: Semi-Quantitative Assessment 
Of the 32 patients detailed in Table 39 27 were selected at random for profile 
analysis. The object of the profile analysis was to determine if differences 
between the reconstruction techniques could be identified in terms of image 
resolution or count distribution.  
Profile analysis was undertaken using the Multi-Modality Display protocol on the 
Hermes System. This protocol allowed the three registered SPET volumes to be 
displayed interchangeably allowing two studies to be displayed at any one time 
with the option of interchanging the second with the third and vice versa when 
required. This allowed profiles defined on the first volume to be superimposed 
onto the same pixel y-position on the other 2 volumes. 
Horizontal and vertical profiles were applied to the transverse slice where an 
organ was demonstrated, Figure 64 shows an example of a horizontal profile 
applied through the liver and spleen. A profile width of 5 pixels was selected for 
use in all analysis performed. Pixel count information along the profiles was 
saved and imported into Excel to allow comparison of the distribution of counts 
across the profiles between the reconstruction techniques.  
The profile analysis allowed characteristics of the distribution of tracer through 
each organ, for example the liver and kidneys (when seen), to be compared as 
shown in Figure 64. Chapter 4    168 
 
Figure 64 - OSEM Versus Flash 3D SAC 
Image shown are of a screen capture from the Hermes system demonstrating profile 
analysis. The transverse slice on the left is from a volume reconstructed with OSEM and the 
volume on the right is reconstructed with Flash 3D SAC. The box placed centrally illustrates 
the profiles obtained through the liver and spleen; the green profile is from the Flash 3D 
with SAC and the red profile hidden along the x-axis is from the OSEM reconstruction. 
 
From the horizontal profile analysis the first significant feature was the increase 
in counts demonstrated in the Flash 3D SAC volume, as shown in Figure 64 (the 
green distribution in counts represents the F3D and the red the O2D). In the slice 
shown, the counts from the Flash 3D SAC reconstruction are approximately 20 
times that of the OSEM reconstruction therefore the characteristics of the OSEM 
profile are hidden along the x-axis. To allow a comparison of the characteristics 
of each profile the data for each reconstruction were normalised to its own 
maximum counts. 
Since the Hermes terminal was dual screen, one of the registered SPET and CT 
could be displayed using the Multi-Modality Display protocol on a second screen. 
This allowed a slice by slice profile comparison of the SPET studies with the CT, 
see Figure 65. Chapter 4    169 
 
Figure 65 - CT Boundary Delineation 
Images shown are transverse CT (on the left) and SPET (on the right) slices which contain 
the kidneys. The red lines illustrate the placement of the profile for analysis and the green 
crosses indicate the markers used to delineate the CT and SPET organ boundaries. 
 
The use of the CT image allowed a measure of the true patient and organ 
boundary to be compared with that defined in the SPET image. Using the CT 
image the boundaries of the organs and or abnormalities were marked along the 
profile length (shown by green crosshairs in Figure 65). The corresponding organ 
edge on the SPET volume was identified and marked.  
 
4.3.3 Results - Corrected Versus Uncorrected 
Of the 32 patients 15 were females and 17 were males. The average age of this 
group was 60 years (38 - 84 years).    
 
 
 
 
Transverse Slice of 
SPET Volume 
Transverse Slice of  
CT Volume 
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OctreoScan #  Age  Activity Administered (MBq)  Scan Outcome 
Oct Pat 1  80  156  Negative Study 
Oct Pat 2  53  200  Positive Study (Liver and Pancreas) 
Oct Pat 3  67  220  Negative Study 
Oct Pat 4   71  185  Negative Study 
Oct Pat 5  44  200  Positive Study ( Lymph nodes) 
Oct Pat 6  84  200  Negative Study 
Oct Pat 7   65  152  Positive Study ( mass pancreas) 
Oct Pat 8  58  181  Negative Study 
Oct Pat 9  44  200  Negative Study 
Oct Pat 10  83  120  Negative Study 
Oct Pat 11  83  199  Negative Study 
Oct Pat 12  77  199  Negative Study 
Oct Pat 13  64  212  Negative Study 
Oct Pat 14  63  217  Positive Study ( 2
nd part of duodenum) 
Oct Pat 15  77  200  Negative Study 
Oct Pat 16  41  197  Negative Study 
Oct Pat 17  64  200  Positive Study ( mass pancreas) 
Oct Pat 18  62  182  Negative Study 
Oct Pat 19  51  220  Negative Study 
Oct Pat 20  74  214  Positive Study (mesenteric nodule) 
Oct Pat 21  53  208  Positive Study ( mass pancreas) 
Oct Pat 22  61  202  Positive Study (Rt femur and greater trochanter) 
Oct Pat 23  40  154  Negative Study 
Oct Pat 24  38  218  Positive Study (Mesenteric mass) 
Oct Pat 25  60  217  Positive Study (Liver) 
Oct Pat 26  56  155  Positive Study (gastric fundas) 
Oct Pat 27  41  191  Negative Study 
Oct Pat 28 
49  201  Positive Study (ascending, transverse & 
descending colon) 
Oct Pat 29  57  121  Positive Study (mass pancreas) 
Oct Pat 30  69  157  Positive Study ( mass pancreas) 
Oct Pat 31  65  200  Negative Study 
Oct Pat 32  39  196  Negative Study 
Table 40 - Scan versus Disease Outcome 
 
Mean activity administered 186MBq +/- 40. Of the 32 patients, 27 patients 
generated 3 reconstructed volumes for review with CT, whilst 5 patients had 2 
SPET-CT volumes acquired and in these instances both volumes were 
reconstructed with each technique outlined in Section 4.3.2. A total of 111 
volumes were created for assessment. Added to this the 10 duplicate volumes 
used to assess observer reproducibility and there was a total of 121 REG SPET-
CT’s which were assessed.  
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4.3.3.1  Investigation 1: Qualitative Assessment Results 
The scores assigned by each observer for each patient and volume were grouped 
by reconstruction type and the total score for each reconstruction technique was 
calculated. This total was then normalised to the ‘maximum total’ for the set to 
allow ease of score comparison between observers. Details of the total score 
observed for the ‘Entire Volume’ are given in Table 41 and illustrated in Figure 
66 for all observers.   
  Entire Volume Score (Including duplicates) 
 
O2D  F3D  F3D SAC 
Observer 1  0.92  1.00  0.96 
Observer 2  0.74  0.96  1.00 
Observer 3  0.73  0.93  1.00 
Observer 4  0.39  0.88  1.00 
Table 41 - Entire Volume Reconstruction Technique Score 
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Figure 66 - Graph of Entire OctreoScan Volume Observer Score 
Bar chart showing the scores allocated by each observer for each reconstruction technique. 
The red bars indicate the scores given for the OSEM reconstruction, the blue bars for the 
Flash 3D with no corrections and the green bars for Flash 3D with corrections. 
 
From the results, it can be seen that 3 out of the 4 observers allocated the F3D 
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the O2D the lowest score. To assess more closely for statistically significant 
differences between the scores allocated to each reconstruction technique for 
each observer the un-normalised data was used and a Friedman test was 
performed, see Table 42 for the results. 
  Entire OctreoScan Volume Score (Including duplicates) 
    O2D  F3D  F3D SAC 
  P-Score  Est. Median  Sum of 
Ranks  Est. Median  Sum of 
Ranks  Est. Median  Sum of 
Ranks 
Observer 1  0.374  3.00  90.0  3.00  103.5  3.00  94.5 
Observer 2  0.000  2.17  65.6  3.00  105.0  3.08  117.5 
Observer 3  0.003  3.00  78.0  4.00  98.5  4.00  111.5 
Observer 4  0.00  1.00  58.0  3.00  107.0  3.00  122.5 
Table 42 - ‘Entire’ Volume Friedman Test Results 
 
For the entire volume set of data only one of the four observers failed to provide 
scores that were statistically significantly different between reconstruction 
techniques. Of the remaining three observers, all three allocated scores which 
ranked the ‘O2D’ reconstruction with the lowest score and ranked ‘F3D SAC’ as 
the reconstruction with the highest score.  
The ‘Lung Volume’ scores for all observers are given in Table 43  and results 
illustrated in Figure 67. 
  Lung Volume Score (Including duplicates) 
  O2D  F3D  F3D SAC 
Observer 1  0.74  0.92  1.00 
Observer 2  0.87  0.90  1.00 
Observer 3  0.78  1.00  0.99 
Observer 4  0.41  0.84  1.00 
Table 43 - Lung Volume Reconstruction Technique Score 
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Figure 67 - Graph of Lung OctreoScan Volume Observer Score 
Bar chart showing the scores allocated by each observer for each reconstruction technique 
over the lung fields. The red bars indicate the scores given for the OSEM reconstruction, the 
blue bars for the Flash 3D with no corrections and the green bars for Flash 3D with 
corrections. 
 
As with the ‘Entire’ volume the results demonstrated that 3 out of the 4 
observers allocated the F3D SAC the largest score, second to this was F3D and 
lastly all 4 observers allocated the O2D the lowest score. To assess for 
statistically significant differences between the scores allocated to each 
reconstruction technique a Friedman test was performed, see Table 44 for the 
results. 
  Lung OctreoScan Volume Score (Including duplicates) 
    O2D  F3D  F3D SAC 
  P-Score  Est. Median  Sum of 
Ranks  Est. Median  Sum of 
Ranks  Est. Median  Sum of 
Ranks 
Observer 1  0.206  1.33  73.5  1.67  83.0  2.00  89.5 
Observer 2  0.866  2.00  62.5  2.00  67.0  3.00  67.5 
Observer 3  0.021  3.00  67.5  4.00  88.0  4.00  90.0 
Observer 4  0.00  1.00  47.0  3.00  72.0  3.00  81.5 
Table 44 - 'Lung' Volume Friedman Test Results 
 
For the lung volume set of data two of the four observers failed to provide 
scores that were statistically significantly different between reconstruction 
techniques (p-score greater than 0.05). Of the two observers who identified Chapter 4    174 
statistically significant differences between the scores, they ranked the ‘O2D’ 
reconstruction with the lowest score and ranked ‘F3D SAC’ as the reconstruction 
with the highest score. Reproducibility between observers was also assessed. 
Individual observer score can be found Appendix D - Reproducibility results for 
each observer. A Wilcoxon Signed Ranks test was undertaken to assess for 
differences between the scores allocated, see Table 45 and Table 46 for the 
results. 
  Entire Volume Score 
  O2D  F3D  F3D SAC 
  P-Score 
Est. Median 
& 95 % CI 
 
P-Score 
Est. Median 
& 95% CI 
 
P-Score 
Est. Median 
& 95% CI 
  Observer 1  1.000  0.00 (-1.00, 0.50)  0.181  0.00 (0.00, 1.00)  0.108  0.50 (0.00, 1.00) 
Observer 2  0.933  0.00 (-0.50, 0.50)  0.225  0.25 (0.00, 0.50)  0.602  0.00 (-0.50, 0.25) 
Observer 3  0.107  -1.00 (-2.20, 0.00)  0.953  0.00 (-1.00, 1.00)  0.870  0.00 (-1.00, 1.00) 
Observer 4  0.181  0.00, (-1.00, 0.00)  0.675  0.00, (-1.00, 0.50)  0.154  0.00, (-1.00,1.00) 
Table 45 - 'Entire' Volume Wilcoxon Signed Ranks Test Results 
 
  Entire Volume Score 
  O2D  F3D  F3D SAC 
  P-Score 
Est. Median 
& 95 % CI 
 
P-Score 
Est. Median 
& 95% CI 
 
P-Score 
Est. Median 
& 95% CI 
  Observer 1  0.402  -0.5 (-2.00, 0.50)  0.499  -0.50 (-3.00, 1.00)  0.353  -0.5, (-2.00, 1.00) 
Observer 2  0.059  0.50 (0.00, 0.76)  0.371  0.00 (0.00, 0.500)  1.000  0.00 (-0.25, 0.25) 
Observer 3  0.401  -0.50 (-1.00, 1.00)  0.612  0.00 (-1.00, 1.50)  0.050  1.00 (0.00, 1.50) 
Observer 4  1.00  0.00 (0.00, 0.50)  0.100  1.0 (0.00, 2.00)  1.00  0.00 (0.00, 1.00) 
Table 46 - 'Lung' Volume Wilcoxon Signed Ranks Test 
 
The Wilcoxon Signed Rank Test was undertaken to test that the median was not 
equal to zero. All the p-scores calculated in Table 45 and Table 46 were greater 
than 0.05 therefore reproducibility for each observer and technique was 
demonstrated.  
4.3.3.2  Investigation 2: Semi-Quantitative Analysis Results 
Profiles were created over solid organs present in the FoV which included the 
liver, spleen, kidneys. These profiles helped to determine which reconstruction 
method resulted in images where the distribution of radiopharmaceutical uptake 
within an organ (in the absence of known disease) was more uniform as would be 
expected. Figure 68 is an example of the expected distribution of uptake within 
the liver. The reconstruction technique shown in this example is flash3d with 
attenuation and scatter correction. Chapter 4    175 
The patients CT was reviewed to determine which dimension of the patient 
would have the greatest impact on attenuation, that is, the width or depth of 
the patient. The width being the greatest factor would indicate the use of a 
horizontal profile, whilst the depth would indicate the use of a vertical profile. 
Profiles were drawn as shown in Figure 68, which demonstrates how the 
distribution of uptake within the liver could be assessed. 
   
 Figure 68 - SPET Liver (Flash3D SAC) with profiles 
Images shown are of a transverse slice through the liver. These images were reconstructed 
with Flash 3D with SAC. The image on the left contains labels used to describe the 
orientation of the patient orientation. The yellow lines on the right show the position of the 
horizontal (horizontal line) and vertical (vertical line) profiles in relation to the labelled 
annotation. 
 
The examples of relevant profiles are shown in Figure 69 and Figure 70. 
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Figure 69 - Liver Vertical profile 
Image shown is a plot of the pixel data obtained from vertical line profiles placed though the 
transaxial liver slice for each reconstruction technique. The dashed vertical lines are used 
to highlight the anatomical boundaries of the liver as defined by the CT.   
 
Figure 69 shows the results of a vertical profile placed through a cross section 
of a patient’s liver (transverse slice). The dashed vertical lines show the 
delineation of the patient’s liver boundaries taken from the CT image.  Line 1 
corresponds to the posterior edge of the liver and line 2 is the anterior edge of 
the liver.  
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Vertical Profile of Liver: arms across chest
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Figure 70 –Liver Vertical profile; patient arms across chest 
Image shown is a plot of the pixel data obtained from vertical line profiles placed though the 
transverse liver slice for each reconstruction technique. The dashed vertical lines are used 
to highlight the anatomical boundaries of the various organs as defined by the CT.   
 
Figure 70 shows the results of a vertical profile placed through a cross section 
of another patient’s liver (transverse slice) where the patient had their arms 
placed over their chest in addition to the breast tissue in the FoV, as shown in 
Figure 71. The dashed vertical lines show the delineation of the patient’s liver 
boundaries.  Line 1 corresponds to the posterior edge of the patient, line 2 is the 
posterior edge of the liver, line 3 is anterior edge of liver, line 4 is the anterior 
edge of patient and finally line 5 is the anterior edge of the arms.  
F3D and O2D profiles both demonstrate a rise in the counts at the posterior edge 
of the liver (line 2), followed by a dip a slight rise in counts at the anterior edge 
of liver (line 3). The F3D SAC, however, demonstrated almost equal rises in 
counts at both the posterior and anterior edge of liver. The reduction counts 
seen in the F3D and O2D reconstructions is clearly a direct result of the 
uncorrected attenuation cause by the arms being placed over the chest in 
addition to breast attenuation. 
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Figure 71 - CT of Liver Vertical Profile 
Image shown is a CT transverse slice of a patient who had their arms placed over their 
chest during the SPET and CT acquisition. The yellow line is used to highlight the 
placement of the line profile which produced the plot shown in Figure 70.  
 
Both examples of profiles demonstrate clear evidence that the profile across a 
solid organ (in this case the liver) is more uniform when using the F3D SAC 
reconstruction. Neither patient showed any definite evidence of liver disease on 
the CT therefore the expected profile would be relatively flat with the anterior 
and posterior edges of the liver being similar in counts. The solid organ profile 
results suggest the fully corrected reconstruction algorithm to be closer to the 
expected distribution than those from the other reconstructions.  
One of the major difficulties with the NEOSPECT images in Chapter 2 was the 
significant apparent uptake within the lung volumes as a result of both 
physiological uptake and the effects of scatter and attenuation within the 
patient. This non-specific uptake hampered accurate quantification of tumour 
uptake as the background lung uptake was relatively high. Profile analysis was 
also performed over the lungs (when present in the volume) for all three 
reconstructions types. The profile analysis from the lung data was quite striking, 
an example of which is shown in Figure 72.  Chapter 4    179 
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Figure 72 - Graph of Lung profiles 
Image shown is a plot of the pixel data obtained from horizontal line profiles placed though 
the transaxial thorax slice for each reconstruction technique. The dashed vertical lines are 
used to highlight the anatomical boundaries of the various organs as defined by the CT.   
 
Figure 72 are the results of a horizontal profile placed through a cross section of 
a patient’s thorax (transverse slice). The dashed vertical lines show the 
delineation of the patient as determined by the CT image.  Line 1 corresponds to 
the edge of the patient (right side), line 2 is the lateral edge of the right lung, 
line 3 the medial edge of the right lung, line 4 the medial edge of the left lung, 
line 5 the lateral edge of the left lung and finally line 6 the edge of the patient 
(left side). 
Figure 72 clearly demonstrates differences in the reconstruction techniques. As 
can be seen, the OSEM reconstruction produces a fairly flat profile indicating 
very little difference in the distribution of counts across the thorax and 
subsequent lung. This is very similar to the images seen with NeoSPECT. Whilst 
both the F3D and F3D SAC reconstructions demonstrate a non-uniform 
distribution in the counts across the thorax, a dip in the number of counts over 
the lung volume and a corresponding rise over the cardiac cavity is present in 
both cases, with the F3D SAC reconstruction providing a more pronounced 
distribution relative to the F3D reconstruction. 
1  2  3  4  5 
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Corresponding images are shown in Figure 73 to highlight this issue. The middle 
row of images in Figure 73 shows lung with the OSEM reconstruction showing 
that the lung areas contain a significant amount of non-specific physiological 
radiopharmaceutical uptake.  
   
     
   
Figure 73 - SPET-CT Lung (CT, OSEM & F3D SAC). 
Images showing coronal (on the left) and transverse (on the right) slices through the thorax 
of an OctreoScan patient. CT images appears on the top row whilst the middles and bottom 
row are the corresponding SPET data reconstructed with OSEM and Flash 3D SAC 
respectively.  
 
Whilst the lower row in Figure 73 shows lung with Flash 3D with both 
attenuation and scatter corrections. The F3D SAC clearly demonstrates a lack of 
non-specific physiological uptake of pharmaceutical within the lungs in keeping 
with the profile analysis.  Chapter 4    181 
The example profile analysis included in this section correlates with the findings 
from the qualitative analysis. That is, a marked improvement in image quality is 
demonstrated with the use of F3D in comparison with OSEM. In particular the 
additional use of attenuation and scatter correction with F3D produces a 
significant improvement in the quality of images which include the lungs in the 
FoV. 
 
4.3.4 Discussion and Conclusion  
The qualitative results demonstrated a clear trend in observer preference, in 
terms of image quality, as the F3D SAC reconstruction was scored the highest by 
3 out of 4 observers, followed by the F3D and lastly the O2D. Despite this 
preference, statistically differences in scores were only significant between O2D 
and F3D, and O2D and F3D SAC. No significant statistical difference in the scores 
was demonstrated between F3D and F3D SAC.  
Again when the lungs were scored in isolation of the remaining volume there was 
also a clear trend in preferences for 3 out of the 4 observers towards the F3D 
SAC, followed by the F3D and lastly the O2D. Statistically, however, the 
difference in scores between reconstruction techniques was only considered 
significant for 2 out of the 4 observer’s scores. 
Semi-quantitative profile analysis of solid organs demonstrated a significant 
improvement in image quality with the use of F3D SAC reconstruction. A clear 
differentiation between O2D and F3D SAC, and F3D and F3D SAC was 
demonstrated. Profiles through solid organs like the liver using F3D SAC 
demonstrated a more uniform distribution in uptake when compared with O2D 
and F3D.  
The most striking improvement in image quality was demonstrated when the 
lungs were included in the FoV. Profile analysis of the lungs demonstrated F3D 
and F3D SAC to clearly delineate between lung and surrounding tissue within the 
body, whereas O2D produced a fairly flat profile across the thorax regardless of 
tissue type. Of the F3D and F3D SAC reconstructions, F3D SAC produced images 
and profiles which delineated the lung in such a way that in the absence of Chapter 4    182 
disease there was minimal background activity present. This would likely have 
benefited the NEOSPECT data, as it would have delineated any abnormal tissue 
within the lung better and in particular allowed better visualization of small 
nodal disease within the lungs. 
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4.4 
111In Phantom Acquisition Data  
In addition to increasing the ability to localize the anatomical localization of 
functional abnormalities a great deal an emphasis has also been made on SPET 
CT’s capabilities to correct for soft tissue attenuation. The previous section 
considered OSEM and Flash3D with and without corrections from an image 
quality perspective, however, there is a need to assess image reconstruction 
technique from a quantitative perspective which allows comparison to be made 
with the previous NeoSPET work.  
The in-house built SPET-CT phantom, described in Chapter 3, was used in this 
section to investigate the following: 
Investigation 1  Optimise post reconstruction filter setting for Flash 3D.   
Investigation 2  Accuracy of hybrid imaging quantification techniques.  
 
4.4.1  Investigation 1 - Optimisation of post reconstruction filter  
Nuclear medicine is limited in terms of its resolution. This low resolution can be 
compounded further by the use of a post reconstruction smoothing filters and 
this can make the ability to distinguish between true uptake and scatter or 
extension of areas of increased uptake very difficult. The first use of the in-
house built SPET-CT phantom, was to investigate the influence of various post 
reconstruction filter settings used for OctreoScan imaging. For all iterative 
reconstructions on the Symbia-T there is only one filter type available namely a 
Gaussian Filter. This is a low pass filter used to remove high frequency (noise) 
components from the image data. 
4.4.1.1  Methods for Investigation 1 - Optimisation of post reconstruction 
filter 
To establish an optimal setting for the post reconstruction filter the SPET-CT 
phantom was used, each of the components within the phantom was filled as 
shown in Figure 74.  Chapter 4    184 
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Figure 74 - In111 Filled Phantom 
Image showing a screen capture of the various energy windows acquired of the phantom 
when filled with In111.  
 
The phantom was acquired under the acquisition parameters described in Table 
47. To minimise the effect of air bubbles gathering over areas of interest the 
phantom was tilted. The SPET acquisition was followed by a CT acquisition to 
allow a comparison of the true morphology of the internal structures of the 
phantom.  
Collimator:  MELP 
Orbit:  360 degrees 
Frame time:  30 seconds  
Interval:  3 degrees 
Energy Windows (keV):  5 Windows; See Figure 74 
Set Up @:  For the purpose of these acquisitions the heads were set round the circumference of the 
phantom. 
Table 47 - OctreoScan Acquisition Parameters 
 
The SPET raw images were reconstructed as described in Table 48, as a result 
there were 7 reconstructed data sets to compare. Using the Symbia software the 
reconstructed SPET volume was co-registered to the sharp CT volume. 
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Reconstruction Method:  Siemens OSEM – Ordered Subset Expectation Maximisation 
Subsets:  4 
Iterations:  8 
Number of slices:  82 
Low Pass Filter Setting:  Gaussian FWHM of 1.0mm, 3.7mm, 5.5mm,  8.4mm (default settings), 10.25mm, 17mm, 
30mm 
Zoom:  No Zoom 
Table 48 - OctreoScan Reconstruction Parameters 
 
The reconstruction parameters, including post reconstruction filters, were all 
derived for clinical use. The clinicians and physicists at GRI had originally 
selected filter settings for FBP prior to the SPET-CT unit installation. When the 
Symbia-T was installed advice was taken from Siemens as to their recommended 
parameters. These were compared with previously acquired data in order to 
maintain clinical reporting capability and the routinely used parameters were 
set using the remit of maintaining a consistent image quality as best possible. 
Both the registered SPET and CT volume were simultaneously viewed on the 
Hermes system using the Multi-Modality function for display which allowed the 
SPET and CT volume to be displayed side by side along with allowing the SPET 
volume to be superimposed onto the CT volume and vice versa (image fusion). 
To aid identification of the inside cavity of the tumour volume both images were 
manipulated in the transverse plane to identify the section of phantom of 
interest. The images were reoriented to correct for the off centre placement of 
the phantom on the bed (because the phantom was tilted to avoid air bubbles 
around the area of interest), and finally zoomed as described in Table 49: 
Zoom  Reorientation  Pan 
X  150  XY  -15  X  0 
XY  100  YZ  0  Y  -32 
Y  150  XZ  2  Z  0 
Table 49 - Optimised Display Parameters  
 
Visualisation of the inside boundaries of the tumour cavity was achieved by 
adjusting the truncation of the CT image as there was little contrast between 
Perspex and the inside of the tumour cavity which was filled with the water.   Chapter 4    186 
To assess the influence each filter setting had on the overall spatial resolution of 
the SPET volume, ROI analysis was undertaken. ROIs were drawn on the 
transverse plane of the Sharp Registered CT images, ROI 1 (in red) is the ROI 
defined by the CT and ROI 2 (in yellow) is the ROI defined by the area of 
radioactivity on the SPET image- see Figure 75. Chapter 4    187 
 
 
 
                  
Figure 75 - ROI's defined by structure & radioactive contents 
Images showing transverse slices from the SPET-CT phantom and the associated ROIs 
drawn. Images on the bottom row are zoomed versions of the upper row to show more 
clearly the boundaries of the tumour compartment on the CT.  
  
The ‘tumour ROI’ was drawn on the mid slice of the cavity visualized. For each 
filter setting the number of slices over which the ‘tumour’ area was visible was 
noted but the counts were only recorded and compared for slice 31 of each set 
as this represented the mid section of the phantom’s tumour cavity.  
The influence of the range of filter settings investigated are described in Table 
50. 
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Low Pass type  Setting FWHM (mm)  Range CT  Range NM  REG ROI OK? 
Gaussian  1.0  63-69  59-72  Y 
Gaussian  3.7  63-69  59-72  Y 
Gaussian  5.5  63-69  59-72  Y 
Gaussian  8.4  63-69  59-72  Ref ROI 
Gaussian  10.25   63-69  58-73  Y 
Gaussian  17  63-69  57-74  N 
Gaussian  30  63-69  57-74  N 
Table 50 - Settings for In111 filled phantom 
 
For comparison, this measurement was also undertaken using a Tc99m filled 
phantom, the results of which are detailed in Table 51. 
Low Pass type  Setting FWHM (mm)  Range CT  Range NM  REG ROI OK? 
Gaussian  1.0  24-37  21-44  Y 
Gaussian  3.7  24-37  18-77  Y 
Gaussian  5.5  24-37  19-44  Y 
Gaussian  8.4  24-37  18-46  Ref ROI 
Gaussian  10.25   24-37  18-46  Y 
Gaussian  17  24-37  14-50  N 
Gaussian  30  24-37  7-58  N 
Table 51 - Setting for Tc99m filled phantom 
 
Correct filter selection for image reconstruction is paramount as an incorrect 
filter setting has the potential to create or remove small areas of increased 
radioisotope uptake. The CT generated ROI was successfully correlated with all 
reconstructed data sets with the exception of Gaussian settings FWHM 17mm and 
30mm. It was noticed that filter settings above FWHM of 10.25mm provided too 
much smoothing of the data and failed to accurately detect the edge as there 
was over blurring of the edges and expansion of the volume. This is significant as 
clinically this may lead to the overestimation of tumour volume especially where 
small tumour volumes are present. Despite the NM volume correlating with the 
CT volume on the remaining filter settings there was an increase in the noise 
component which led to decrease in the image quality.  This reduction in image 
quality was more notable when using the Gaussian settings 1.0 and 3.7.  
Summary of work 
As with most nuclear medicine studies each individual patient should be assessed 
on an individual basis and optimized as appropriate, in terms of the order of the Chapter 4    189 
post reconstruction filter used. Despite slight adjustments this work was 
successful in defining a useful range of filter settings for OctreoScan studies. The 
range of useful values of Gaussian settings identified was FWHM 5.5mm - 
10.25mm. Since the default setting of 8.4mm lay within this range, it was 
deemed suitable to continue to use the default setting of 8.4mm for phantom 
reconstructions and therefore made for a more like for like comparison with the 
actual patient data. 
 
4.4.2 Investigation 2 - Accuracy of hybrid imaging quantification 
techniques 
Over the years there has been great a deal of consideration given to the use of 
some diagnostic radiopharmaceuticals as tumour-targeted radiation therapy 
agents. In determining the efficacy of these agents image quantification has 
been performed using planar diagnostic images. An example of such work which 
investigated the efficacy of OctreoScan described planar geometric mean 
methods to quantify uptake (Lener et al, 1996). 
However, in recent years nuclear medicine imaging has moved away from planar 
imaging towards SPET hybrid imaging. In addition to the work undertaken 
previously quantitating NeoSPECT it was important to assess if SPET-CT could be 
used to accurately quantify tumour and organ uptake using other 
radiopharmaceuticals, in this case OctreoScan. This might also allow postulation 
as to whether the addition of CT data to the NeoSPECT group would have 
significantly affected accuracy. 
Since the work undertaken in the Section 4.3.3.1 demonstrated that the largest 
qualitative improvement in image quality between reconstruction techniques lay 
between OSEM and Flash3D with or without scatter and CT-attenuation 
corrections, it was decided to only assess differences in image quantification 
between Siemens Flash3D with and without scatter and CT-attenuation 
corrections. Chapter 4    190 
4.4.2.1  Methods for Investigation 2 - Accuracy of hybrid imaging 
quantification techniques 
The in-house manufactured phantom for SPET-CT was used in this work to 
determine the accuracy of the new techniques in image quantification of In-111 
acquisitions. The phantom was filled with activities as described in Table 52. 
Lung Phantom Details 
  Activity (MBq)  Time 
Background  29  11.18 
Lung   16  10.53 
Liver  58  10.46 
Tumour  5  10.39 
SPET-CT Acquisition Details 
Acquisition Start Time  15.05   
Lung Phantom Details Corrected to Start of SPET-CT Acquisition 
Background  27.9  15.05 
Lung  15.3  15.05 
Liver  55.5  15.05 
Tumour  4.77  15.05 
Table 52 - SPET-CT Phantom Activities and Acquisition Times 
 
Figure 76 demonstrates slices of the images acquired.  Chapter 4    191 
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Figure 76 - SPET-CT Acquisition of Hybrid Phantom 
Images showing transverse, sagittal and coronal slices of the SPET-CT phantom when filled 
with In111 on the top row. The bottom row is a fused SPET-CT coronal slice of the standard 
volume used to calculate sensitivity, also filled with In111.  
 
As can be seen from Figure 76 a standard acquisition was also acquired, this was 
acquired using the thyroid phantom which is a solid perspex cylinder with a small 
aperature for placement of a 5ml vial, refer to Table 53 for details of activities 
used.  
STD  Details 
  Activity (MBq)  Time 
STD  5.0  11.18 
SPET-CT Acquisition Details 
Acquisition Start Time  15.49   
STD Details Corrected to Start of SPET-CT Acquisition 
STD  4.77  15.49 
Table 53 - SPET-CT STD Activities and Acquisition Times 
 
The acquisition protocol for the phantom and the STD were the same as those 
used for routine patient imaging, as described in Table 37, with the exception Chapter 4    192 
of a reduced frame time for the STD acquisition (3 seconds was used as 
previously in Chapter 2).  
Both the SPET-CT phantom and the STD were reconstructed as follows: 
1.  Siemens Flash 3D, F3D - No corrections. 
2.  Siemens Flash 3D Corrected, F3D SAC - with scatter and CT-attenuation 
based corrections. 
Regardless of the application of corrections the reconstructions parameters used 
matched those described in Table 38, and are those routinely used for the 
patient data reconstruction.  As in previous chapters, ROI analysis was 
performed, an example of which is shown in Figure 77. 
1 - Tumour ROI
2 – BKG + Tumour ROI
1 – STD ROI
2 & 3 – BKG ROIs
 
Figure 77 - In-111 SPET-CT ROIs 
Images showing the different ROIs used to obtain data from the SPET-CT phantom on the 
left and the ROIs used to obtain data from the standard volume on the right.  
 
From the ROIs, values of total counts along with the number of pixels (area) 
were extracted. This information was saved from all slices over which the 
tumour and STD vial were demonstrated. CT images were used to aid 
identification of the edges of each.  Chapter 4    193 
4.4.2.2  Results for Investigation 2 - Accuracy of hybrid imaging 
quantification techniques 
To calculate absolute activity, a value of sensitivity for each reconstruction 
technique had to be determined. The sensitivity for each technique was 
calculated from the STD acquisition using Equation 6 in Chapter 2. Using the 
ROI data from each reconstruction, a value of total counts was obtained by 
summing the total counts in each slice over the entire volume of the standard 
vial. From Table 53 it can be seen that the activity in the standard vial at the 
time of imaging was 4.77 MBq. Each frame was 3 seconds long with 120 frames 
acquired in total, therefore, the total duration of the acquisition of was 360 
seconds. Using these values the sensitivity (counts per second per MBq) was 
calculated - see Table 54. 
  Symbia 
  No Corrections  Scatter & CT-attenuation Correction 
Sensitivity No BKG Correction  5979 cps MBq
-1  8158 cps MBq
-1 
Sensitivity BKG Correction  5961 cps MBq
-1  8113 cps MBq
-1 
Table 54 - Sensitivities 
 
For this work a different phantom was used for the STD acquisition and it was 
therefore important to investigate the effect of background correction.  
From the ROIs of the SPET-CT phantom, values of counts and number of pixels 
were extracted. The ‘tumour’ counts where then corrected for background using 
the technique described by Equation 7 in section 2.3.2.3 of Chapter 2. The 
background corrected counts for each slice were summed over the entire volume 
of the ‘tumour’ or vial and are shown in Table 55 along with the uncorrected 
counts. 
  Symbia 
  Phantom No Corrections  Phantom Corrected for Scatter & CT-attenuation Correction 
Total Counts  64741349  110221777 
Total Counts BKG Cor  49825602  85668873 
Table 55 - Total Counts for Each Reconstruction Technique 
 
The values in Table 55 were used along with the values of sensitivity in Table 54 
to calculate a value of absolute activity for each reconstruction technique. The 
results are shown in Table 56.  Chapter 4    194 
Activity   
Phantom Total Counts 
(MBq) 
Phantom Total Counts 
BKG Corrected (MBq) 
STD Total Counts  3.01  2.31  STD & Phantom 
No A + SC  STD Total Counts BKG 
Corrected  3.02  2.32 
STD Total Counts  3.75  2.92   
STD & Phantom 
with A + SC  STD Total Counts BKG 
Corrected  3.77  2.93 
Table 56 - Activities Calculated  
 
Figure 78 provides a graphical comparison between the actual known activity 
and those calculated from the various reconstruction techniques. 
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Figure 78 - Graph of Calculated Versus Actual Activity (MBq) In111 SPET-CT phantom 
Bar chart showing the calculated versus actual activity for each reconstruction technique. 
The blue bars correspond to values of activity calculated using total counts, the lighter blue 
bars are of values of activities calculated from background corrected total counts and 
finally the red bars are of the actual value of activity measured on the radionuclide 
calibrator.  
 
Table 56 and Figure 78 demonstrate a difference between the actual and 
calculated which is dependant upon the reconstruction technique used. The 
results clearly demonstrate that the use of a background correction on the STD 
reconstructions made very little difference.  Chapter 4    195 
Looking specifically at the results and at the difference between the actual and 
calculated activity the use of a scatter and CT - attenuation correction (SAC) 
provide the better estimate of activity. However, when a background correction 
is applied in conjunction with reconstruction implemented corrections the data 
significantly underestimated the activity within the volume  
This is perhaps to be expected, when the data has been properly corrected for 
scatter and attenuation, the counts within the volume of interest should be 
correct and in SPET unlike planar data there is no overlying tissue so in principle 
no background corrections should be necessary. The data in Figure 78 shows 
that where corrections are in place the activity measured is very close to the 
actual known activity when no background subtraction in employed.  
Without proper correction for scatter and attenuation the counts within the 
volume are likely to be incorrect and there will be increased scatter in 
surrounding tissue and decreased and non uniform counts within the volume due 
to attenuation.  
Summary of work 
The percentage difference calculated between the image derived activity and 
the actual activity went from 37% for the uncorrected data to 21% for the 
corrected data, therefore work in this section clearly demonstrated that the 
addition of scatter and CT-attenuation correction helped improve the accuracy 
of calculating activity from SPET data using 
111In.  
 
4.4.3 Discussion/Conclusion - 
111In Phantom Data Acquisition  
Investigation of several post reconstruction filters showed a range of Gaussian 
cut-off values which gave reasonable image quality and definitive limits where 
image quality became unacceptable. 
Assessment of the accuracy of image quantification from 
111In based SPET-CT 
studies demonstrated an underestimation in the value of activity calculated for 
both the corrected and uncorrected SPET volumes when compared with the Chapter 4    196 
actual value. However, the corrected data did demonstrate a notable 
improvement in the accuracy of the image quantification. 
Comparison to the original phantom work undertaken in Section 2.3.2.3 of 
Chapter 2 disappointingly failed to demonstrated a large improvement in the 
accuracy of the calculation of activity from the hybrid data. However, it is worth 
bearing in mind that a different isotope was used and therefore a direct 
comparison may not be appropriate as 
99mTc (used in chapter 2) has only one 
photo peak whilst 
111In has two photo peaks. 
Whilst quantification using hybrid imaging of 
111In based acquisitions may not 
provide the most accurate measure of activity within a specified volume the 
technique could be used to monitor disease response fairly accurately when data 
is reconstructed with F3D SAC. 
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4.5 
99mTc Phantom Acquisition Data  
Both OctreoScan patient and phantom work indicated a clear improvement in 
the image quality and accuracy of the calculation of absolute activity when 
scatter and CT-attenuation corrections were applied. However, since 
99mTc has a 
single photo peak and In111 has 2 photo peak it may not be appropriate to 
compare. It was important to validate these results using Tc99m data in order to 
comment on what impact the new techniques would have had on the NeoSPECT 
results.  
4.5.1 Methods - 
99mTc Phantom Acquisition Corrected Versus 
Uncorrected 
The in-house designed lung phantom involved in the NeoSPECT phantom work in 
Chapter 2 was used. This phantom was filled with activity as described in Table 
57 and acquired using the standard NeoSPECT acquisition protocol as described 
previously in Chapter 2. 
Lung Phantom Details 
  Activity (MBq)  Time 
Background  442  12.06 
Lung (each lung)  110  11.18 
Tumour  1.1  11.57 
SPET-CT Acquisition Details 
Acquisition Start Time  18.15   
Lung Phantom Details Corrected to Start of SPET-CT Acquisition 
Background  217  18.15 
Lung (each lung)  98  18.15 
Tumour  0.53  18.15 
Table 57 - Phantom Activities and Acquisition Times 
 
In addition to the lung phantom a STD acquisition was also undertaken, refer to 
Table 58 for further details. 
STD  Details 
  Activity (MBq)  Time 
STD  5.91  16.49 
SPET-CT Acquisition Details 
Acquisition Start Time  16.53   
Lung Phantom Details Corrected to Start of SPET-CT Acquisition 
STD  5.86  16.53 
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As previously noted, one of the largest factors influencing the degradation of 
NeoSPECT or indeed any SPET imaging is attenuation and scatter as a result of 
body habitus and the presence and/or extent of breast tissue. The new 
technique aimed to remove this degradation, however, the phantom was fixed in 
its size with very little attenuating material which made assessment of these 
new techniques limited. In an attempt to introduce attenuating material two 
saline bags were placed over what would be considered as the anterior aspect of 
the phantom, these are highlighted by red arrows in Figure 79. These saline 
bags therefore could be considered as mimicking a breast component.  
SPET-CT of Lung Phantom
SPET-CT of STD
Transverse Sagittal Coronal
Coronal
 
Figure 79 - SPET-CT Acquisition of Lung Phantom and STD 
Images showing fused SPET-CT transverse, sagittal and coronal slices of the lung phantom 
filled with Tc99m on the top row - red arrows indicate additional attenuating material placed 
on the phantom to simulate a breast component. The bottom row is a fused SPET-CT 
coronal slice of the standard volume used to calculate sensitivity, also filled with Tc99m. 
To allow a comparison of the new techniques with those used in Chapter 2, 
reconstruction of the lung phantom data was undertaken as follows: 
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1.  NeoSPECT Technique - Hermes OSEM with attenuation correction (HOSEM 
AC). 
2.  New Technique - Siemens Flash 3D with scatter and CT-attenuation based 
corrections (F3D SAC). 
Previous results in Chapter 2 demonstrated that the use of an attenuation 
correction in the reconstruction of the STD data resulted in a gross 
overestimation in the calculation of sensitivity and a subsequent 
underestimation in the value of absolute activity calculated. However, as this 
was a geometric attenuation correction it was important to assess if a CT-
attenuation based correction would provide a more accurate measure of 
sensitivity from the STD reconstructed images.  
The STD data was reconstructed as follows: 
1.  Hermes OSEM without attenuation correction (STD No Corr). 
2.  Siemens Flash 3D without scatter and CT-attenuation based corrections 
(STD No Corr). 
3.  Siemens Flash 3D with scatter and CT-attenuation based corrections    
(STD Corr). 
As in previous chapters, ROI analysis was performed, an example of which is 
shown in Figure 80. Chapter 4    200 
 
Figure 80 - Lung Phantom and STD ROIs 
Images show a transverse slice of the lung phantom with ROI’s on the left (ROI 1 - 
Tumour/abnormality and ROI 2 - Tumour/abnormality with background) and a transverse 
slice of the standard vial acquisition on the right (ROI 1 - standard vial and ROI 2- 
background). 
 
To assess the accuracy of image quantification, in other words the value of 
absolute uptake, values of total counts along with the number of pixels (area) 
were extracted from the ROIs. Data were obtained from all transverse slices 
which demonstrated the tumour vial. 
 
4.5.2 Results - 
99mTc Phantom Acquisition Corrected Versus 
Uncorrected 
To calculate absolute activity the first step was to calculate a value of 
sensitivity for each reconstruction technique. Sensitivity was calculated using 
Equation 6 in Chapter 2. Values of total counts were obtained by summing the 
total counts over the entire volume of the standard vial. From Table 58 it can 
seen that the activity in the standard vial at the time of imaging was 5.86 MBq. 
Each frame was 3 seconds long with 120 frames acquired therefore the total 
duration of the acquisition of was 360 seconds. Using these values the sensitivity 
(counts per second per MBq) was calculated - see Table 59. 
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  Hermes  Symbia 
  No Attenuation Correction  No Attenuation Correction  Attenuation Correction 
Sensitivity  34 cps MBq
-1  4661 cps MBq
-1  1860 cps MBq
-1 
Table 59 - Sensitivities 
 
No background correction was undertaken since, as was demonstrated in section 
2.3.2.3 of Chapter 2 and section 4.4.2.2 the background activity was 
essentially negligible relative to the STD volume activity.  
Finally, from the ROIs of the lung phantom, values of counts and number of 
pixels were extracted. The tumour counts where then corrected for background 
using the technique described by Equation 7 in section 2.3.2.3 of Chapter 2. 
The background corrected counts for each slice were summed over the entire 
volume of the tumour/vial and are shown in Table 60 along with the 
uncorrected counts. 
  Hermes  Symbia 
  Lung Phantom Corrected for AC  Lung Phantom Corrected for SAC 
Total Counts  183421  8911814 
Total Counts BKG Cor  108683  5629456 
Table 60 - Total Counts and Sensitivity for Each Reconstruction Technique 
 
The values in Table 60 were used along with the values of sensitivity in Table 59 
to calculate a value of absolute activity for each reconstruction. The Hermes 
and Symbia results are shown in Table 61.  
  Hermes  Symbia 
  Lung Phantom Corrected for AC  Lung Phantom Corrected for SAC 
  STD NO AC (MBq)  STD No SAC (MBq)  STD SAC (MBq) 
Activity - Total Cts  1.51  1.33  0.53 
Activity - Total Cts BKG  0.89  0.84  0.34 
Table 61 - Activities Calculated 
 
For the Hermes two values of activity were calculated from one reconstructed 
volume, namely, a value from total counts and from total counts corrected for 
background. This was also the case for the Symbia phantom volume, however, 
values of activity were calculated using values of sensitivity calculated from 
both the corrected and uncorrected standard volume. Figure 81 provides a 
comparison between the actual and those calculated using the various 
techniques.  Chapter 4    202 
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Figure 81 - Graph of Calculated Versus Actual Activity (MBq) Tc99m Lung Phantom 
Bar chart showing the calculated versus actual activity for each reconstruction technique. 
The red bars correspond to values of activity calculated and the blue bars are of the actual 
value of activity measured on the radionuclide calibrator. 
 
Where, “Total Cts” are the counts within the ROI of the abnormality. “Corr Cts” 
are the total counts within the ROI abnormality that have been corrected for 
background.  
For both the phantom and STD SPET-CT’s the CT component was used to identify 
the number of slices over which the abnormality and the standard volume were 
demonstrated. Only counts from these slices were used in the calculation. From 
Figure 81 it can be seen that the use of a scatter and CT-attenuation correction 
in the reconstruction of the standard volume reduced the difference 
demonstrated between the value of activity calculated and the actual value.  
A negligible difference was demonstrated when the activity was calculated 
without correcting the phantom abnormality ROI counts for background. This 
increase in accuracy can therefore be attributed to the ability to identify and 
delineate the abnormality using CT in addition to the use of scatter and CT-
attenuation.   Chapter 4    203 
In addition to differences demonstrated quantitatively, it was also important to 
review the images to determine if qualitative differences were also present. This 
was achieved by simple slice by slice visual comparison (- see Figure 82) and 
also via profile analysis (- see Figure 83).   
From the transverse image slice it can be seen that there is a significant 
difference in the distribution of activity in the lung region. The slices chosen 
contain additional attenuating material added to the phantom to replicate 
breast as shown previously in Figure 79 
   
   
    
Figure 82 - Qualitative Differences Demonstrated 
Images showing SPET transverse, sagittal and coronal slices of the lung phantom filled with 
Tc99m. Images on the left have been reconstructed with HOSEM and images on the right 
wih Flash 3D SAC. The red arrows on the images on the left indicate areas of low count 
density. 
HOSEM Slices 
HOSEM Slices 
F3D SAC Slices 
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The red arrows on the HOSEM images highlight areas of reduced counts caused 
by the additional attenuation (the synthetic breast component). The HOSEM 
images also show quite marked background activity with the lungs in comparison 
to the corrected F3D SAC images.  
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Figure 83 - Vertical Profiles; HOSEM Versus F3D SAC 
Image shown is a plot of the pixel data obtained from vertical line profiles placed though 
transaxial slice of the main body of the phantom which contained the tumour compartment. 
The dashed vertical lines are used to highlight the physical boundaries of the various 
compartment and attenuating material as defined by the CT. 
 
Figure 83 are the results of a vertical profile placed through a cross section of 
the in-house lung phantom (transverse slice). The dashed vertical lines show the 
delineation of the phantom as determined by the CT image.  Line 1 corresponds 
to the posterior edge of the phantom, line 2 is the posterior edge of the right 
lung compartment, line 3 is the posterior edge of the tumour component, line 4 
the anterior edge of the tumour and lung components and line 5 the anterior 
edge of the phantom.  
Profile analysis has further highlighted the difference in the distribution of 
activity in the lung between the old and new technique (HOSEM and F3D SAC). In 
terms of the lung component the F3D SAC demonstrates a reduction in lung 
background activity but also an increase in tumour activity which is clearly 
1  2  3  4 
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reduced in the HOSEM images as a result of the attenuating material. There is 
also a clear reduction in counts on the HOSEM images at the anterior edge of the 
phantom as a result of the attenuating material.  
The change in distribution, that is the reduced tumour counts and higher 
background activity, would therefore have resulted in an underestimation of 
both values of T:B and values of % uptake.  
 
4.5.3 Discussion and Conclusion - 
99mTc Phantom Acquisition 
Corrected Versus Uncorrected 
Quantitative analysis work performed in this chapter was undertaken using 
Hermes Volume Fusion Display. This program allowed 2 SPET volumes to be 
loaded simultaneously and ROI analysis to be undertaken. However, care should 
be exercised when performing comparative quantification work using the Hermes 
system or any other image display and analysis software, as the Hermes systems 
takes the first volume selected and matches the matrix of the second volume to 
that of the first. Work in this chapter was originally undertaken using this display 
and analysis protocol to compare the Hermes reconstruction technique (128x128 
matrix) with the new technique, the Symbia (512x512). This led to the corrected 
volume from the Symbia being binned down into a 128x128 matrix and 
subsequently pixel data was lost. This loss in pixel data led to inaccurate values 
of activity calculated. This was corrected and the data presented here are 
accurate.  The ‘pixel loss’ is a function of the display program rather than a real 
pixel loss, it is therefore important to use a registered volume SPET data with its 
target volume CT data on the Hermes system.  
Work in this section demonstrated that the use of scatter and CT-attenuation 
corrections improved not only the overall image quality of the SPET volume but 
also the accuracy of the pixel data for the volume. The accuracy of the image 
quantification was greatly improved when using SPET-CT in comparison the SPET 
only quantification. The accuracy of this technique, however, also relied on the 
corrected SPET volume being viewed with the CT image component, as the CT Chapter 4    206 
image component was essential in the identification and delineation of any 
abnormalities.  
The semi-quantitative profile analysis demonstrated a change in the distribution 
and a reduction in the background activity using the new technique, which 
implied that values of T:B’s calculated in Chapter 2 were underestimated. This 
could have masked differences between the groups although the data were so 
mixed that this is extremely unlikely. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4    207 
4.6 Discussion and Conclusion 
The work in this chapter was driven by questions raised in Chapter 2 over the 
impact hybrid imaging would have with regards to improvements in SPET image 
reconstruction from both a qualitative and quantitative perspective. 
In an attempt to answer these questions both patient and phantom work were 
undertaken. Since NeoSPECT was no longer on the market the patient work was 
undertaken using a radiopharmaceutical which had a similar mechanism of 
uptake, OctreoSCAN. OctreoScan unlike NeoSPECT is not a 
99mTc based 
radiopharmaceutical but is 
111In based. Phantom work was undertaken using both 
99mTc and 
111In. 
Hybrid imaging based reconstruction improvements were assessed firstly by 
reviewing patient data. Patient data were reconstructed using the existing 
OSEM2D technique and comparing this with newly available resolution recovery 
techniques (with and with scatter and CT based attenuation corrections, F3D and 
F3D SAC). Data were anonymised in terms of patient demographics and 
reconstruction details. Four observers experienced in OctreoSCAN image 
interpretation were asked to review the data and provide a score in terms of 
image quality. Each observer was asked to take into accounts factors such as 
delineation of patient habitus, delineation of the lungs as air, uniformity of 
uptake across solid organs and finally delineation of any abnormalities including 
loops of gut. Based of these factors a score was assigned between 1 and 5 (5 
indicating a good quality and 1 indicating a poor quality).    
The scores from the observers indicated a preference towards F3D SAC, followed 
by F3D and lastly O2D. One of the most notable features of F3D SAC in 
comparison to the other reconstruction techniques was the delineation of body 
outline and the bio-distribution of uptake within the lung fields.  
The scores for each observer were assessed statistically. Of the 4 observers 3 
were found to demonstrate a statistically significant difference between the 
existing technique and the improved image reconstruction as a result of hybrid 
imaging.  Chapter 4    208 
From the patient qualitative cohort semi-quantitative analysis was also 
performed. This was in the form of profile analysis which was able to assess the 
distribution of OctreoScan uptake across organs in the body. The findings from 
the semi-quantitative profile analysis results of solid organs demonstrated a 
significant improvement in image quality with the use of F3D SAC reconstruction. 
A clear differentiation between O2D and F3D SAC, and F3D and F3D SAC was 
demonstrated. Profiles through solid organs like the liver using F3D SAC 
demonstrated a more uniform distribution in uptake when compared with O2D 
and F3D. Whilst profile analysis through the thorax demonstrated a significant 
dip in counts across the lungs with both the F3D and F3D SAC, whereas O2D 
produced a fairly flat profile across the thorax regardless of tissue type 
indicating very little differentiation between the lungs and surrounding tissue 
within the body. As with the qualitative analysis, semi-quantitative analysis also 
demonstrated a clear improvement in SPET image quality as a result of hybrid 
imaging.  
Finally quantitative analysis was undertaken, since the patient cohort was a 
retrospective review no standard image acquisition had been acquired that 
would allow image quantification to be performed. The accuracy of image 
quantification with hybrid imaging was therefore assessed using an in-house 
designed and manufactured SPET-CT phantom.  
The first phantom work was undertaken using 
111In, results from this work 
concluded that regardless of reconstruction technique the image calculated 
value of activity failed to closely meet the value of actual activity. However, the 
hybrid imaging techniques with corrections reduced the difference between the 
calculated and actual value of activity from 37% for the uncorrected data to 21% 
for the corrected data. Although this work failed to accurately calculate the 
value of absolute activity there was a clear improvement demonstrated when 
scatter and CT-attenuation correction were corrected for as part of the 
reconstruction. This is in keeping with results reported by Assie et al (2010), 
however, whilst it is acknowledged that all phantom work is idealistic, the work 
undertaken by Assie et al (2010) involved a separate CT acquisition. The use of a 
separate CT is not desirable for quantifying OctreoSCAN, as co-registration of 
the SPET-CT may be subject to significant errors. Errors which would result from 
differences in patient set-up between the modalities i.e. arms up or down, Chapter 4    209 
breath hold or simply because there is a spatial differences in the anatomical 
distribution of organs within the abdomen and pelvis as a result of variations in 
bowel, bladder and stomach content.   
Unlike 
111In phantom work the 
99mTc phantom work demonstrated hybrid imaging 
to provide a significant improvement in the overall accuracy of image 
quantification using 
99mTc when compared with the existing reconstruction 
techniques used in the chapter 2 for the NeoSPECT work. It is also worthwhile 
noting that for both 
111In and 
99mTc the closest match to the actual activity was 
calculated without a background correction for the counts, presumably as the 
activity was calculated from data from transverse slices and therefore there was 
no need to correct for overlying structures as would normally be the case with 
planar imaging.   
The work in this chapter clearly indicates hybrid imaging’s ability to improve 
SPET image quality. As a result there is no doubt that the accuracy of the 
quantitative and semi-quantitative NeoSPECT work in chapter 2 would have 
benefited. The use of the SPET-CT would have led to improved accuracy of 
tumour volume delineation and better identification of ‘other’ disease processes 
within the lungs. The improved reduction in non-physiological tracer distribution 
would also have allowed better visualization of small nodal disease within the 
lungs.  
Incidentally, from reviewing the patient OctreoScan images in this chapter, as a 
result of hybrid imaging, new consideration should be given to the standard 
imaging protocol for OctreoScan studies. OctreoScan studies are normally 
performed at 24 and 48 hrs to help distinguish between physiological uptake and 
abnormal uptake in bowel. However, now that anatomical information is 
available and the quality of the SPET reconstruction has improved as a result of 
various corrections, it may be time to amend current protocols. If abnormal 
uptake at 24 hours can be characterised using the SPET-CT fused volume then 
there would be no need to perform addition 48 hour imaging. A recent editorial 
published in Nuclear Medicine Communications also recognised the 
improvements in OctreoScan as a result of hybrid imaging particularly when its 
role in distinguishing physiological from pathological uptake in the abdomen 
(Navalkissoor & Buscombe, 2011). Amendment to current standard OctreoScan Chapter 4    210 
imaging protocols would increase the number of patients imaged in a 
department by freeing up camera time. This would also optimise the time spent 
by the patient within the department as the overall length of the current 
protocol from injection to final set of images, requires a certain level of 
tolerance and general fitness of patient. There would therefore be a number of 
patients who do not have this investigation because they were unable to comply 
fully.   211 
Chapter 5 - Thesis Conclusion and Discussion 
The main aim of this thesis was to investigate the use of SPET and SPET-CT 
image quantification and its role in tissue characterisation of somatostatin 
receptor imaging. 
Work initially involved the 
99mTc labeled somatostatin analogue, NeoSPECT. This 
radiopharmaceutical was licensed for use in Europe to image NSCLC solitary 
pulmonary nodules. The work in Chapter 2 aimed to determine if dual time 
imaging and quantification using iterative SPET reconstruction techniques could 
be used to differentiate between benign and malignant disease within the 
mediastinum. It was believed that the consequence of a positive finding would 
have great benefits in staging disease without the need for invasive methods 
such as mediastinoscopy and CT guided biopsy. Furthermore, accurate image 
quantification could also be considered as a useful tool in determining therapy 
efficacy. Two forms of image quantification were undertaken in Chapter 2. The 
first was simple ratio calculation between the tumour and the surrounding 
background tissue. The second was a calculation of percentage uptake from the 
tumour volume.   
Differences between SPET volumes reconstructed with FBP and Iterative 
reconstruction techniques were assessed via T:B ratio’s. Despite there being no 
statistically significant difference between the techniques quantitatively there 
was a noticeable improvement in image quality when using Iterative techniques. 
This difference was considered important as the lower quality FBP technique 
meant accurate delineation of the tumour volume was more difficult, this in 
turn, would have an impact on the accuracy of the percentage uptake value 
calculated. 
In terms of tumour histology, neither the T:B ratio nor values of percentage 
uptake calculated from the 2 hours acquisition were able to differentiate 
between benign and malignant disease.  
Leading on from this, the patients who had undergone dual time imaging at 2 
and 4 hours were assessed to determine if there was any difference Chapter 5    212 
demonstrated quantitatively in the malignant group between the 2 and 4 hour 
SPET volumes. Neither the T:B or the more sensitive measure of percentage 
uptake, were able to demonstrate any statistically significant change in the 
distribution of the NeoSPECT within the tumour volume and surrounding lung 
tissue between the images acquired at 2 and 4 hours. Separate analysis 
undertaken of the NSCLC group only, also failed to identify any quantitative 
differences in T:B or percentage uptake within the histological subtypes of 
NSCLC. 
In terms of the mediastinum, direct correlation of quantification performed in 
the mediastinum with histology findings could not be undertaken due to a lack to 
anatomical information. Therefore nodes could only be characterized based on 
their size and shape and therefore nodal disease could not be definitively 
confirmed. Previous work by Waxman, 2002, claimed that NeoSPECT could be 
used to accurately stage disease within the mediastinum, however, the 
mechanism as to how node identified on SPET imaging were validated was 
omitted from this abstract. Work in this thesis failed to identify an accurate 
technique to do this with SPET imaging alone, directly as a result of lack of 
anatomical information.  
Work in chapter 2 clearly demonstrated that quantification of NeoSPECT imaging 
was not a suitable technique to differentiate benign from malignant disease. In 
the past consideration had been given to the use of radio-labeled Depreotide as 
a radionuclide targeted therapy agent, however, the fact that significant uptake 
exists in benign disease makes the use of a therapy agent based on NeoSPECT of 
no value. 
The NeoSPECT work undertaken identified a number of pitfalls in SPET image 
quantification. Firstly patient compliance, there were a number of physical 
difficulties which could not be overcome such as the patient’s limited flexibility 
and general compliance to remain still throughout the duration of the study. 
These often led to large orbits of rotation and image degradation. Another 
similar problem encountered in the dual time imaging, but relevant to any 
repeated study, was the reproducibility of the patient set-up in patients with 
large BMIs. Body habitus greatly affected the orbit of rotation, this significantly 
affected the correction for attenuation using Chang’s technique. This work also Chapter 5    213 
highlighted a low confidence in the correct identification of anatomical features 
predominantly nodal disease within the mediastinum due to a lack of anatomical 
information.  
Shortly after the NeoSPECT work was undertaken the department installed the 
latest in hybrid imaging, a Siemens Symbia T SPET-CT unit. In theory, not only 
was hybrid imaging able to provide anatomical information to the SPET volume 
but both CT and software components were able to correct for factors which 
degraded SPET images such as attenuation and scatter. All of these new features 
could have impacted on the quality of the data and on the qualitative and 
quantitative results. It was therefore important to re-evaluate the role of 
NeoSPECT image quantification in light of the availability of better 
reconstruction algorithms. Work was undertaken with another SSTR imaging 
agent, OctreoScan, to determine if hybrid imaging could have improved image 
quality and accuracy of SPET image quantification.  
Little published work is available investigating the use of SPET-CT and in 
particular work looking at image quantification using new reconstruction 
techniques in patient data other than in the field of cardiology. The work within 
this thesis using OctreoScan allowed important analysis to be undertaken to 
determine whether these new techniques did improve image quality. 
Firstly, a qualitative comparison was undertaken using patient data which looked 
for differences in image quality between images reconstructed as in Chapter 2 
and using new techniques as a result of hybrid imaging. From the results it was 
clear that hybrid imaging reconstruction techniques provided a better quality 
SPET volume when compared with existing reconstruction technique.  
Using the same patient cohort semi-qualitative analysis was also undertaken.  
Profile analysis of the main organs within the abdomen and thorax was 
undertaken to assess the distribution of OctreoScan uptake across the organs 
between the existing and new reconstruction techniques. Results demonstrated 
a significant improvement in image quality when using the hybrid based 
reconstruction techniques, the distribution of OctreoScan uptake in solid organs 
like the liver were more uniform and areas such as the thorax demonstrated Chapter 5    214 
pronounced differentiation between lung with surrounding tissue when 
compared with the existing reconstruction techniques. 
Finally, analysis was undertaken to assess the accuracy SPET image 
quantification using hybrid imaging techniques. Results from the 
111In based 
phantom demonstrated an improvement in the accuracy of the absolute activity 
calculation when using hybrid imaging, although the difference between the 
actual and calculated activity differed from the actual value by approximately 
21%. 
99mTc phantom work on the other hand demonstrated hybrid imaging to 
provide a significant improvement in the overall accuracy of image 
quantification using 
99mTc in comparison to the reconstruction techniques used in 
the chapter 2 for the NeoSPECT work. This conclusion is in keeping with work 
undertaken by Zeintl et al. (2010) which involved both a patient cohort and 
phantoms.  
The work in this thesis clearly demonstrated hybrid imaging’s ability to improve 
SPET image quality for both 
111In and 
99mTc based radiopharmaceuticals this is an 
important factor in image quantification. In particular a great improvement in 
the accuracy of the calculation of absolute uptake was demonstrated for 
99mTc 
which would have benefited the work in chapter 2. It is unlikely that hybrid 
imaging would have added any additional value to NeoSPECT as a diagnostic 
imaging product for NSCLC. In fact despite its rebranding, NeoSPECT has recently 
been withdrawn from having a European license. This is as a direct of result of a 
decrease in demand for the product brought about by the increased availability 
of PET-CT imaging within mainland Europe and the UK. In Scotland one of the 
key roles of PET-CT imaging lies in the diagnosis and staging of NSCLC cancer. 
There has been work published recently which redefines the role of NeoSPECT in 
patients in SCLC, Gerasimou et al. (2010), it may be that NeoSPECT is made 
available again in the future.  
In terms of further work, as mentioned in Chapter 4, the EANM has published 
new guidelines on OctreoScan imaging. The acquisition parameters in these new 
guidelines differ from the acquisition parameters currently used at Glasgow 
Royal Infirmary and probably many other centres across the UK. The guidelines 
indicate extended planar and SPET acquisition times. In terms of the SPET 
imaging there is no indication as to whether or not these new guidelines have Chapter 5    215 
been drawn up with SPET resolution recovery in mind and whether there is a real 
need to extend the already lengthy SPET acquisition. Further work will be 
undertaken to investigate if SPET-CT acquisitions with resolution recovery could 
impact the SPET acquisition times advised by the EANM guidelines. In addition to 
this, the department will also seek to undertake an audit of the OctreoScan 
findings of 24 hour SPET-CT versus 48 hour imaging to determine how many 
patients continue to have indeterminate findings at 24 hours.  
Currently, there are a number of research groups working with commercial 
partners looking to incorporate Monte Carlo based scatter corrections into their 
resolution recovery software. As SPET image reconstruction techniques continue 
to evolve, it may be that greater improvements are demonstrated in image 
quantification which could see a major role emerge for nuclear medicine SPET 
imaging techniques as accurate and effective quantitative tools for the 
measurement of therapy efficacy.  
The work of this thesis has produced some novel work leading to a number of 
important conclusions in the field of somatostatin imaging in particular and in 
general for SPET-CT hybrid imaging reconstruction tools. These can be 
summarised as follows: 
·  No difference could be found between uptake in malignant and benign 
disease in NeoSPECT imaging using conventional image acquisition. 
o  NeoSPECT should not be considered as a therapy agent. 
·  Using hybrid imaging (SPET-CT) significantly improves both image quality and 
quantification of images from somatostatin receptor radiopharmaceuticals.  
This work has not been previously published. 
·  The use of SPET-CT and SPET iterative reconstruction using resolution 
recovery, scatter and attenuation correction show clear improvements in 
both Tc
99m and In
111 images from a quantitative perspective. 216 
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Appendix D - Reproducibility results for each observer 
Results - Observer 1  
Entire OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  4  4  Oct062 / 118  5  4  Oct060 / 119  4  3 
Oct027 / 135  2  2  Oct036 / 143  3  3  Oct077 / 139  3  2 
Oct053 / 134  2  4  Oct070 / 132  4  2  Oct068 / 138  4  3 
Oct030 / 121  3  3  Oct039 / 141  3  3  Oct042 / 125  3  2 
Oct081 / 140  2  2  Oct101 / 126  2  2  Oct033 / 120  2  2 
Oct094 / 130  3  3  Oct017 / 145  3  3  Oct084 / 137  2  2 
Oct045 / 131  3  3  Oct005 / 142  4  4  Oct020 / 123  4  3 
Oct051 / 144  3  3  Oct100 / 127  3  3  Oct079 / 129  3  4 
Oct103 / 122  4  4  Oct108 / 124  4  3  Oct114 / 128  3  3 
Oct112 / 136  4  3  Oct116 / 146  3  3  Oct109 / 133  3  2 
Sum  30  31  Sum  34  30  Sum  31  26 
 
Lung OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  0  4  Oct062 / 118  0  4  Oct060 / 119  0  3 
Oct027 / 135  2  2  Oct036 / 143  0  3  Oct077 / 139  2  2 
Oct053 / 134  0  0  Oct070 / 132  2  2  Oct068 / 138  2  3 
Oct030 / 121  1  2  Oct039 / 141  2  1  Oct042 / 125  2  2 
Oct081 / 140  2  1  Oct101 / 126  1  1  Oct033 / 120  3  1 
Oct094 / 130  0  0  Oct017 / 145  0  3  Oct084 / 137  2  2 
Oct045 / 131  0  2  Oct005 / 142  1  4  Oct020 / 123  1  2 
Oct051 / 144  0  3  Oct100 / 127  2  0  Oct079 / 129  2  0 
Oct103 / 122  3  0  Oct108 / 124  4  0  Oct114 / 128  0  3 
Oct112 / 136  0  0  Oct116 / 146  0  0  Oct109 / 133  0  2 
Sum  8  14  Sum  12  18  Sum  14  20 
 
 
 
 
 222 
 
Results - Observer 2  
Entire OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  2.5  2.5  Oct062 / 118  3  3.5  Oct060 / 119  3  4 
Oct027 / 135  2  1  Oct036 / 143  3.5  2.5  Oct077 / 139  3.5  3 
Oct053 / 134  2  1.5  Oct070 / 132  3  3  Oct068 / 138  3  3 
Oct030 / 121  3  3.5  Oct039 / 141  3  3  Oct042 / 125  4  4 
Oct081 / 140  2  2.5  Oct101 / 126  3  3  Oct033 / 120  3  4 
Oct094 / 130  2.5  2.5  Oct017 / 145  3.5  3  Oct084 / 137  3.5  3 
Oct045 / 131  2  2.5  Oct005 / 142  3.5  3  Oct020 / 123  3  3.5 
Oct051 / 144  2  2  Oct100 / 127  3  3  Oct079 / 129  3.5  3.5 
Oct103 / 122  2  3  Oct108 / 124  3  2.5  Oct114 / 128  3  3 
Oct112 / 136  2.5  1  Oct116 / 146  2.5  2.5  Oct109 / 133  2.5  2 
Sum  22.5  22  Sum  31  29  Sum  32  33 
 
Lung OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  1.5  1  Oct062 / 118  2.5  2  Oct060 / 119  3.5  4 
Oct027 / 135  1  0.5  Oct036 / 143  1  1  Oct077 / 139  0  0 
Oct053 / 134  1  1  Oct070 / 132  1  1  Oct068 / 138  1  1 
Oct030 / 121  4  4  Oct039 / 141  3.5  3.5  Oct042 / 125  4  4 
Oct081 / 140  3  1.5  Oct101 / 126  3.5  2.5  Oct033 / 120  3.5  4 
Oct094 / 130  0  0  Oct017 / 145  0  0  Oct084 / 137  0  0 
Oct045 / 131  2  1  Oct005 / 142  0  0  Oct020 / 123  1  0 
Oct051 / 144  1  0  Oct100 / 127  0  0  Oct079 / 129  0  0 
Oct103 / 122  0  0  Oct108 / 124  0  0  Oct114 / 128  0  0 
Oct112 / 136  0  0  Oct116 / 146  0  0  Oct109 / 133  0  0 
Sum  13.5  9  Sum  11.5  10  Sum  13  13 223 
Results - Observer 3  
Entire OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  4  3  Oct062 / 118  3  2  Oct060 / 119  3  4 
Oct027 / 135  2  4  Oct036 / 143  5  2  Oct077 / 139  4  4 
Oct053 / 134  1  4  Oct070 / 132  4  3  Oct068 / 138  4  3 
Oct030 / 121  1  4  Oct039 / 141  4  4  Oct042 / 125  4  5 
Oct081 / 140  4  4  Oct101 / 126  2  3  Oct033 / 120  4  4 
Oct094 / 130  3  4  Oct017 / 145  4  5  Oct084 / 137  4  3 
Oct045 / 131  1  3  Oct005 / 142  5  3  Oct020 / 123  5  3 
Oct051 / 144  2  4  Oct100 / 127  3  5  Oct079 / 129  5  4 
Oct103 / 122  2  2  Oct108 / 124  2  3  Oct114 / 128  3  3 
Oct112 / 136  3  1  Oct116 / 146  3  4  Oct109 / 133  2  4 
Sum  23  33  Sum  35  34  Sum  38  37 
 
Lung OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  3  2  Oct062 / 118  3  4  Oct060 / 119  4  3 
Oct027 / 135  2  2  Oct036 / 143  3  2  Oct077 / 139  4  3 
Oct053 / 134  2  3  Oct070 / 132  3  3  Oct068 / 138  4  2 
Oct030 / 121  3  4  Oct039 / 141  3  4  Oct042 / 125  4  5 
Oct081 / 140  3  4  Oct101 / 126  2  1  Oct033 / 120  5  3 
Oct094 / 130  3  4  Oct017 / 145  2  4  Oct084 / 137  4  3 
Oct045 / 131  1  2  Oct005 / 142  5  3  Oct020 / 123  4  3 
Oct051 / 144  1  3  Oct100 / 127  4  4  Oct079 / 129  4  3 
Oct103 / 122  0  0  Oct108 / 124  0  0  Oct114 / 128  0  0 
Oct112 / 136  3  0  Oct116 / 146  3  0  Oct109 / 133  0  0 
Sum  21  24  Sum  28  25  Sum  33  25 224 
Results - Observer 4  
Entire OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  1  2  Oct062 / 118  4  3  Oct060 / 119  4  5 
Oct027 / 135  1  1  Oct036 / 143  3  4  Oct077 / 139  3  3 
Oct053 / 134  1  1  Oct070 / 132  3  3  Oct068 / 138  3  4 
Oct030 / 121  3  3  Oct039 / 141  5  3  Oct042 / 125  5  5 
Oct081 / 140  1  1  Oct101 / 126  3  4  Oct033 / 120  4  5 
Oct094 / 130  1  1  Oct017 / 145  4  5  Oct084 / 137  4  5 
Oct045 / 131  1  1  Oct005 / 142  4  4  Oct020 / 123  5  3 
Oct051 / 144  1  1  Oct100 / 127  1  3  Oct079 / 129  3  3 
Oct103 / 122  1  3  Oct108 / 124  3  3  Oct114 / 128  5  3 
Oct112 / 136  1  3  Oct116 / 146  1  1  Oct109 / 133  3  1 
Sum  12  17  Sum  31  33  Sum  39  37 
 
Lung OctreoScan Volume Score 
O2D  F3D  F3D SAC 
 
Score 1  Score 2 
 
Score 1  Score 2 
 
Score 1  Score 2 
Oct080 / 147  1  1  Oct062 / 118  5  3  Oct060 / 119  5  5 
Oct027 / 135  1  1  Oct036 / 143  3  3  Oct077 / 139  3  3 
Oct053 / 134  1  1  Oct070 / 132  3  3  Oct068 / 138  3  3 
Oct030 / 121  5  4  Oct039 / 141  5  3  Oct042 / 125  5  5 
Oct081 / 140  1  1  Oct101 / 126  3  3  Oct033 / 120  5  5 
Oct094 / 130  1  1  Oct017 / 145  4  0  Oct084 / 137  4  4 
Oct045 / 131  1  1  Oct005 / 142  4  3  Oct020 / 123  5  3 
Oct051 / 144  1  1  Oct100 / 127  0  0  Oct079 / 129  3  3 
Oct103 / 122  0  0  Oct108 / 124  0  0  Oct114 / 128  0  0 
Oct112 / 136  0  0  Oct116 / 146  0  0  Oct109 / 133  0  0 
Sum  12  11  Sum  27  18  Sum  33  31 225 
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